<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><article article-type="research-article" dtd-version="1.2" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">65759</article-id><article-id pub-id-type="doi">10.7554/eLife.65759</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Cell Biology</subject></subj-group></article-categories><title-group><article-title>RNF43 inhibits WNT5A-driven signaling and suppresses melanoma invasion and resistance to the targeted therapy</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-219163"><name><surname>Radaszkiewicz</surname><given-names>Tomasz</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-4850-9933</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-219164"><name><surname>Nosková</surname><given-names>Michaela</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-219165"><name><surname>Gömöryová</surname><given-names>Kristína</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-219166"><name><surname>Vondálová Blanářová</surname><given-names>Olga</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-5998-5348</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-219167"><name><surname>Radaszkiewicz</surname><given-names>Katarzyna Anna</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-9604-3950</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-219168"><name><surname>Picková</surname><given-names>Markéta</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-219169"><name><surname>Víchová</surname><given-names>Ráchel</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-219170"><name><surname>Gybeľ</surname><given-names>Tomáš</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-219171"><name><surname>Kaiser</surname><given-names>Karol</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-4705-2003</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-219172"><name><surname>Demková</surname><given-names>Lucia</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-219173"><name><surname>Kučerová</surname><given-names>Lucia</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-247980"><name><surname>Bárta</surname><given-names>Tomáš</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-217712"><name><surname>Potěšil</surname><given-names>David</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-219175"><name><surname>Zdráhal</surname><given-names>Zbyněk</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con14"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-219176"><name><surname>Souček</surname><given-names>Karel</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con15"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-156392"><name><surname>Bryja</surname><given-names>Vítězslav</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-9136-5085</contrib-id><email>bryja@sci.muni.cz</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con16"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution>Department of Experimental Biology, Faculty of Science, Masaryk University</institution><addr-line><named-content content-type="city">Brno</named-content></addr-line><country>Czech Republic</country></aff><aff id="aff2"><label>2</label><institution>Department of Cytokinetics, Institute of Biophysics CAS</institution><addr-line><named-content content-type="city">Brno</named-content></addr-line><country>Czech Republic</country></aff><aff id="aff3"><label>3</label><institution>International Clinical Research Center FNUSA-ICRC</institution><addr-line><named-content content-type="city">Brno</named-content></addr-line><country>Czech Republic</country></aff><aff id="aff4"><label>4</label><institution>Laboratory of Molecular Oncology, Cancer Research Institute, Biomedical Research Center of the Slovak Academy of Sciences</institution><addr-line><named-content content-type="city">Bratislava</named-content></addr-line><country>Slovakia</country></aff><aff id="aff5"><label>5</label><institution>Department of Histology and Embryology, Faculty of Medicine, Masaryk University</institution><addr-line><named-content content-type="city">Brno</named-content></addr-line><country>Czech Republic</country></aff><aff id="aff6"><label>6</label><institution>Central European Institute of Technology, Masaryk University</institution><addr-line><named-content content-type="city">Brno</named-content></addr-line><country>Czech Republic</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Robles-Espinoza</surname><given-names>C Daniela</given-names></name><role>Reviewing Editor</role><aff><institution>International Laboratory for Human Genome Research</institution><country>Mexico</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Golemis</surname><given-names>Erica A</given-names></name><role>Senior Editor</role><aff><institution>Fox Chase Cancer Center</institution><country>United States</country></aff></contrib></contrib-group><pub-date date-type="publication" publication-format="electronic"><day>27</day><month>10</month><year>2021</year></pub-date><pub-date pub-type="collection"><year>2021</year></pub-date><volume>10</volume><elocation-id>e65759</elocation-id><history><date date-type="received" iso-8601-date="2020-12-14"><day>14</day><month>12</month><year>2020</year></date><date date-type="accepted" iso-8601-date="2021-09-28"><day>28</day><month>09</month><year>2021</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at bioRxiv.</event-desc><date date-type="preprint" iso-8601-date="2021-02-10"><day>10</day><month>02</month><year>2021</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2021.02.08.430210"/></event></pub-history><permissions><copyright-statement>© 2021, Radaszkiewicz et al</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>Radaszkiewicz et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-65759-v1.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-65759-figures-v1.pdf"/><abstract><p>RNF43 is an E3 ubiquitin ligase and known negative regulator of WNT/β-catenin signaling. We demonstrate that RNF43 is also a regulator of noncanonical WNT5A-induced signaling in human cells. Analysis of the RNF43 interactome using BioID and immunoprecipitation showed that RNF43 can interact with the core receptor complex components dedicated to the noncanonical Wnt pathway such as ROR1, ROR2, VANGL1, and VANGL2. RNF43 triggers VANGL2 ubiquitination and proteasomal degradation and clathrin-dependent internalization of ROR1 receptor and inhibits ROR2 activation. These activities of RNF43 are physiologically relevant and block pro-metastatic WNT5A signaling in melanoma. RNF43 inhibits responses to WNT5A, which results in the suppression of invasive properties of melanoma cells. Furthermore, RNF43 prevented WNT5A-assisted development of resistance to BRAF V600E and MEK inhibitors. Next, RNF43 acted as melanoma suppressor and improved response to targeted therapies in vivo. In line with these findings, <italic>RNF43</italic> expression decreases during melanoma progression and RNF43-low patients have a worse prognosis. We conclude that RNF43 is a newly discovered negative regulator of WNT5A-mediated biological responses that desensitizes cells to WNT5A.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>RNF43</kwd><kwd>WNT5A</kwd><kwd>melanoma</kwd><kwd>ROR1</kwd><kwd>VANGL1</kwd><kwd>BRAF V600E</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001824</institution-id><institution>Czech Science Foundation</institution></institution-wrap></funding-source><award-id>GX19-28347X</award-id><principal-award-recipient><name><surname>Radaszkiewicz</surname><given-names>Tomasz</given-names></name><name><surname>Bryja</surname><given-names>Vítězslav</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001823</institution-id><institution>Ministry of Education, Youth and Sports</institution></institution-wrap></funding-source><award-id>LM2018127</award-id><principal-award-recipient><name><surname>Zdráhal</surname><given-names>Zbyněk</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001823</institution-id><institution>Ministry of Education, Youth and Sports</institution></institution-wrap></funding-source><award-id>LM2018140</award-id><principal-award-recipient><name><surname>Zdráhal</surname><given-names>Zbyněk</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>RNF43 interacts with receptor complexes of the Wnt/PCP signaling and its enzymatic activity results in the reduced cells sensitivity to WNT5A what translates in melanoma into decreased invasive properties and increased response to targeted therapies of this skin cancer.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Ubiquitination is a post-translational modification (PTM) based on the addition of the evolutionary conserved protein ubiquitin (Ub) to the lysine residue(s) of the modified protein (<xref ref-type="bibr" rid="bib61">Hershko and Ciechanover, 1998</xref>). Ubiquitination controls the turnover, activation state, cellular localization, and interactions of target proteins. Undoubtedly, it is a process that has a direct impact on various aspects of cell biology (<xref ref-type="bibr" rid="bib140">Rape, 2018</xref>). Ubiquitination requires sequential activation of ubiquitin, its transfer to the carrier protein, and subsequent linkage reaction with the substrate lysine residues. This last step, mediated by the E3 ubiquitin protein ligases (E3s), determines target specificity.</p><p>Ring Finger protein 43 (RNF43) is a E3 ubiquitin ligase with a single transmembrane domain from the PA-TM-RING family. RNF43 and its close homolog Zinc and Ring Finger 3 (ZNRF3) act as negative regulators of the Wnt/β-catenin signaling pathway (<xref ref-type="bibr" rid="bib88">Koo et al., 2012</xref>; <xref ref-type="bibr" rid="bib56">Hao et al., 2012</xref>). Wnt/β-catenin signaling is an evolutionary conserved pathway and a crucial regulator of embryonal development and tissue homeostasis. RNF43 and ZNRF3 control via regulation of Wnt/β-catenin multiple processes including liver zonation (<xref ref-type="bibr" rid="bib133">Planas-Paz et al., 2016</xref>), limb specification (<xref ref-type="bibr" rid="bib160">Szenker-Ravi et al., 2018</xref>), and mammalian sex determination (<xref ref-type="bibr" rid="bib60">Harris et al., 2018</xref>). Mechanistically, RNF43 and ZNRF3 ubiquitinate plasma membrane Wnt receptors called Frizzleds (FZDs) and a co-receptor low-density lipoprotein receptor-related protein 6 (LRP6), which results in their internalization and degradation (<xref ref-type="bibr" rid="bib56">Hao et al., 2012</xref>; <xref ref-type="bibr" rid="bib88">Koo et al., 2012</xref>). Therefore, cells become less sensitive or insensitive to Wnt ligands. Activity of RNF43/ZNRF43 is regulated by secreted proteins from R-spondin (RSPO) family (<xref ref-type="bibr" rid="bib82">Kazanskaya et al., 2004</xref>; <xref ref-type="bibr" rid="bib86">Kim et al., 2008</xref>; <xref ref-type="bibr" rid="bib85">Kim et al., 2006</xref>; <xref ref-type="bibr" rid="bib84">Kim et al., 2005</xref>; <xref ref-type="bibr" rid="bib115">Nam et al., 2007</xref>; <xref ref-type="bibr" rid="bib114">Nam et al., 2006</xref>; <xref ref-type="bibr" rid="bib131">Peng et al., 2013</xref>; <xref ref-type="bibr" rid="bib184">Xie et al., 2013</xref>) that trigger internationalization of RNF43/ZNRF3 and function as physiologically relevant activators of Wnt/β-catenin pathway (<xref ref-type="bibr" rid="bib18">Binnerts et al., 2007</xref>; <xref ref-type="bibr" rid="bib26">Carmon et al., 2011</xref>; <xref ref-type="bibr" rid="bib37">de Lau et al., 2011</xref>; <xref ref-type="bibr" rid="bib57">Hao et al., 2016</xref>; <xref ref-type="bibr" rid="bib56">Hao et al., 2012</xref>; <xref ref-type="bibr" rid="bib72">Jiang et al., 2015</xref>; <xref ref-type="bibr" rid="bib88">Koo et al., 2012</xref>; <xref ref-type="bibr" rid="bib188">Zebisch et al., 2013</xref>; <xref ref-type="bibr" rid="bib189">Zebisch and Jones, 2015</xref>).</p><p>Because deregulation of Wnt/β-catenin pathway promotes tumor formation (<xref ref-type="bibr" rid="bib98">Lim and Nusse, 2013</xref>; <xref ref-type="bibr" rid="bib174">van Kappel and Maurice, 2017</xref>; <xref ref-type="bibr" rid="bib182">Wiese and Nusse, 2018</xref>), RNF43/ZNRF3 can act as tumor suppressors. Indeed, mutation or inactivation of <italic>RNF43</italic>/<italic>ZNRF3</italic> leads to the oncogenic activation of Wnt signaling and associates with colorectal, liver, gastric, endometrial, ovarian, and pancreatic cancers (<xref ref-type="bibr" rid="bib22">Bond et al., 2016</xref>; <xref ref-type="bibr" rid="bib44">Eto et al., 2018</xref>; <xref ref-type="bibr" rid="bib51">Giannakis et al., 2014</xref>; <xref ref-type="bibr" rid="bib71">Jiang et al., 2013</xref>; <xref ref-type="bibr" rid="bib73">Jo et al., 2015</xref>; <xref ref-type="bibr" rid="bib121">Niu et al., 2015</xref>; <xref ref-type="bibr" rid="bib133">Planas-Paz et al., 2016</xref>; <xref ref-type="bibr" rid="bib144">Ryland et al., 2013</xref>; <xref ref-type="bibr" rid="bib156">Spit et al., 2020</xref>; <xref ref-type="bibr" rid="bib170">Tsukiyama et al., 2020</xref>).</p><p>Some members of the Wnt family – such as WNT5A and WNT11 – preferentially activate downstream signaling that is distinct from Wnt/β-catenin pathway and is referred to as β-catenin-independent or noncanonical Wnt pathway (<xref ref-type="bibr" rid="bib129">Pandur et al., 2002</xref>; <xref ref-type="bibr" rid="bib67">Humphries and Mlodzik, 2018</xref>; <xref ref-type="bibr" rid="bib175">VanderVorst et al., 2019</xref>; <xref ref-type="bibr" rid="bib5">Andre et al., 2015</xref>). Noncanonical Wnt pathway shares some features with the Wnt/β-catenin pathway – such as the requirement for FZD receptors, dishevelled (DVL) phosphoprotein and casein kinase 1 (CK1) – but clearly differs in others. In the mammalian noncanonical pathway, receptor tyrosine kinase-like orphan receptor 1 (ROR1) and ROR2 act as primary (co-)receptors (in contrast to LRP5/6 that have this role in the Wnt/β-catenin pathway) and four-transmembrane Vang-like protein 1 (VANGL1) and VANGL2 participate in the signal transduction (<xref ref-type="bibr" rid="bib12">Asem et al., 2016</xref>; <xref ref-type="bibr" rid="bib175">VanderVorst et al., 2019</xref>). This signaling axis is also referred to as planar cell polarity pathway (PCP), and its activation leads to changes in actin cytoskeleton dynamics, facilitating, that is, polarized cell migration (<xref ref-type="bibr" rid="bib5">Andre et al., 2015</xref>; <xref ref-type="bibr" rid="bib69">Janovská and Bryja, 2017</xref>; <xref ref-type="bibr" rid="bib81">Kaucká et al., 2015</xref>; <xref ref-type="bibr" rid="bib181">Weeraratna et al., 2002</xref>).</p><p>FZD receptors, the best-defined targets of RNF43/ZNRF3, are shared among all Wnt pathways and their endocytosis and/or degradation have the potential, at least in theory, to prevent signaling by any Wnt ligands. So far, there is only one study that suggests the role of RNF43/ZNRF3 in noncanonical Wnt signaling in mammals (<xref ref-type="bibr" rid="bib169">Tsukiyama et al., 2015</xref>). In addition, secreted inhibitor of RNF43/ZNRF3 called r-spondin 3 (RSPO3) potentiated noncanonical PCP pathway in <italic>Xenopus</italic> in a Wnt5a and dishevelled-dependent manner (<xref ref-type="bibr" rid="bib52">Glinka et al., 2011</xref>; <xref ref-type="bibr" rid="bib122">Ohkawara et al., 2011</xref>). In mouse embryos, <italic>Znrf3</italic> knockout caused open neural tube defects, which is a common consequence of the Wnt/PCP signaling disruption (<xref ref-type="bibr" rid="bib56">Hao et al., 2012</xref>). Other report showed a similar phenotype in <italic>Xenopus</italic> embryos after <italic>Rnf43</italic> mRNA injection (<xref ref-type="bibr" rid="bib169">Tsukiyama et al., 2015</xref>). And finally, in <italic>Caenorhabditis elegans</italic>, the homolog of RNF43 and ZNRF3 called plr-1 was shown to control not only the surface localization of frizzled, but also proteins related to mammalian noncanonical Wnt co-receptors ROR1/2 and RYK (<xref ref-type="bibr" rid="bib111">Moffat et al., 2014</xref>). However, it is worth underlining that RSPO family homologs are absent in <italic>C. elegans</italic> (<xref ref-type="bibr" rid="bib96">Lebensohn and Rohatgi, 2018</xref>), so the mode of action of RNF43/ZNRF3 in the worm might be different than in mammalian cells.</p><p>In this study, we have directly addressed the role of RNF43 in the WNT5A-induced signaling. We demonstrate that RNF43 controls the noncanonical Wnt pathway similarly to Wnt/β-catenin pathway. Further, we show that RNF43 is a relevant inhibitor of pro-metastatic WNT5A signaling in melanoma where it prevents both WNT5A-induced invasive behavior and WNT5A-assisted development of resistance to B-RAF and MEK inhibitors.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>RNF43 inhibits WNT5A-driven noncanonical Wnt signaling pathway</title><p>In order to test whether or not RNF43/ZNRF3 controls noncanonical Wnt signaling, we have decided to study T-REx 293 cells. T-REx 293 cells secrete endogenous WNT5A that constitutively activates the noncanonical Wnt pathway – this can be demonstrated by the CRISPR/Cas9-mediated knockout of <italic>WNT5A</italic> (<xref ref-type="bibr" rid="bib78">Kaiser et al., 2020</xref>). Removal of endogenous WNT5A in T-REx 293 cells is sufficient to eliminate the activation of readouts of WNT5A signaling such as phosphorylation of ROR1, DVL2, and DVL3 that can be monitored by western blotting as the decrease in the phosphorylation-mediated electrophoretic mobility shifts (<xref ref-type="fig" rid="fig1">Figure 1A</xref>; <xref ref-type="bibr" rid="bib24">Bryja et al., 2007b</xref>; <xref ref-type="bibr" rid="bib90">Kotrbová et al., 2020</xref>; <xref ref-type="bibr" rid="bib136">Radaszkiewicz and Bryja, 2020</xref>). Autocrine WNT5A signaling was promoted by the inhibition of endogenous RNF43/ZNRF3 by RSPO1 treatment (<xref ref-type="fig" rid="fig1">Figure 1B</xref>, compare lanes 1 and 2) and inhibited by RNF43 overexpression under the tetracycline (Tet)-controlled promoter (TetON) or by block of WNT secretion using Porcupine inhibitor Wnt-C59 (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). To confirm that the effects are indeed caused by the block of WNT5A signaling, T-REx 293 cells pretreated with Wnt-C59 and as such unable to produce Wnt ligands were stimulated with increasing doses of recombinant WNT5A. As shown in <xref ref-type="fig" rid="fig1">Figure 1C</xref>, overexpression of RNF43 completely blocked signaling induced by recombinant WNT5A. Altogether, this demonstrates that RNF43 has the potential to block WNT5A signaling in mammalian cells.</p><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>RNF43 interactome is enriched with the Wnt planar cell polarity pathway components.</title><p>(<bold>A</bold>) Western blot analysis of T-REx 293 wild type (WT) and <italic>WNT5A</italic> KO cells. Phosphorylation-dependent shifts of endogenous ROR1, DVL2, and DVL3 were suppressed upon WNT5A loss (TCL: total cell lysate; CM: conditioned medium). Signal of β-actin serves as a loading control. Empty arrowhead marks phosphorylation-dependent shift; black arrowhead indicates unphosphorylated protein. (<bold>B</bold>) Western blot showing activation of the noncanonical Wnt pathway components: ROR1, DVL2, and DVL3 upon rhRSPO1 overnight treatment (arrowheads as in <bold>A</bold>). Tetracycline-forced RNF43 overexpression (as visualized by HA tag-specific antibody) suppressed this effect. Inhibition of Wnt ligands secretion by the Porcupine inhibitor Wnt-C59 shows dependency of the rhRSPO1-mediated effect on endogenous Wnt ligands; representative blots from N = 3. (<bold>C</bold>) Western blot analysis of cellular responses to the increasing doses of rhWNT5A. ROR1 shift and phosphorylation of DVL2 and DVL3 (empty arrowhead) were inhibited upon tetracycline-induced RNF43-HA-BirA* overexpression. All samples were treated with Wnt-C59 Porcupine inhibitor to ascertain assay specificity to the exogenous rhWNT5A, N = 3. (<bold>D</bold>) Volcano plot of the RNF43 interactome identified by BioID and subsequent mass spectrometric detection (see Materials and methods for details). Significantly enriched proteins annotated as the components of the noncanonical Wnt signaling pathway are highlighted and their log fold change and adjusted p values are presented (<bold>D′</bold>). A full list of BioID-based identified interactors of RNF43 is presented in <xref ref-type="supplementary-material" rid="fig1sdata1">Figure 1—source data 1</xref> and GO terms enrichment analysis in <xref ref-type="supplementary-material" rid="fig1sdata2">Figure 1—source data 2</xref>.</p><p><supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>BioID RNF43 interactors.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-65759-fig1-data1-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig1sdata2"><label>Figure 1—source data 2.</label><caption><title>gProfiler GO terms analysis.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-65759-fig1-data2-v1.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-65759-fig1-v1.tif"/></fig></sec><sec id="s2-2"><title>RNF43 physically interacts with key proteins from the noncanonical Wnt pathway</title><p>To address the molecular mechanism of RNF43 action in the noncanonical Wnt pathway, we decided to describe RNF43 interactome by the proximity-dependent biotin identification (BioID; <xref ref-type="bibr" rid="bib143">Roux et al., 2012</xref>), which was already successfully applied in the challenging identification of E3s substrates (<xref ref-type="bibr" rid="bib33">Coyaud et al., 2015</xref>; <xref ref-type="bibr" rid="bib38">Deshar et al., 2016</xref>). We have exploited our recently published dataset (<xref ref-type="bibr" rid="bib156">Spit et al., 2020</xref>) based on T-REx 293 TetON cells that inducibly expressed RNF43 fused C-terminally (intracellularly) with BirA* biotin ligase. Several core proteins of the noncanonical Wnt signaling pathway – namely, ROR1, ROR2, VANGL1, VANGL2, SEC24B, and all three isoforms of DVL – were strongly and specifically biotinylated by RNF43-BirA* (<xref ref-type="fig" rid="fig1">Figure 1D and D′</xref>, <xref ref-type="supplementary-material" rid="fig1sdata1">Figure 1—source data 1</xref>). Furthermore, the noncanonical Wnt pathway was significantly enriched also in the gene ontology (GO) terms (<xref ref-type="supplementary-material" rid="fig1sdata2">Figure 1—source data 2</xref>). Altogether, it suggests that RNF43 can at least transiently interact with multiple proteins involved in the Wnt/PCP pathway, including essential receptor complex components from the ROR, DVL, and VANGL protein families.</p><p>To validate the protein-protein interactions identified by BioID, we performed a series of co-immunoprecipitation (co-IP) and co-localization experiments (<xref ref-type="fig" rid="fig2">Figure 2</xref>, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>). We have focused on the interactions of RNF43 with ROR1/ROR2 and with VANGL1/VANGL2 mainly because these interactions are novel and at the same time highly relevant for the noncanonical Wnt pathway. RNF43 co-immunoprecipitated with both VANGL2 (<xref ref-type="fig" rid="fig2">Figure 2A</xref>) and VANGL1 (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A</xref>). More detailed analysis of VANGL2 showed co-localization of VANGL2 and RNF43 in the cell membrane (<xref ref-type="fig" rid="fig2">Figure 2B and B′</xref>). RNF43 also efficiently pulled down ROR1 (<xref ref-type="fig" rid="fig2">Figure 2C</xref>) and ROR2 (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1B</xref>). Deletion of the cysteine-rich domain (CRD) (ROR2, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1B</xref>) had no impact on the amount of co-immunoprecipitated RNF43, which suggests that RNF43 primarily interacts with RORs intracellularly. Both ROR1/ROR2 co-localized with RNF43 at the level of the plasma membrane (<xref ref-type="fig" rid="fig2">Figure 2D and D′</xref> and <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1C and C′</xref>). It was described that RORs and VANGLs also bind DVL (<xref ref-type="bibr" rid="bib48">Gao et al., 2011</xref>; <xref ref-type="bibr" rid="bib110">Mentink et al., 2018</xref>; <xref ref-type="bibr" rid="bib153">Seo et al., 2017</xref>; <xref ref-type="bibr" rid="bib183">Witte et al., 2010</xref>; <xref ref-type="bibr" rid="bib187">Yang et al., 2017</xref>) and at the same time DVL proteins mediate ubiquitination of FZD receptors by RNF43 in the Wnt/β-catenin pathway (<xref ref-type="bibr" rid="bib72">Jiang et al., 2015</xref>). To address whether DVL also acts as a physical link between RNF43 and the analyzed PCP proteins, we performed the co-IP experiments with VANGL2 and ROR1 in the T-REx 293 cells lacking all free DVL isoforms (DVL triple knockout cells) (<xref ref-type="bibr" rid="bib128">Paclíková et al., 2017</xref>). As shown in <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1D and E</xref>, RNF43 was able to bind both VANGL2 and ROR1 as efficiently as in the wild-type cells (compare with <xref ref-type="fig" rid="fig2">Figure 2A and D</xref>). In summary, our results indicate that RNF43 interacts, in a DVL-independent way, with PCP proteins from VANGL and ROR families.</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>RNF43 interacts with Wnt/planar cell polarity (PCP) components.</title><p>(<bold>A</bold>) RNF43 interacts with VANGL2, but not with its mutants lacking N- or C-termini. VANGL2-EGFP and its variants (schematized) were overexpressed with RNF43-HA in Hek293 T-REx cells, immunoprecipitated by anti-HA and anti-GFP antibodies and analyzed by western blotting. Representative experiment from N = 3. Scheme illustrates secondary structure of the wild-type VANGL2 protein and its shortened variants used in this study. (<bold>B</bold>, <bold>B′</bold>) RNF43 (anti-HA, red) co-localized with transiently expressed VANGL2 (GFP, green). Co-localization was analyzed utilizing histograms of red, green, and blue channels signals along selection (yellow line) (<bold>B′</bold>). TO-PRO-3 Iodide was used to stain nuclei (blue). Scale bar: 25 μm. (<bold>C</bold>) RNF43 binds to the ROR1 and deletion of the intracellular part of ROR1 disrupts this interaction. RNF43-HA was detected in the ROR1 pull down prepared from lysates of Hek293 T-REx cells overexpressing RNF43-HA and ROR1-V5, N = 3. ROR1 wild-type and truncated mutants are represented in the scheme. (<bold>D</bold>, <bold>D′</bold>) RNF43 (anti-HA, red) co-localized with transiently expressed ROR1-V5 (anti-V5, green). Signals along selection (yellow line) were analyzed (<bold>D′</bold>). TO-PRO-3 was employed nuclei staining (blue). Scale bar: 25 μm. RNF43 interactions with VANGL1 and ROR2 are studied in <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>.</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>RNF43 interacts with Wnt/planar cell polarity (PCP) components.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-65759-fig2-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-65759-fig2-v1.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>RNF43 interacts with Wnt/planar cell polarity (PCP) components.</title><p><bold>A</bold>. RNF43 interacts with VANGL1. VANGL1-Myc was co-immunoprecipitated in the HA pull-down, prepared from lysate of Hek293 T-REx cells transiently overexpressing RNF43-HA and VANGL1-Myc, but not from the lysate containing only VANGL1-Myc overexpressed transgene, N=3. <bold>B</bold>. RNF43 interacts with the ROR2 in the CRD domain dispensable manner. Wild type ROR2 and ΔCRD-ROR2 mutant were detected in HA and FLAG pull downs, prepared from lysates of the Hek293 T-REx cells transiently overexpressing RNF43-HA and ROR2-FLAG or ΔCRD-ROR2, N=3. <bold>C., C’</bold> Exogenous ROR2 (anti-FLAG, green) colocalizes with the RNF43-BirA*-HA (anti-HA, red) in the TetON Hek293 T-Rex cells. DNA was visualized by TO-PRO-3 Iodide. Scale bar represents 25 μm. Co-localization of ROR2 and RNF43 was analyzed utilizing histograms (<bold>C’</bold>) of red, green and blue channels along selection (yellow line). Data is present in the <xref ref-type="supplementary-material" rid="fig2s1sdata1">Figure 2—figure supplement 1—source data 1</xref>. <bold>D</bold>. RNF43 interacts with the VANGL2 in the absence of all three Disheveled isoforms. RNF43 binding to VANGL2 in the DVL1/2/3 deficient cells was confirmed in the two-directional co-IP assay, N=3. <bold>E</bold>. Interaction between ROR1-V5 and RNF43-HA is preserved in the DVL1-3 null cells. ROR1 was detected in the HA pull-down and RNF43 in the V5 immunoprecipitation. T-REx DVL1/2/3 tKO cells were transfected with highlighted plasmids, N=3.</p><p><supplementary-material id="fig2s1sdata1"><label>Figure 2—figure supplement 1—source data 1.</label><caption><title>RNF43 interacts with Wnt/planar cell polarity (PCP) components.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-65759-fig2-figsupp1-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-65759-fig2-figsupp1-v1.tif"/></fig></fig-group></sec><sec id="s2-3"><title>RNF43 ubiquitinates VANGL2 and triggers its degradation</title><p>Since RNF43 is an E3 ubiquitin ligase, we next tested whether it can ubiquitinate its binding partners from the noncanonical Wnt pathway. Enzymatically inactive RNF43 Mut1 variant (<xref ref-type="bibr" rid="bib88">Koo et al., 2012</xref>) served here as a negative control. Using His-ubiquitin pulldown assay, we were able to show that VANGL2 (<xref ref-type="fig" rid="fig3">Figure 3A</xref>), as well as DVL1 and DVL2 (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A</xref>), was ubiquitinated when co-expressed with RNF43 but not with RNF43 Mut1. However, we were unable to detect RNF43-induced ubiquitination of ROR1 or ROR2 (negative data, not shown).</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Mechanism of Wnt/planar cell polarity (PCP) inhibition by RNF43.</title><p>(<bold>A</bold>) Hek293 T-REx cells were transfected with plasmid encoding His-tagged ubiquitin, VANGL2-GFP and HA-tagged wild-type or Mut1 RNF43 constructs. Ubiquitinated proteins were enriched by His pull down and analyzed by western blotting. VANGL2 is ubiquitinylated by the E3 ubiquitin ligase RNF43, but not by its enzymatically inactive variant (RNF43Mut1). Representative experiment from N = 3. RNF43-mediated ubiquitination of DVL1 and DVL2 together in <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>. (<bold>B</bold>) Tetracycline-induced overexpression of the wt RNF43 (HA), but not enzymatically inactive RNF43Mut1 (HA), decreased VANGL2 protein level and suppressed phosphorylation of ROR1 and DVL3 (empty arrowhead; full arrowhead indicates unphosphorylated protein). CRISPR/Cas9-derived <italic>RNF43</italic>/<italic>ZNRF3</italic> (R/Z) dKO cell lines #1 and #2 display phenotype reversed to the RNF43 overexpression. Quantified in <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1B</xref>, N = 3. (<bold>C</bold>) Inhibition of the proteasomal degradation pathway by MG132 (but not by lysosomal inhibitor chloroquine) blocked the RNF43 effects on ROR1, DVL2, DVL3 (empty arrowhead: phosphorylated; full arrowhead indicates unphosphorylated) and VANGL2 as shown by the western blotting analysis, N = 3. (<bold>D</bold>) Flow cytometric analysis of surface ROR1 in wild-type (WT) and <italic>RNF43</italic>/<italic>ZNRF3</italic> (R/Z) dKO cells; unpaired two-tailed t-test: p=0.0298, N = 4. ROR1 was stained using ROR1-APC conjugate on the nonpermeabilized cells. Validation of the a-ROR1-APC antibody is shown in <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1D</xref>. (<bold>E</bold>, <bold>E′</bold>’) Surface ROR1 levels upon 3 hr and overnight (ON) induction of RNF43 in RNF43 TetON <italic>RNF43</italic>/<italic>ZNRF3</italic> dKO cells; unpaired t-test p&lt;0.0001, N = 6. Representative histogram of ROR1-APC signal in the analyzed conditions is shown (<bold>E′</bold>). (<bold>F</bold>) Dansylcadaverine, inhibitor of clathrin-mediated endocytosis, blocked the effect of RNF43 overexpression on surface ROR1, performed as in (<bold>E</bold>); unpaired t-test p=0.0037 3 hr Tet. vs 3 hr Tet.+ dansylcadaverine; N = 5 and 6 (3 hr Tet. condition). (<bold>G</bold>) Immunofluorescence imaging showed enhanced ROR1 (anti-V5, magenta) co-localization with the marker of early endosomes RAB5 (GFP, green) after 3 hr tetracycline treatment in RNF43 TetON <italic>RNF43</italic>/<italic>ZNRF3</italic> dKO cells. RAB11-positive (GFP, green) recycling endosomes were recruited to the ROR1 (anti-V5, magenta) at the plasma membrane after overnight tetracycline treatment. Cells were transfected, treated, fixed, and stained. DNA was visualized by Hoechst 33342 (blue). Other tetracycline time points are shown in <xref ref-type="fig" rid="fig3s3">Figure 3—figure supplement 3A</xref>. Similar results were obtained for T-REx RNF43 TetON cell line (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1E</xref>). Raw data used in (<bold>D–F</bold>) are given in <xref ref-type="supplementary-material" rid="fig3sdata1">Figure 3—source data 1</xref>.</p><p><supplementary-material id="fig3sdata1"><label>Figure 3—source data 1.</label><caption><title>Mechanism of Wnt/planar cell polarity (PCP) inhibition by RNF43.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-65759-fig3-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-65759-fig3-v1.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Mechanism of Wnt/planar cell polarity (PCP) inhibition by RNF43.</title><p>(<bold>A</bold>) DVL1 and DVL2 are ubiquitinylated by the E3 ubiquitin ligase RNF43, but not by its enzymatically inactive mutant (RNF43Mut1). Hek293 T-REx cells were transfected with plasmid encoding His-tagged ubiquitin, DVL1-FLAG or DVL2-FLAG, and wild-type or Mut1 RNF43 constructs and subjected to His-tag pull down and subsequent western blotting. N = 3. (<bold>B</bold>) Quantification of western blots from <xref ref-type="fig" rid="fig3">Figure 3B</xref>. Unpaired two-tailed t-test, *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, N = 3. (<bold>C</bold>) Western blotting showing the lack of ROR1 protein in the T-REx 293 <italic>ROR1</italic> KO cell lines. (<bold>D</bold>) T-REx <italic>ROR1</italic> KO line was used for validation of the ROR1-APC antibody used for the flow cytometric determination of the ROR1 cell surface level. (<bold>E</bold>) Immunofluorescence imaging of enhanced ROR1 (anti-V5, magenta) co-localization with marker of early endosomes RAB5 (GFP, green) after 3 hr of tetracycline treatment in the T-REx RNF43 TetON cell line. RAB11 (GFP, green) was recruited to the ROR1 at plasma membrane upon overnight tetracycline exposition. DNA was visualized by Hoechst 33342 (blue). Scale bars represent 10 µm. Cells were treated 24 hr post-transfection for indicated time points. Images representing RAB5 control and ON tetracycline treatment together with RAB11 control and 3 hr tetracycline conditions are presented in <xref ref-type="fig" rid="fig3s3">Figure 3—figure supplement 3B</xref>. Data presented in (<bold>B</bold>) is presented in <xref ref-type="supplementary-material" rid="fig3s1sdata1">Figure 3—figure supplement 1—source data 1</xref>.</p><p><supplementary-material id="fig3s1sdata1"><label>Figure 3—figure supplement 1—source data 1.</label><caption><title>Mechanism of Wnt/planar cell polarity (PCP) inhibition by RNF43.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-65759-fig3-figsupp1-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-65759-fig3-figsupp1-v1.tif"/></fig><fig id="fig3s2" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 2.</label><caption><title>Mechanism of Wnt/planar cell polarity (PCP) inhibition by RNF43.</title><p>(<bold>A</bold>) Tetracycline-induced RNF43 (anti-HA, green) co-localized with transiently expressed lysosomal marker (Lamp1-mCherry, red). TO-PRO-3 Iodide was used to stain nuclei (blue). Scale bar: 25 μm. (<bold>B</bold>) Transiently overexpressed VANGL2 (GFP, green) and lysosomal marker (Lamp1-mCherry, red) in the presence and absence of tetracycline-induced RNF43 (anti-HA, magenta). Hoechst 33342 was used to stain nuclei (blue). Scale bar: 10 μm. (<bold>C</bold>) Tetracycline-forced expression of RNF43 (anti-HA, magenta) caused retention of VANGL2 (GFP, green) in Golgi complex (anti-endogenous Golgin-97, red). DAPI was used to stain nuclei (blue). Scale bar: 10 μm.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-65759-fig3-figsupp2-v1.tif"/></fig><fig id="fig3s3" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 3.</label><caption><title>Mechanism of Wnt/planar cell polarity (PCP) inhibition by RNF43.</title><p>(<bold>A, B</bold>) Confocal imaging of the inducible T-REx <italic>RNF43</italic>/<italic>ZNRF3</italic> dKO (<bold>A</bold>) and T-REx WT RNF43 TetON (<bold>B</bold>) and transfected with plasmids encoding ROR1-V5 (anti-V5, magenta) and RAB11-GFP-HA (GFP, green). 24 hr post-transfection, cells were treated with tetracycline for indicated time and then paraformaldehyde fixed, permeabilized, and stained for ROR1 (anti-V5) and nuclei detection (DAPI, blue). Scale bars represent 10 μm. Other tetracycline time points are presented in <xref ref-type="fig" rid="fig3">Figure 3</xref> and <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-65759-fig3-figsupp3-v1.tif"/></fig></fig-group><p>Further analysis showed that overexpression of RNF43, but not its E3 ligase dead variant, decreased VANGL2 protein level (<xref ref-type="fig" rid="fig3">Figure 3B</xref>, quantified in <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1B</xref>). Decrease in VANGL2 caused by RNF43 was accompanied by impeded phosphorylation of ROR1 (<xref ref-type="fig" rid="fig3">Figure 3B</xref>) and DVL3 (<xref ref-type="fig" rid="fig3">Figure 3B</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1B</xref>). On the other side, two independent clones of cells deficient in both RNF43 and ZNRF3 (<italic>RNF43</italic>/<italic>ZNRF3</italic> dKO; <italic>R</italic>/<italic>Z</italic> dKO) showed higher VANGL2 levels and higher DVL phosphorylation (<xref ref-type="fig" rid="fig3">Figure 3B</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1B</xref>). These confirm that also endogenous RNF43/ZNRF3 module affects the noncanonical Wnt signaling. Interestingly, treatment with the proteasome inhibitor MG132 but not with autophagosome-lysosome inhibitor chloroquine blocked these effects of RNF43 (<xref ref-type="fig" rid="fig3">Figure 3C</xref>). This suggests that RNF43 action in the noncanonical Wnt pathway depends on the proteasomal degradation pathway, which differs from the Wnt/β-catenin pathway, where RNF43 triggers FZD degradation via the lysosomal pathway (<xref ref-type="bibr" rid="bib88">Koo et al., 2012</xref>). This is in accordance with immunofluorescence analysis, which did not show an increased co-localization of VANGL2 and RNF43 in lysosomes (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2B</xref>). However, RNF43 overexpression led to the retention of VANGL2 in the Golgin-97-positive area (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2C</xref>). This suggests that RNF43 can act via similar mechanism that was described for WNT5A-induced regulation of VANGL2 plasma membrane localization during planar cell polarity maintenance (<xref ref-type="bibr" rid="bib45">Feng et al., 2021</xref>; <xref ref-type="bibr" rid="bib53">Guo et al., 2013</xref>; <xref ref-type="bibr" rid="bib168">Tower-Gilchrist et al., 2019</xref>; <xref ref-type="bibr" rid="bib187">Yang et al., 2017</xref>).</p></sec><sec id="s2-4"><title>RNF43 induces ROR1 endocytosis by a clathrin-dependent pathway</title><p>ROR1 and ROR2 are the key receptors for WNT5A that we found to interact with RNF43 (<xref ref-type="fig" rid="fig1">Figures 1</xref> and <xref ref-type="fig" rid="fig2">2</xref>). We thus speculated that RNF43 can regulate ROR1/ROR2 surface levels. T-REx cells express dominantly ROR1, and indeed flow cytometric analysis demonstrated that cell lacking endogenous RNF43 and ZNRF3 have more ROR1 receptor on the surface than parental T-REx cells (<xref ref-type="fig" rid="fig3">Figure 3D</xref>). The staining is specific as demonstrated by the validation of the ROR1-APC antibody in <italic>ROR1</italic> KO T-REx 293 cells (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1C and D</xref>). When we introduced inducible RNF43 into <italic>RNF43</italic>/<italic>ZNRF3</italic> dKO T-REx cell line, we were able to rescue this phenotype, and after 3 hr of tetracycline treatment, we detected decreased surface ROR1 and the overnight exposition to tetracycline had no significant effect (<xref ref-type="fig" rid="fig3">Figure 3E and E′</xref>).</p><p>In our analysis of RNF43 interactors (<xref ref-type="fig" rid="fig1">Figure 1D</xref>), we identified also multiple proteins involved in endosomal transport. It included proteins involved in the clathrin endocytic pathway – STAM1, HRS, ZFYVE16, PICALM, NUMB, RAB11-FIP2, and subunits of the associated adaptor protein complexes AP-3 and AP-4 (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>; <xref ref-type="bibr" rid="bib14">Bache et al., 2003</xref>; <xref ref-type="bibr" rid="bib34">Cullis et al., 2002</xref>; <xref ref-type="bibr" rid="bib62">Hirst et al., 2013</xref>; <xref ref-type="bibr" rid="bib137">Raiborg et al., 2001</xref>; <xref ref-type="bibr" rid="bib149">Santolini et al., 2000</xref>; <xref ref-type="bibr" rid="bib151">Seet and Hong, 2005</xref>; <xref ref-type="bibr" rid="bib165">Tebar et al., 1999</xref>). Based on the BioID results analysis, we speculated that RNF43 may promote clathrin-mediated endocytosis of ROR1. Thus, we applied dansylcadaverine to block this pathway (<xref ref-type="bibr" rid="bib20">Blitzer and Nusse, 2006</xref>). In agreement with our hypothesis, treatment with this inhibitor prevented RNF43-mediated effect on the ROR1 surface expression in T-REx 293 RNF43/ZNRF3 dKO RNF43 TetON cells (<xref ref-type="fig" rid="fig3">Figure 3F</xref>).</p><p>To get a better insight into the mechanism of RNF43-induced internalization of ROR1, we analyzed the co-localization of ROR1 and RAB5 (marker of early endosomes) and RAB11 (marker of recycling endosomes) in T-REx 293 R/Z dKO RNF43 TetON (<xref ref-type="fig" rid="fig3">Figure 3G</xref> and <xref ref-type="fig" rid="fig3s3">Figure 3—figure supplement 3A</xref>) and T-REx 293 RNF43 TetON cells (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1E</xref> and <xref ref-type="fig" rid="fig3s3">Figure 3—figure supplement 3B</xref>). Hyperactivation of Rab5 by overexpression of wild-type Rab5 leads to the formation of giant early endosomes (<xref ref-type="bibr" rid="bib25">Bucci et al., 1992</xref>) where we observed ROR1/RAB5 co-localization after 3 hr of tetracycline treatment. The co-localization decreased after overnight exposition to tetracycline. RAB11<sup>+</sup> endosomes were recruited to the ROR1 as well as after RNF43 induction and RAB11 co-localized strongly with ROR1 even after ON treatment. We conclude that surface ROR1 is controlled by RNF43 via interference with RAB5- and RAB11-mediated endocytosis and RNF43-mediated effect is not persistent due to the activity of recycling RAB11 recycling pathway (<xref ref-type="bibr" rid="bib172">Ullrich et al., 1996</xref>).</p></sec><sec id="s2-5"><title>RNF43 expression is decreased in human melanoma</title><p>Our data shown in <xref ref-type="fig" rid="fig1">Figures 1</xref>—<xref ref-type="fig" rid="fig3">3</xref> demonstrate that RNF43 can inhibit WNT5A-induced noncanonical signaling via downregulation of the receptor complexes. But is RNF43 capable of blocking WNT5A-induced biological processes? WNT5A signaling plays a crucial role in melanoma, one of the most malignant tumor types. High expression of <italic>WNT5A</italic> in this cancer is a negative overall survival and positive metastasis formation factor (<xref ref-type="bibr" rid="bib35">Da Forno et al., 2008</xref>; <xref ref-type="bibr" rid="bib102">Luo et al., 2020</xref>; <xref ref-type="bibr" rid="bib181">Weeraratna et al., 2002</xref>). Signaling cascade activated by WNT5A in melanoma drives epithelial–mesenchymal transition-like program (EMT), resulting in increased metastatic properties of melanoma cells in vitro and in vivo (<xref ref-type="bibr" rid="bib41">Dissanayake et al., 2008</xref>; <xref ref-type="bibr" rid="bib40">Dissanayake et al., 2007</xref>; <xref ref-type="bibr" rid="bib145">Sadeghi et al., 2018</xref>). In melanoma, WNT5A acts through FZD and ROR1/ROR2 (<xref ref-type="bibr" rid="bib126">O’Connell et al., 2010</xref>; <xref ref-type="bibr" rid="bib167">Tiwary and Xu, 2016</xref>; <xref ref-type="bibr" rid="bib181">Weeraratna et al., 2002</xref>). The importance of WNT5A-driven signaling in melanoma is thus well recognized, and melanoma represents probably the most characterized (and most clinically relevant) pathophysiological condition where noncanonical WNT5A signaling drives cell invasion and disease progression (<xref ref-type="bibr" rid="bib9">Arozarena and Wellbrock, 2017b</xref>; <xref ref-type="bibr" rid="bib35">Da Forno et al., 2008</xref>; <xref ref-type="bibr" rid="bib40">Dissanayake et al., 2007</xref>; <xref ref-type="bibr" rid="bib94">Lai et al., 2012</xref>; <xref ref-type="bibr" rid="bib100">Liu et al., 2018</xref>; <xref ref-type="bibr" rid="bib126">O’Connell et al., 2010</xref>; <xref ref-type="bibr" rid="bib124">O’Connell et al., 2008</xref>; <xref ref-type="bibr" rid="bib181">Weeraratna et al., 2002</xref>).</p><p>Interestingly, the in silico analysis of gene expression (<xref ref-type="bibr" rid="bib162">Talantov et al., 2005</xref>; <xref ref-type="bibr" rid="bib185">Xu et al., 2008</xref>) showed that <italic>RNF43</italic> expression dramatically decreases between benign melanocytic skin nevus and cutaneous melanoma (<xref ref-type="fig" rid="fig4">Figure 4A</xref>; <xref ref-type="bibr" rid="bib162">Talantov et al., 2005</xref>) and further between primary site and metastasis (<xref ref-type="bibr" rid="bib185">Xu et al., 2008</xref>; <xref ref-type="fig" rid="fig4">Figure 4B</xref>). Importantly, analysis of other datasets (<xref ref-type="bibr" rid="bib4">Anaya, 2016</xref>) showed that <italic>RNF43</italic> low melanoma patients have shorter overall survival (OS; <xref ref-type="fig" rid="fig4">Figure 4C</xref>). <italic>ZNRF3</italic> expression had no prognostic value (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A</xref>). Interestingly, the expression of two genes encoding direct targets ubiquitinated by RNF43, namely, <italic>DVL3</italic> and <italic>VANGL1</italic>, increased during melanoma progression (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1B and C</xref>) and high expression in both cases correlates with bad prognosis and shorter overall survival (<xref ref-type="fig" rid="fig4">Figure 4D</xref>, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1D</xref>). All these findings are in line with the hypothesis that RNF43 acts in melanoma as a tumor suppressor that restricts WNT5A-induced biological processes and gets silenced during melanoma progression.</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>RNF43 in melanoma.</title><p>(<bold>A</bold>, <bold>B</bold>) <italic>RNF43</italic> expression is lower in melanoma when compared with the skin and benign melanocytic skin nevus (<bold>A</bold>) and in the case of distant metastasis compared to the primary tumors (<bold>B</bold>), unpaired two-tailed t-test: ****p&lt;0.0001. (<bold>C, D</bold>) <italic>RNF43</italic> expression is a negative prognostic factor in melanoma. <italic>RNF43</italic> low patients have shorter overall survival (logrank p-value=0.0311). Contrary, patients with low-expression <italic>VANGL1</italic> (<bold>D</bold>) had longer survival (logrank test, p-value=0.00518). Expression of <italic>DVL3</italic>, <italic>VANGL1</italic>,and <italic>ZNRF3</italic> is analyzed in <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A–D</xref>. (<bold>E</bold>,<bold> E′, E′′</bold>) Culture media from melanoma A375, A375 IV, and A2058 cell lines were collected after 48 hr and analyzed by western blotting for the presence of WNT5A (<bold>E′</bold>) and WNT11 (<bold>E′′</bold>). Densitometric analysis has been done using the ImageJ software. Graphs represent ratio of corresponding WNT (medium) and β-actin (lysate) signals. Unpaired two-tailed t-test: p=0.0092 (<bold>E′</bold>); 0.0320 and 0.0001 (<bold>E′′</bold>); N = 3. (<bold>F</bold>) Schematic representation of the melanoma cell lines and their genetically modified variants used in this study. (<bold>G</bold>) Effects of the stable RNF43 overexpression and <italic>RNF43</italic>/<italic>ZNRF3</italic> knockout in A375 and in its invasive derivate A375 IV. Exogenous RNF43 expression blocked DVL2 and DVL3 activation (arrowheads showing phosphorylation-dependent change of the electrophoretic mobility). Removal of endogenous RNF43 and ZNRF3 proteins had an opposite effect, N = 6. Quantification is given in <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1E,F</xref>. Expression of <italic>WNT5A</italic>, <italic>RNF43</italic>, <italic>ZNRF3</italic>, <italic>ROR1</italic>, <italic>DVL2,</italic> and DVL3 in tested cell lines was checked and shown in <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2</xref>. (<bold>H–J</bold>) Western blot showing inhibitory effect of RNF43 on A375 (<bold>H</bold>), A375 IV (<bold>I</bold>), and A2058 RNF43 TetON (<bold>J</bold>) cell lines in response to the 40 and 80 ng/ml 3 hr-long rhWNT5A treatments. <italic>RNF43</italic>/<italic>ZNRF3</italic> dKO A375 (<bold>H</bold>), A375 IV (<bold>I</bold>) cell lines had stronger response to rhWNT5A than parental line. β-actin served as a loading control. Empty arrowhead: phosphorylated; full arrowhead: unphosphorylated protein. Porcupine inhibitor LGK-974 was used to block endogenous Wnt ligands secretion and RNF43 was probed by HA antibody, N = 3 and N = 4 (A2058). Quantification of DVL2 and DVL3 activation status and their protein levels in A2058 cells is given in <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1G and H</xref>. <xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3</xref> presents rhWNT5A treatment and consequences of RNF43-induced expression in RAS-mutant melanoma cell line MelJuso (<bold>A</bold>) and A375 (<bold>B</bold>) together with isogenic control (<bold>C</bold>). <xref ref-type="supplementary-material" rid="fig4sdata1">Figure 4—source data 1</xref> contains raw data.</p><p><supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>RNF43 in melanoma.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-65759-fig4-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-65759-fig4-v1.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>RNF43 in melanoma.</title><p>(<bold>A</bold>) <italic>ZNRF3</italic> gene expression has no impact on melanoma patients’ survival (logrank p-value=0.897). (<bold>B</bold>) <italic>DVL3</italic> expression level is elevated in human melanoma, unpaired two-tailed t-test, *p=0,0159, ****p&lt;0.0001. (<bold>C</bold>) <italic>VANGL1</italic> is more expressed in the metastasis than in primary melanoma, unpaired two-tailed t-test, p=0.0241. (<bold>D</bold>) High expression of <italic>DVL3</italic> is a negative prognostic factor (50% lower and 50% upper percentiles). Logrank p-value=0.0269. (<bold>E</bold>, <bold>F</bold>) Quantification of western blots presented in <xref ref-type="fig" rid="fig4">Figure 4G</xref>. Exogenous RNF43 expression blocked in both tested cell lines DVL2 (<bold>E</bold>) DVL3 (<bold>F</bold>) phosphorylation-dependent shifts. CRISPR/Cas9-mediated knockout of <italic>RNF43</italic>/<italic>ZNRF3</italic> resulted in the more activated DVL2 and DVL3 isoforms in case A375 IV cell line. Data were normalized to 1 for the parental cell lines values, unpaired two-tailed t-test: *p&lt;0.05, **p&lt;0.01, ***p&lt;0.01, ****p&lt;0.0001, N = 6 (<bold>F</bold> – A375 IV R/Z dKO N = 5). Total DVL2 and DVL3 protein levels accompanied by <italic>WNT5A</italic>, <italic>RNF43</italic>, <italic>ZNRF3</italic>, <italic>ROR1</italic>, <italic>DVL2,</italic> and <italic>DVL3</italic> genes expression analysis are presented in <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2</xref>. (<bold>G, H</bold>) Phosphorylation and total protein levels of DVL2 (<bold>G</bold>) and DVL3 (<bold>H</bold>) in A2058 cells inducibly overexpressing RNF43, unpaired two-tailed t-test: ****p&lt;0.0001, N = 4. Western blots are presented in <xref ref-type="fig" rid="fig4">Figure 4J</xref>. <xref ref-type="supplementary-material" rid="fig4s1sdata1">Figure 4—figure supplement 1—source data 1</xref> contains raw results.</p><p><supplementary-material id="fig4s1sdata1"><label>Figure 4—figure supplement 1—source data 1.</label><caption><title>RNF43 in melanoma.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-65759-fig4-figsupp1-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-65759-fig4-figsupp1-v1.tif"/></fig><fig id="fig4s2" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 2.</label><caption><title>RNF43 in melanoma.</title><p>(<bold>A</bold>–<bold>D</bold>) RT-qPCR results – expression of the <italic>WNT5A</italic> (<bold>A</bold>), <italic>RNF43</italic> (<bold>B</bold>), <italic>ZNRF3</italic> (<bold>C</bold>), and <italic>ROR1</italic> (<bold>D</bold>) genes was analyzed in the tested melanoma cells and presented as 2<sup>−ΔΔCt</sup> ± SD, two-tailed t-test: *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001; N = 3 (A375 N = 2 for <bold>A</bold> and <bold>B</bold>). Relative expression level was normalized to the <italic>B2M</italic> and <italic>GAPDH</italic> genes expression. (<bold>E, F</bold>) Western blot quantification results (<xref ref-type="fig" rid="fig4">Figure 4G</xref>) showing total levels of DVL2 (<bold>E</bold>) and DVL3 (<bold>F</bold>) not affected by RNF43 overexpression, nor by <italic>RNF43</italic>/<italic>ZNRF3</italic> knockout. DVL3 protein level decreased only in the case of A375 <italic>R</italic>/<italic>Z</italic> dKO cells (<bold>F</bold>), unpaired two-tailed t-test: ***p&lt;0.001, N = 3. Results were normalized to the A375 values. (<bold>G, H</bold>). RT-qPCR analysis of <italic>DVL2</italic> (<bold>G</bold>) and <italic>DVL3</italic> (<bold>H</bold>) genes expression in A375, A375 IV cell lines and their derivates. Relative expression level was normalized to the <italic>B2M</italic> and <italic>GAPDH</italic> genes expression values and presented as 2<sup>−ΔΔCt</sup> ± SD. Data used in (<bold>A–G</bold>) is presented in <xref ref-type="supplementary-material" rid="fig4s2sdata1">Figure 4—figure supplement 2—source data 1</xref>. (<bold>I</bold>–<bold>M</bold>) Expression analysis of <italic>WNT5A</italic> (<bold>I</bold>), <italic>RNF43</italic> (<bold>J</bold>), <italic>ZNRF3</italic> (<bold>K</bold>), <italic>ROR1</italic> (<bold>L</bold>), and <italic>ROR2</italic> (<bold>M</bold>) genes in A2058 cells. Relative expression levels are presented as 2<sup>−ΔΔCt</sup> ± SD and normalized to the levels of <italic>B2M</italic> and <italic>GAPDH</italic> genes.</p><p><supplementary-material id="fig4s2sdata1"><label>Figure 4—figure supplement 2—source data 1.</label><caption><title>RNF43 in melanoma.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-65759-fig4-figsupp2-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-65759-fig4-figsupp2-v1.tif"/></fig><fig id="fig4s3" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 3.</label><caption><title>RNF43 in melanoma.</title><p>(<bold>A-A’’, B-B’’</bold>) Effects of the inducible RNF43 overexpression in RAS-mutant MelJuso (<bold>A</bold>) and BRAF V600E A375 (<bold>B</bold>) cells. Exogenous RNF43 expression blocked response to the 40 and 80 ng/ml 3 hr-long rhWNT5A treatments. Porcupine inhibitor LGK-974 was used to block endogenous Wnt ligands secretion and RNF43 was probed by HA antibody. β-actin is shown as a loading control. Phosphorylation status and total protein level of DVL2 (<bold>A’ B’</bold>) and DVL3 (<bold>A’’, B’’</bold>) were quantified, unpaired t-test *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, N = 3. Results were normalized to 1, for the ‘DOX-’ condition. (<bold>C</bold>) Western blot analysis of control to A375 RNF43 TetON cell line. Cells were treated with doxycycline and Porcupine inhibitor LGK-974 for cells validation. <xref ref-type="supplementary-material" rid="fig4s3sdata1">Figure 4—figure supplement 3—source data 1</xref> file presents raw data. Empty arrowhead: phosphorylated; full arrowhead: unphosphorylated protein.</p><p><supplementary-material id="fig4s3sdata1"><label>Figure 4—figure supplement 3—source data 1.</label><caption><title>RNF43 in melanoma.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-65759-fig4-figsupp3-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-65759-fig4-figsupp3-v1.tif"/></fig></fig-group></sec><sec id="s2-6"><title>RNF43 inhibits invasive properties of melanoma cells in vitro</title><p>A375 and A2058 are human melanoma cell lines carrying BRAF V600E mutations that are broadly used to study WNT5A role in melanoma (<xref ref-type="bibr" rid="bib3">Anastas et al., 2014</xref>; <xref ref-type="bibr" rid="bib32">Connacher et al., 2017</xref>; <xref ref-type="bibr" rid="bib35">Da Forno et al., 2008</xref>; <xref ref-type="bibr" rid="bib43">Ekström et al., 2014</xref>; <xref ref-type="bibr" rid="bib99">Linnskog et al., 2016</xref>; <xref ref-type="bibr" rid="bib100">Liu et al., 2018</xref>). For the purpose of our study, we chose A375 wild-type (A375) cells and their derivate with the increased metastatic potential referred to as A375 IV (<xref ref-type="bibr" rid="bib92">Kucerova et al., 2014</xref>). Both A375 variants and A2058 express <italic>WNT5A</italic>, <italic>RNF43,</italic> and <italic>ZNRF3</italic> (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2A–C, I–K</xref>). A375 and A375 IV secrete WNT5A and WNT11 to the culture medium, whereas A2058 produces only WNT11 (<xref ref-type="fig" rid="fig4">Figure 4E</xref>). WNT5A protein levels are higher and WNT11 levels lower in case of A375 IV metastatic derivate in comparison to parental A375 cell line (<xref ref-type="fig" rid="fig4">Figure 4E′ and E′′</xref>). Interestingly, <italic>RNF43</italic> expression in the A375 IV cells was significantly lower than that in the A375 parental cells (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2B</xref>). Expression of <italic>ZNRF3</italic> did not differ and it was not affected by RNF43 overexpression (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2C</xref>). Further, A375 line has lower expression of <italic>ROR1</italic> than IV derivate (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2D</xref>). A2058 cells are <italic>ROR1</italic> and <italic>ROR2</italic> positive with <italic>ROR1</italic> level being higher (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2L and M</xref>).</p><p>To study the RNF43 function, we generated A375 cells lacking <italic>RNF43/ZNRF3</italic> (<italic>R</italic>/<italic>Z</italic> dKO) by CRISPR/Cas9 method (sequencing results are presented in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>), cells stably overexpressing RNF43 (RNF43 OE) as well as A375, A2058, and additionally NRAS<sup>Q61L/WT</sup> HRAS<sup>G13D/G13D</sup> MelJuso -based doxycycline-inducible RNF43 TetON lines (<xref ref-type="fig" rid="fig4">Figure 4F</xref>). The initial characterization of A375 derivatives essentially confirmed the findings from T-REx 293 (see <xref ref-type="fig" rid="fig1">Figure 1</xref>), where RNF43 loss- and gain of function correlated strongly with the level of Wnt pathway activation assessed as DVL phosphorylation (<xref ref-type="fig" rid="fig4">Figure 4G</xref>, quantified in <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1E and F</xref>). Total protein levels of DVL2, DVL3, as well as expression of their genes remained unaffected by the RNF43 manipulation (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2E–H</xref>). Similarly to T-REx 293 cells, in A375 (<xref ref-type="fig" rid="fig4">Figure 4H</xref>), A375 IV (<xref ref-type="fig" rid="fig4">Figure 4I</xref>), and A2058 (<xref ref-type="fig" rid="fig4">Figure 4J</xref> and quantified effect of RNF43 OE on the endogenous WNT pathway activity in <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1G and H</xref>) melanoma cells RNF43 overexpression efficiently blocked WNT5A-induced signaling. To extend the importance of our studies further, we tested the RNF43-mediated effect also in the <italic>RAS</italic>-mutant MelJuso cells. Here we also confirmed the suppression of ROR1, DVL2, and DVL3 shifts by forced RNF43 expression (<xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3A</xref>). Inducible model of A375 RNF43 TetON cells drew a similar picture (<xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3B</xref>), compared to the control cells that underwent the same procedures (<xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3C</xref>).</p><p>WNT5A signaling has been related to numerous biological features that support the invasive properties of melanoma (<xref ref-type="bibr" rid="bib9">Arozarena and Wellbrock, 2017b</xref>; <xref ref-type="bibr" rid="bib125">O’Connell and Weeraratna, 2009</xref>; <xref ref-type="bibr" rid="bib134">Prasad et al., 2015</xref>; <xref ref-type="bibr" rid="bib181">Weeraratna et al., 2002</xref>). To address if RNF43 affects any of these WNT5A-controlled properties, we have compared parental and RNF43-derivative melanoma cells in a panel of functional assays that included (1) wound healing assay, (2) collagen I hydrogel 3D chemotaxis assay, (3) Matrigel invasion assay, (4) invadopodia formation assay, and (5) gelatin degradation assay. Firstly, all A375, A375 IV, and A2078 cells overexpressing RNF43 showed suppressed 2D collective migration in the wound healing assay (<xref ref-type="fig" rid="fig5">Figure 5A–E</xref>). Next, we analyzed the impact of RNF43 expression on directional invasion through the collagen I hydrogel in response to chemokines. This assay mimics the taxis of melanoma cells in body: CCL21 drives lymph nodes metastasis and CXCL12 promotes lung invasion (<xref ref-type="fig" rid="fig5">Figure 5F</xref>; <xref ref-type="bibr" rid="bib68">Jacquelot et al., 2018</xref>; <xref ref-type="bibr" rid="bib109">McArdle et al., 2016</xref>). A375 IV and A2058 cell lines showed significant response to these treatments and RNF43 blocked completely these invasion events (<xref ref-type="fig" rid="fig5">Figure 5G and H</xref>). Importantly, the response of A375 cells in this assay was negligible (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1B</xref>), confirming their decreased metastatic capacity compared to the A375 IV. In line, invasion of individual cells through the extracellular matrix (ECM) mimicking Matrigel was higher in A375 IV in comparison to A375 but in both cases reduced by RNF43 OE (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1D</xref>). The same is true for the number of invadopodia-specialized structures mediating adhesion and remodeling of the surrounding ECM (<xref ref-type="bibr" rid="bib42">Eddy et al., 2017</xref>; <xref ref-type="bibr" rid="bib106">Masi et al., 2020</xref>). A375 IV cells formed more invadopodia than A375 parental cells (<xref ref-type="fig" rid="fig5">Figure 5I</xref>) and cells overexpressing RNF43 formed less of them (<xref ref-type="fig" rid="fig5">Figure 5I</xref>). In agreement, we also observed reduced gelatin degradation activity in A375 and A375 IV cells overexpressing RNF43 (<xref ref-type="fig" rid="fig5">Figure 5J</xref>). Furthermore, treatment with WNT5A enhanced the gelatin degradation capacity of A375 cells, but not their RNF43-overexpressing derivate (<xref ref-type="fig" rid="fig5">Figure 5J</xref>). Representative images from the conducted assays are shown in <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>, <xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2</xref>, <xref ref-type="fig" rid="fig5s3">Figure 5—figure supplement 3</xref>, <xref ref-type="fig" rid="fig5s4">Figure 5—figure supplement 4</xref>. All these assays strongly support the conclusion that RNF43 acts as a strong molecular inhibitor of WNT5A-triggered proinvasive features of melanoma. Interestingly, <italic>RNF43</italic>/<italic>ZNFR3</italic> removal did not lead to significant potentiation in these functional assays, which suggests that the noncanonical Wnt pathway-controlled pro-metastatic features of these cells are already close to its maximum. In agreement, treatment with WNT5A showed the effect only in case A375 cells in the gelatin degradation assay (<xref ref-type="fig" rid="fig5">Figure 5J</xref>).</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>RNF43 inhibits WNT5A-dependent invasive properties of human melanoma.</title><p>(<bold>A</bold>–<bold>E</bold>) RNF43 reduced migration of A375 (<bold>B</bold>), A375 RNF43 TetON (<bold>C</bold>), A375 IV (<bold>D</bold>), and A2058 RNF43 TetON (<bold>E</bold>) in the wound healing assay. Wound was photographed 48 hr after scratch and presented as % of cell-free surface at the end of the experiment. Cells proliferation was suppressed by serum starvation, unpaired two-tailed t-test: *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, N = 3 (<bold>B, D</bold>) or 4 (<bold>C, E</bold>). Representative photos at the end of the experiment are shown in (<bold>A</bold>) and in <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A</xref>. (<bold>F–H</bold>) RNF43 blocked collagen I hydrogel 3D invasion in response to CCL21 (100 ng/ml) and CXCL12 (100 ng/ml) of A375 IV (<bold>G</bold>) and A2058 (<bold>H</bold>) cell lines. Cells were serum starved, collagen I (1.5 mg/ml) was overlaid and polymerized. Doxycycline was applied for RNF43 induction during starvation. After 24 hr, cells were fixed and stained for DNA (Hoechst 33342, blue) and F-actin (phalloidin, red) and imaged by confocal microscopy. Invasion index was calculated as the ratio of invaded cells at specified height to the number of noninvasive cells at the glass level, unpaired two-tailed t-test: **p&lt;0.01, ****p&lt;0.0001, N = 3 (<bold>G</bold>) or N = 4 (<bold>H</bold>). A375 cells did not invaded collagen I hydrogel (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1B</xref>). Representative photos are presented in <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1C and C′</xref>. (<bold>I</bold>) RNF43 overexpression in A375 and A375 IV decreased number of invadopodia. Quantification of the invadopodia formed by melanoma cells, based on the analysis of confocal images. Number of cortactin/F-actin double-positive puncta in the individual cells was calculated in the ImageJ software, unpaired two-tailed t-test: ***p&lt;0.001, ****p&lt;0.0001. Examples of confocal imaging are shown: green, phalloidin; red, cortactin; blue, DNA. See <xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2</xref> for images from all experimental conditions. (<bold>J</bold>) Gelatin degradation assay; both A375 and A375 IV RNF43-overexpressing cell lines showed decreased capacity to locally degrade the extracellular matrix. rhWNT5A treatment induced gelatin degradation by A375 cells. Serum-starved cells were plated onto gelatin-Oregon Green-coated coverslips and incubated for 24 hr. Images obtained by Leica SP8 confocal microscope were analyzed for the presence of gelatin degradation by individual cells using ImageJ software, unpaired two-tailed t-test: *p&lt;0.05, **p&lt;0.01, N = 3. Example of gelatin degradation is shown; more pictures are presented in <xref ref-type="fig" rid="fig5s3">Figure 5—figure supplement 3</xref> and <xref ref-type="fig" rid="fig5s4">Figure 5—figure supplement 4</xref>. Numerical data are given in <xref ref-type="supplementary-material" rid="fig5sdata1">Figure 5—source data 1</xref> file.</p><p><supplementary-material id="fig5sdata1"><label>Figure 5—source data 1.</label><caption><title>RNF43 inhibits WNT5A-dependent invasive properties of human melanoma.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-65759-fig5-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-65759-fig5-v1.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>RNF43 inhibits Wnt5a-dependent invasive properties of human melanoma.</title><p>(<bold>A</bold>) Wound healing experiment – representative photos at the experimental end point (data <xref ref-type="fig" rid="fig5">Figure 5B–E</xref>). (<bold>B</bold>) Collagen I hydrogel chemotaxis assay A375 cell line results. After 24 hr, cells did not significantly respond to the treatments, unpaired two-tailed t-test: p&gt;0.05, N = 3. (<bold>C, C′</bold>) Representative confocal photos of collagen I hydrogel chemotaxis assay for A375 IV (<bold>C</bold>) and A2058 (<bold>C′</bold>) cells (data presented in <xref ref-type="fig" rid="fig5">Figure 5G and H</xref>). (<bold>D, D′</bold>) Matrigel invasion assay – stable RNF43 overexpression-inhibited invasive properties of the A375 and A375 IV. Serum-starved cells were plated onto Matrigel-coated porous membrane. Medium containing 20% of serum was used as chemoattractant. After 18 hr of incubation, cells were fixed in methanol, noninvaded ones were removed from the upper part of transwell insert by cotton swab. Results were normalized to 1 for the number of invaded A375 cells, unpaired two-tailed t-test: *p&lt;0.05, N = 4. (<bold>D′</bold>) Representative photos assay after crystal violet staining. <xref ref-type="supplementary-material" rid="fig5s1sdata1">Figure 5—figure supplement 1—source data 1</xref> contains raw data.</p><p><supplementary-material id="fig5s1sdata1"><label>Figure 5—figure supplement 1—source data 1.</label><caption><title>RNF43 inhibits Wnt5a-dependent invasive properties of human melanoma.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-65759-fig5-figsupp1-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-65759-fig5-figsupp1-v1.tif"/></fig><fig id="fig5s2" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 2.</label><caption><title>RNF43 inhibits Wnt5a-dependent invasive properties of human melanoma.</title><p>Confocal imaging of A375, A375 IV, and RNF43 overexpressing and <italic>RNF43</italic>/<italic>ZNRF3</italic> double knockout cell lines modifications. Cells were paraformaldehyde fixed, Triton X-100 permeabilized and stained for cortactin by antibody (secondary antibody Alexa 568, red) and F-actin using fluorescent phalloidin conjugate (Alexa 488, green) and TO-PRO-3 Iodide for DNA visualization (blue). Number of double-positive puncta in single cells was quantified using ImageJ software. Scale bars represent 100 μm. Results are presented in <xref ref-type="fig" rid="fig5">Figure 5I</xref>.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-65759-fig5-figsupp2-v1.tif"/></fig><fig id="fig5s3" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 3.</label><caption><title>RNF43 inhibits Wnt5a-dependent invasive properties of human melanoma.</title><p>Confocal imaging of gelatin degradation assay without (<xref ref-type="fig" rid="fig5s3">Figure 5—figure supplement 3</xref>) and after (<xref ref-type="fig" rid="fig5s4">Figure 5—figure supplement 4</xref>) rhWNT5A treatment. Serum-starved cells were plated onto gelatin-Oregon Green (green)-coated coverslips and incubated for 24 hr. Fixed cells were stained with phalloidin-Alexa 594 for F-actin visualization (red) and TO-PRO-3 Iodide for nuclei (blue). Foci showing gelatin degradation are marked. Scale bars represent 50 μm. Experiment was repeated three times. Results are presented in <xref ref-type="fig" rid="fig5">Figure 5J</xref>.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-65759-fig5-figsupp3-v1.tif"/></fig><fig id="fig5s4" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 4.</label><caption><title>RNF43 inhibits Wnt5a-dependent invasive properties of human melanoma.</title><p>Confocal imaging of gelatin degradation assay after rhWNT5A treatment. Serum-starved cells were plated onto gelatin-Oregon Green (green)-coated coverslips and incubated for 24 hr. Fixed cells were stained with phalloidin-Alexa 594 for F-actin visualization (red) and TO-PRO-3 Iodide for nuclei (blue). Foci showing gelatin degradation are marked. Scale bars represent 50 μm. Experiment was repeated three times. Results are presented in <xref ref-type="fig" rid="fig5">Figure 5J</xref>.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-65759-fig5-figsupp4-v1.tif"/></fig></fig-group></sec><sec id="s2-7"><title>RNF43 prevents acquisition of resistance to BRAF V600E targeted therapy</title><p>The mitogen-activated protein kinase (MAPK) pathway is hyperactivated in melanoma (<xref ref-type="bibr" rid="bib36">Davies et al., 2002</xref>) as a result of UV-induced mutations triggering constitutive activation of this signaling axis. The most common genetic aberration – <italic>BRAF V600E</italic> is a target of anti-melanoma therapy (<xref ref-type="bibr" rid="bib2">Akbani et al., 2015</xref>; <xref ref-type="bibr" rid="bib19">Birkeland et al., 2018</xref>; <xref ref-type="bibr" rid="bib27">Chapman et al., 2011</xref>; <xref ref-type="bibr" rid="bib47">Flaherty et al., 2010</xref>; <xref ref-type="bibr" rid="bib64">Hodis et al., 2012</xref>; <xref ref-type="bibr" rid="bib154">Shain et al., 2015</xref>). Drugs targeting mutated BRAF (e.g., vemurafenib/PLX4032) in melanoma have improved patients’ survival (<xref ref-type="bibr" rid="bib27">Chapman et al., 2011</xref>; <xref ref-type="bibr" rid="bib47">Flaherty et al., 2010</xref>; <xref ref-type="bibr" rid="bib75">Joseph et al., 2010</xref>). Unfortunately, patients receiving BRAF inhibitors (BRAFi) relapse after several months of monotherapy because of the acquired resistance (<xref ref-type="bibr" rid="bib118">Nazarian et al., 2010</xref>). WNT5A was shown to play a crucial role in the process leading to the vemurafenib resistance (<xref ref-type="bibr" rid="bib3">Anastas et al., 2014</xref>; <xref ref-type="bibr" rid="bib10">Arozarena and Wellbrock, 2019</xref>; <xref ref-type="bibr" rid="bib112">Mohapatra et al., 2019</xref>; <xref ref-type="bibr" rid="bib127">O’Connell et al., 2013</xref>; <xref ref-type="bibr" rid="bib134">Prasad et al., 2015</xref>; <xref ref-type="bibr" rid="bib179">Webster et al., 2015</xref>). Therefore, we were interested in checking whether RNF43 inhibits, via its effects on WNT5A signaling, cellular plasticity in response to vemurafenib (PLX4032), a clinically used <italic>BRAF</italic> V600E inhibitor.</p><p>The process of vemurafenib resistance acquisition can be modeled in vitro. We applied an experimental scheme optimized for A375 (<xref ref-type="bibr" rid="bib3">Anastas et al., 2014</xref>). This model (<xref ref-type="fig" rid="fig6">Figure 6A</xref>) allows to study both acute responses to vemurafenib (24 hr treatment) as well as the gradual adaptation of long-term cell culture to increasing vemurafenib doses. Vemurafenib-resistant (VR) cells can be obtained after approximately 2 months. As shown in <xref ref-type="fig" rid="fig6">Figure 6B</xref>, treatment with vemurafenib resulted in rapid and complete inhibition of ERK1/2 phosphorylation, the readout of MAPK activation (compare lanes 1 and 2). In contrast, A375 VR cells showed constitutive ERK1/2 phosphorylation in the presence of 2 μM vemurafenib (compare lanes 2 and 3). Interestingly, transient exposition to vemurafenib resulted in the impeded phosphorylation of ROR1, DVL2, and DVL3 and increased ROR2 protein level without change in its mRNA (<xref ref-type="fig" rid="fig6">Figure 6B–D</xref>, <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1A and B</xref>). On the other side, VR cells displayed elevated ROR1 levels (both protein and mRNA) and increased phosphorylation of DVL2 and DVL3 (<xref ref-type="fig" rid="fig6">Figure 6B–D</xref>, <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1A and B</xref>). Strikingly, the expression of <italic>WNT5A</italic> was also higher in the resistant VR cells (<xref ref-type="fig" rid="fig6">Figure 6E</xref>). This suggests that activation of noncanonical WNT5A-induced signaling and ROR1 and ROR2 changes is indeed a part of the melanoma adaptation mechanism to vemurafenib. Therefore, we challenged A375 and its RNF43-expressing derivatives with vemurafenib. As shown in <xref ref-type="fig" rid="fig6">Figure 6F</xref>, exogenous RNF43 decreased colony formation and proliferation of cells seeded in low density and vemurafenib further enhanced this effect. Importantly, both A375 and A375 IV-overexpressing RNF43 completely failed to develop resistance to vemurafenib and died off during selection at 1 μM vemurafenib concentration (<xref ref-type="fig" rid="fig6">Figure 6G</xref>). Both A375 and A375 IV <italic>RNF43</italic>/<italic>ZNRF3</italic> double KO cells survived selection with BRAFi but showed decreased proliferation rate. Lower proliferation of <italic>RNF43</italic>/<italic>ZNRF3</italic> dKO cells can be caused by senescence because these cells have elevated WNT5A pathway activity (i.e., <xref ref-type="fig" rid="fig3">Figures 3B</xref> and <xref ref-type="fig" rid="fig4">4I</xref>, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1E and F</xref>) and WNT5A at the same time causes a senescence-like phenotype of melanoma after exposition to vemurafenib (<xref ref-type="bibr" rid="bib179">Webster et al., 2015</xref>). Alternatively, <italic>RNF43</italic>/<italic>ZNRF3</italic> KO could affect also canonical Wnt/β-catenin pathway that was shown to drive distinct features of melanoma cells than the ones related to the WNT5A-specific events (<xref ref-type="bibr" rid="bib7">Arozarena et al., 2011</xref>; <xref ref-type="bibr" rid="bib10">Arozarena and Wellbrock, 2019</xref>; <xref ref-type="bibr" rid="bib171">Uka et al., 2020</xref>; <xref ref-type="bibr" rid="bib178">Webster and Weeraratna, 2013</xref>).</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>RNF43-overexpressing melanoma cells do not develop resistance to BRAF V600E targeted therapies.</title><p>(<bold>A</bold>) Scheme showing the experimental model used for the analysis of vemurafenib resistance (VR) acquisition. Melanoma cells are exposed to the increasing doses of the <italic>BRAF</italic> V600E inhibitor vemurafenib and following initial decrease in cell numbers recover and obtain capacity to grow in the presence of vemurafenib. (<bold>B–D</bold>) Western blot analysis of the cellular responses to the acute vemurafenib treatment (0.5 µM, 24 hr) in comparison to the signaling in VR cells growing in the presence of 2 µM vemurafenib. Transient treatment resulted in decreased DVL2 and DVL3 phosphorylation and increased ROR2 signal. In VR cells, ERK1/2 is constitutively phosphorylated in the vemurafenib presence. β-actin served as a loading control. A375 VR cells showed increased activation of DVL2 and DVL3 (empty arrowheads; quantifications in <bold>C</bold> and <bold>D</bold>) and higher expression of ROR1. Unpaired two-tailed t-test: *p&lt;0.05, **p&lt;0.01, N = 3. <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1A and B</xref> presents changes in <italic>ROR1</italic> and <italic>ROR2</italic> genes expression and quantification of ROR1 and ROR2 proteins signals. (<bold>E</bold>) Expression of <italic>WNT5A</italic> gene is elevated in the VR A375 cells in comparison to the parental line, unpaired two-tailed t-test: **p=0.0013, N = 3. Data presented are normalized to 1. Relative expression was normalized to the <italic>HSPCB and RPS13 genes</italic> (2<sup>−ΔΔCt</sup>). (<bold>F</bold>) Melanoma cell lines A375 and A375 IV overexpressing RNF43 showed decreased ability to grow and form colonies when seeded in the low density. After 7 days, colonies were fixed and stained with crystal violet. Paired (vemurafenib – vs+) and unpaired (A375 vs. IV) two-tailed t-tests: *p&lt;0.05, ****p&lt;0.0001, N ≥ 5. (<bold>G</bold>) RNF43-overexpressing A375 and A375 IV did not develop resistance to the BRAF V600E inhibition by vemurafenib treatment. Cells were cultured for approximately 2 months in the presence of increasing doses of the inhibitor. Photos show crystal violet-stained cultures at the end of the selection process. (<bold>H</bold>) A2058 cells (marked as ‘ctrl’) were exposed to the 24 hr-long treatments with vemurafenib (2.5 μM), cobimetinib (0.1 μM), or their combination. These short treatments were compared with cells cultured for approximately 2 months in the presence of vemurafenib (5 μM; VR), cobimetinib (0.5 μM; Cob. <bold>R</bold>) or their combination (V + C R). Experiment is schematized in <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1C’</xref>. Selected proteins were analyzed by western blot. Cells chronically exposed to inhibitors showed shifts of VANGL1 and VANGL2 bands (empty arrowhead) and changes in the MITF signal. Signal of pERK1/2 was used as treatments control. β-actin signal served as a loading control, N = 3. <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1C</xref> presents DVL2, DVL3 and total ERK1/2 signals. (<bold>I–K</bold>) Expression analysis of <italic>MITF</italic> (<bold>I</bold>)<italic>, RNF43</italic> (<bold>J</bold>), and <italic>WNT5A</italic> (<bold>K</bold>) genes. <italic>MITF</italic> is significantly upregulated in cells resistant to 5 μM Vemurafenib and downregulated in cells derived from the long-term culture in the presence of 0.5 μM cobimetinib alone and in combination with vemurafenib. (<bold>I′</bold>) VR A2058 show higher pigmentation. <italic>RNF43</italic> expression decreased in the derived cells, while <italic>WNT5A</italic> increased. Relative expression levels are presented as 2<sup>−ΔΔCt</sup> ± SD and normalized to the levels of <italic>B2M</italic> and <italic>GAPDH</italic> genes, unpaired two-tailed t-tests: *p&lt;0.05, **p&lt;0.01, N = 3. <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1D–F</xref> shows expression analysis of <italic>ZNRF3</italic>, <italic>ROR1,</italic> and <italic>ROR2</italic>. (<bold>L</bold>) RNF43-overexpressing A2058 cells did not develop resistance to the cobimetinib and its combination with vemurafenib. Cells were cultured for approximately 2 months in the presence of increasing doses of the inhibitors (up to 5 μM for vemurafenib and 0.5 μM for cobimetinib), schematized in <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1C’</xref>. <xref ref-type="supplementary-material" rid="fig6sdata1">Figure 6—source data 1</xref> presents raw data.</p><p><supplementary-material id="fig6sdata1"><label>Figure 6—source data 1.</label><caption><title>RNF43-overexpressing melanoma cells do not develop resistance to BRAF V600E targeted therapies.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-65759-fig6-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-65759-fig6-v1.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 1.</label><caption><title>RNF43-overexpressing melanoma cells do not develop resistance to BRAF V600E targeted therapies.</title><p>(<bold>A, B</bold>) Protein levels of ROR1 (<bold>A</bold>) and ROR2 (<bold>B</bold>) (western blot shown in <xref ref-type="fig" rid="fig6">Figure 6B</xref>) were quantified using ImageJ software, two-tailed t-test: *p&lt;0.05, **p&lt;0.01; N = 3. Expression ROR1 (<bold>A′</bold>) and ROR2 (<bold>B′</bold>) genes in parental, cells transiently treated with BRAFi and vermurafenib-resistant A375 cells and presented as 2−ΔΔCt ± SD. Relative expression level was normalized to the HSPCB and RPS13. (<bold>C</bold>, <bold>C′</bold>) Western blot analysis of 24 hr and chronic response to vemurafenib, cobimetinib, and their combination in A2058 cells, continuation of <xref ref-type="fig" rid="fig6">Figure 6H</xref>. Empty arrowhead represents phosphorylation-dependent shift; full arrowhead indicates unphosphorylated status. Scheme of the experiment is presented in (<bold>C′</bold>). (<bold>D–F</bold>) Expression of <italic>ZNRF3</italic> (<bold>D</bold>), <italic>ROR1</italic> (<bold>E</bold>), and <italic>ROR2</italic> (<bold>F</bold>) genes in A2058 control cells, resistant to vemurafenib (VR), cobimetinib (Cob. R), and double treatment (V + C R). <italic>ZNRF3</italic> expression is decreased in the all-derived cells, while <italic>ROR1</italic> in the cobimetinib and cobimetinib + vemurafenib-resistant lines. <italic>ROR2</italic> did not change significantly. Relative expression levels are presented as 2<sup>−ΔΔCt</sup> ± SD and normalized to the levels of <italic>B2M</italic> and <italic>GAPDH</italic> genes, unpaired two-tailed t-tests: *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, N = 3. <xref ref-type="supplementary-material" rid="fig6s1sdata1">Figure 6—figure supplement 1—source data 1</xref> contains raw data.</p><p><supplementary-material id="fig6s1sdata1"><label>Figure 6—figure supplement 1—source data 1.</label><caption><title>RNF43-overexpressing melanoma cells do not develop resistance to BRAF V600E targeted therapies.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-65759-fig6-figsupp1-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-65759-fig6-figsupp1-v1.tif"/></fig></fig-group><p>To strengthen our results, we exposed A375 and A2058 parental and RNF43-expressing cells temporarily and chronically to vemurafenib, MEK inhibitor – cobimetinib and to the FDA-approved combination of these drugs (<xref ref-type="bibr" rid="bib11">Ascierto et al., 2016</xref>; <xref ref-type="bibr" rid="bib155">Signorelli and Shah Gandhi, 2017</xref>; experimental scheme in <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1C’</xref>). We failed to obtain A375-resistant line, but A2058 acquired resistance to cobimetinib alone and its combination with vemurafenib (<xref ref-type="fig" rid="fig6">Figure 6H and L</xref>). Treatments and resistance were validated by pERK1/2 levels (<xref ref-type="fig" rid="fig6">Figure 6H</xref>). A2058 enriched with ectopically expressed RNF43 did not survive cobimetinib monotherapy and cobimetinib with vemurafenib combination, whereas vemurafenib-only treatment did not fully eliminate those cells (<xref ref-type="fig" rid="fig6">Figure 6L</xref>). Thus, we aimed to detect the differences in mechanisms behind targeted therapies resistance acquisition to characterize better the function of RNF43 in melanoma. Firstly, we noticed the shift of VANGL1 in all delivered resistance models, while VANGL2 was shifted only in cells being in the long-term culture with cobimetinib and with cobimetinib and vemurafenib (<xref ref-type="fig" rid="fig6">Figure 6H</xref>). This corresponds with decreased <italic>RNF43</italic> and <italic>ZNRF3</italic> expression (<xref ref-type="fig" rid="fig6">Figure 6J</xref>, <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1D</xref>) and increased <italic>WNT5A</italic> mRNA level (<xref ref-type="fig" rid="fig6">Figure 6K</xref>). Interestingly, both MITF protein level and <italic>MITF</italic> gene expression increased in VR cells and decreased in all cobimetinib-insensitive lines (<xref ref-type="fig" rid="fig6">Figure 6H and I</xref>). Moreover, <italic>MITF</italic> upregulation was accompanied by clear pigmentation of resistant cells (<xref ref-type="fig" rid="fig6">Figure 6I′</xref>), suggesting cell phenotype change (<xref ref-type="bibr" rid="bib10">Arozarena and Wellbrock, 2019</xref>; <xref ref-type="bibr" rid="bib70">Ji et al., 2015</xref>; <xref ref-type="bibr" rid="bib113">Müller et al., 2014</xref>). Expression of <italic>ROR1</italic> decreased in case of MEKi resistance, while ROR2 remained unaffected (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1E and F</xref>). Contrary to A375, <italic>ROR1</italic> did not significantly increase in VR-resistant cells and we did not detect the increased DVL2 and DVL3 phosphorylation (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1C</xref>).</p><p>Altogether, these data confirm earlier findings on the importance of WNT5A signaling in the acquisition of resistance to targeted therapies and demonstrate that RNF43 can block this process. Moreover, we show that RNF43 could be a negative regulator of melanoma phenotype plasticity by targeting MITF<sup>-low</sup>/WNT5A<sup>-high</sup> melanoma cells (<xref ref-type="bibr" rid="bib65">Hoek et al., 2006</xref>; <xref ref-type="bibr" rid="bib87">Kim et al., 2017</xref>; <xref ref-type="bibr" rid="bib152">Sensi et al., 2011</xref>; <xref ref-type="bibr" rid="bib166">Tirosh et al., 2016</xref>).</p></sec><sec id="s2-8"><title>RNF43 as onco-suppressor in vivo: impact on tumors and resistance to vemurafenib</title><p>Next, we aimed to confirm our results also in the in vivo model. We decided to use cell lines with the same origin but varying in the <italic>RNF43</italic> expression. For this purpose, A375 RNF43 TetON cells and A375 control lines (<xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3B and C</xref>) were tested by qPCR. A375 control line had the lowest expression (referred to as ‘<italic>RNF43 low’</italic>) of <italic>RNF43</italic>, and doxycycline-untreated A375 RNF43 TetON showed intermediate expression due to TetON leakage (‘<italic>RNF43 mid’</italic>) that could be further enhanced by the doxycycline treatment (‘<italic>RNF43 high’</italic>) (<xref ref-type="fig" rid="fig7">Figure 7A</xref>). Next, we prepared and tested a novel vemurafenib formulation in 25% Kolliphor-water solution ensuring the solubility of this BRAFi and which could be administrated by oral gavage in the previously published dose 25 mg/kg (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1A</xref>; <xref ref-type="bibr" rid="bib177">Wang et al., 2019</xref>). Cells were injected intradermally into the NOD-Rag1<sup>null</sup> IL2rg<sup>null</sup> mice. Animals were divided into treatment cohorts once tumors became prominent in size (<xref ref-type="fig" rid="fig7">Figure 7B</xref>, <xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1B</xref>). Cohort I (<italic>RNF43 low</italic>) had significantly shorter survival and formed macroscopic tumors earlier than <italic>RNF43 mid</italic> and <italic>high</italic> cohorts (<xref ref-type="fig" rid="fig7">Figure 7C</xref>, <xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1C</xref>). Moreover, tumors originating from cells with the lowest <italic>RNF43</italic> expression were significantly bigger than <italic>RNF43 mid</italic> ones (<xref ref-type="fig" rid="fig7">Figure 7D</xref>). To validate RNF43 expression induction and impact on its targets, protein lysates from tumors were analyzed by western blotting (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1D</xref>). We found out that the level of RNF43-specific signal in cohorts I–III was significantly and inversely correlated with ROR1 and VANGL2 protein levels and similar trend was also noticed for DVL2 phosphorylation (<xref ref-type="fig" rid="fig7">Figure 7E</xref>, <xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1D and E</xref>), recapitulating the described above in vitro effect also in the in vivo experiment. Importantly, we observed the RNF43 leakage (HA signal in <xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1D</xref>), meaning that TetON system did not efficiently suppress the ectopic expression of RNF43 even in the absence of doxycycline, which also provides explanation for different <italic>RNF43</italic> levels in studied here cell lines (<xref ref-type="fig" rid="fig7">Figure 7A</xref>). In conclusion, the dose-dependent effect mediated by RNF43 showed the features of the onco-suppression in melanoma in vivo model.</p><fig-group><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>RNF43 inhibits melanoma proliferation and response to vemurafenib in vivo<italic>.</italic></title><p>(<bold>A</bold>) RT-qPCR results – expression of the <italic>RNF43</italic> gene in control (<italic>RNF43</italic> low) and A375 RNF43 TetON cells in the absence (<italic>RNF43</italic> mid) and presence of doxycycline (<italic>RNF43</italic> high). Results are presented as 2<sup>−ΔΔCt</sup> ± SD, two-tailed t-test: **p&lt;0.01, ****p&lt;0.0001, N = 3. Relative expression level was normalized to the <italic>B2M</italic> and <italic>GAPDH</italic> genes expression. (<bold>B</bold>) Schematic representation of the in vivo experiment based in the immunodeficient NOD-Rag1<sup>null</sup> IL2rg<sup>null</sup> mouse strain. A375 and its variants were injected intradermally (50,000 cells in PBS/mouse). Animals were divided into five cohorts once palpable tumors were formed. Ectopic RNF43 expression was induced by doxycycline presence in the drinking water. Vemurafenib was delivered daily by oral gavage as 25% Kolliphor in water formulation (see <xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1A</xref>). Tumors sizes and animal weight were checked weekly. Mice were sacrificed when tumors reached approximately 1000 mm<sup>3</sup>. (<bold>C</bold>) Survival within cohorts I–III. Injection with cells having the lowest <italic>RNF43</italic> expression led to the shortest mean survival (28 days). Experiment in cohorts II (56 days) and III (62 days) was significantly longer, Mantel–Cox test: *p&lt;0.05, **p&lt;0.01. (<bold>D</bold>) Cells expressing RNF43 higher than the endogenous level have impaired ability to proliferation in vivo. Tumor sizes at end point for the <italic>RNF43</italic> low cohort (N = 5) with RNF43 mid (N = 3), two-tailed t-test: *p=0.0297. (<bold>E</bold>) RNF43 negatively regulates its targets also in vivo. Correlation analysis of RNF43 western blot signals with ROR1, VANGL2 protein levels, and phosphorylation status of DVL2 (shown in <xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1D</xref>). Results for cohorts I–III were analyzed (N = 12), one-tailed Spearman correlation test, p and r values are shown in the graph. (<bold>F</bold>) Survival analysis showing vemurafenib treatment efficacy. Doxycycline treatment for RNF43 induction did not increase further vemurafenib effect. Mean survival: RNF43 mid: 56 days; RNF43 mid + vemurafenib: 84 days; RNF43 high: 62 days; RNF43 high + vemurafenib: 76 days, Mantel–Cox test: *p&lt;0.05, **p&lt;0.01. (<bold>G</bold>) RNF43 delays acquisition of vemurafenib resistance in vivo. Cohort V (N = 4) receiving doxycycline for RNF43 overexpression induction and vemurafenib (RNF43 high + vemurafenib) had significantly smaller tumors at days 49–62 than cohort IV (RNF43 mid + vemurafenib), tumors were not different at the treatments starting point (day 28) two-tailed t-test: *p&lt;0.05, **p&lt;0.01. (<bold>H</bold>) Tumor growth curve – caliper measurements of tumors sizes within experimental groups II–V. Treatment starting points are marked and presented in <xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1B</xref>. All used data are presented in <xref ref-type="supplementary-material" rid="fig7sdata1">Figure 7—source data 1</xref>.</p><p><supplementary-material id="fig7sdata1"><label>Figure 7—source data 1.</label><caption><title>RNF43 inhibits melanoma proliferation and response to vemurafenib in vivo<italic>.</italic></title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-65759-fig7-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-65759-fig7-v1.tif"/></fig><fig id="fig7s1" position="float" specific-use="child-fig"><label>Figure 7—figure supplement 1.</label><caption><title>RNF43 inhibits melanoma proliferation and response to vemurafenib in vivo.</title><p>(<bold>A</bold>) Vemurafenib formulations test for the in vivo application. Vemurafenib 2.5 mg/ml was prepared in aqueous solutions of 1% carboxymethyl cellulose (CMC), 10, 20, and 25% Kolliphor. DMSO was used as reference. Vemurafenib was added to solutions from DMSO-based saturated stock. Formulation in 25% Kolliphor was selected for further tests. (<bold>A′</bold>) A375 cells were treated overnight with 1 μM vemurafenib in DMSO and in 25% Kolliphor formulation, lysed and phosphorylated ERK1/2 signal was used as readout for vemurafenib inhibitory properties. (<bold>B</bold>) Tumors sizes formed by A375 RNF43 TetON cells (RNF43 mid/high after following doxycycline supplementation) in cohorts II–V at the beginning of treatments. (<bold>C</bold>) Tumor growth curve – caliper measurements of tumors sizes within experimental groups I–III. (<bold>D</bold>) Western blot analysis of primary tumors at the experimental end points. Tissues were homogenized, lysed in the 1% SDS lysis buffer, sonicated and clarified by centrifugation, followed by addition of Laemmli buffer and thermal denaturation. Each sample contains 25 µg of total protein. RNF43 was probed by HA tag-specific antibody. Empty arrowhead represents phosphorylation-dependent shift; black arrowhead indicates unphosphorylated status. (<bold>E</bold>) Quantifications of tumor samples western blots. Tumors formed by RNF43 low cells had scientifically higher ROR1 (<bold>E</bold>) and VANGL2 levels (<bold>E′</bold>) and higher phosphorylation of DVL2 (<bold>E′′</bold>) than RNF43 mid-derived tumors. RNF43 high vemurafenib-resistant cells had higher ROR1 protein level than in the RNF43 mid cohort (<bold>E</bold>). Vemurafenib treatment led to the increased WNT5A protein level in tumors at the end of the experiment (<bold>E′′′</bold>). RNF43 low N = 5; RNF43 mid N = 3; RNF43 high N = 4; RNF43 mid + vemurafenib N = 5; RNF43 high + vemurafenib N = 4, unpaired two-tailed t-test *p&lt;0.05, **p&lt;0.01. All used data are presented in <xref ref-type="supplementary-material" rid="fig7s1sdata1">Figure 7—figure supplement 1—source data 1</xref>.</p><p><supplementary-material id="fig7s1sdata1"><label>Figure 7—figure supplement 1—source data 1.</label><caption><title>RNF43 inhibits melanoma proliferation and response to vemurafenib in vivo.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-65759-fig7-figsupp1-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-65759-fig7-figsupp1-v1.tif"/></fig></fig-group><p>Further, we also investigated the synergistic effect of RNF43 and vemurafenib in vivo. RNF43 mid and RNF43 high cohorts received vemurafenib, and this treatment significantly prolonged the survival (<xref ref-type="fig" rid="fig7">Figure 7F</xref>), validating our formulation and dosing efficacy. Importantly, doxycycline supplementation (<italic>RNF43 high</italic>) in addition to vemurafenib resulted in the more efficient suppression of tumor growth, suggesting the delayed the BRAFi resistance acquisition (<xref ref-type="fig" rid="fig7">Figure 7G</xref>). Nevertheless, there was no difference at the experimental end point (<xref ref-type="fig" rid="fig7">Figure 7F and H</xref>), possibly due to the loss of transgene expression observed in cells during this long-term experiment (HA signal in <xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1D</xref>). Moreover, the protein level of WNT5A was significantly increased in tumors treated with vemurafenib, which could help to bypass the RNF43-related effect as well (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1E′′′</xref>). Our main findings are summarized as a graphical abstract (<xref ref-type="fig" rid="fig8">Figure 8</xref>).</p><fig id="fig8" position="float"><label>Figure 8.</label><caption><title>RNF43 inhibits WNT5A-driven signaling and suppresses melanoma invasion and resistance to the targeted therapy.</title><p>Graphical summary. RNF43 is an inhibitor of the noncanonical WNT5A-induced pathway. RNF43 interacts with receptor complexes of the Wnt/PCP signaling and its enzymatic activity results in the reduced cells sensitivity to WNT5A (<bold>A</bold>). In melanoma, WNT5A promotes invasion and metastasis (<bold>B</bold>) as well as resistance to targeted therapies, including treatments with vemurafenib – inhibitor of commonly mutated BRAF kinase and cobimetinib-targeting activity of the MEK enzyme (<bold>C</bold>). RNF43 blocks melanoma-invasive properties via interference with the nonconical Wnt pathway, leading to the increased sensitivity to treatment (<bold>D</bold>).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-65759-fig8-v1.tif"/></fig></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Our study identified RNF43 as an inhibitor of noncanonical WNT5A-induced signaling. RNF43 physically interacted with multiple receptor components of the Wnt/PCP pathway such as ROR1/2, VANGL1/2, or DVL1/2/3 and triggered degradation of VANGL2 and membrane clearance of ROR1, ultimately resulting in the reduced cell sensitivity to WNT5A. The newly discovered RNF43 action in WNT5A-mediated signaling seems to be mechanistically different than the well-known function in the Wnt/β-catenin pathway. For example, we observed ROR1 and VANGL2 interaction with RNF43 in the absence of DVL. In contrast, DVL seems to be essential for the activity of RNF43 in the Wnt/β-catenin pathway (<xref ref-type="bibr" rid="bib72">Jiang et al., 2015</xref>). Further, the inhibitory action of RNF43 in WNT5A signaling could not be blocked by inhibition of lysosomal pathway, in contrast to the earlier observations in WNT/β-catenin pathway (<xref ref-type="bibr" rid="bib88">Koo et al., 2012</xref>). On the other side, WNT5A signaling can be, similarly to Wnt/β-catenin, promoted by RNF43 inhibitors from R-SPO family. Also, in line with the earlier findings that RNF43 leads to the packing of ubiquitinated FZD to the RAB5<sup>+</sup> endosomes (<xref ref-type="bibr" rid="bib88">Koo et al., 2012</xref>), ROR1 is as well internalized via a clathrin-dependent mechanism into RAB5<sup>+</sup> and RAB11+ endosomes. Interestingly, ROR1 internalization is transient. We can speculate that it represents the first step in the silencing of the noncanonical Wnt pathway, which further translates into stable inhibition, for example, via VANGL2 sequestration. It remains to be studied how RNF43 in a coordinated manner controls both WNT/β-catenin and noncanonical WNT pathways.</p><p>We demonstrate that the newly characterized RNF43-WNT5A regulatory module controls WNT5A signaling and biology in melanoma. WNT5A-induced signaling plays a crucial role in this cancer type. Up to date, 5-year survival of metastatic melanoma patients rates between 5 and 19%, depending on the location and the number of metastases (<xref ref-type="bibr" rid="bib148">Sandru et al., 2014</xref>). Elevated expression of <italic>WNT5A</italic> associates with negative overall survival in melanoma (<xref ref-type="bibr" rid="bib35">Da Forno et al., 2008</xref>; <xref ref-type="bibr" rid="bib102">Luo et al., 2020</xref>; <xref ref-type="bibr" rid="bib181">Weeraratna et al., 2002</xref>); we have observed an inverse correlation for <italic>RNF43</italic>, which was a positive prognostic factor in melanoma and got silenced as melanoma progressed. WNT5A promotes multiple proinvasive features of melanoma cells such as EMT-like process, invasion, metastasis, cell proliferation, and ECM remodeling by melanoma cells (<xref ref-type="bibr" rid="bib41">Dissanayake et al., 2008</xref>; <xref ref-type="bibr" rid="bib40">Dissanayake et al., 2007</xref>; <xref ref-type="bibr" rid="bib46">Fernández et al., 2016</xref>; <xref ref-type="bibr" rid="bib94">Lai et al., 2012</xref>). Moreover, WNT5A ligand co-receptors – ROR1 and ROR2 – have been already described in melanoma as key factors driving invasion in vitro and in vivo (<xref ref-type="bibr" rid="bib46">Fernández et al., 2016</xref>; <xref ref-type="bibr" rid="bib94">Lai et al., 2012</xref>; <xref ref-type="bibr" rid="bib127">O’Connell et al., 2013</xref>; <xref ref-type="bibr" rid="bib126">O’Connell et al., 2010</xref>). Ultimately, RNF43 overexpression here efficiently suppressed all tested pro-metastatic properties of melanoma cells associated with WNT5A and its (co)receptors. Among those, the clinically most relevant is the acquisition of resistance to BRAF inhibitor vemurafenib (<xref ref-type="bibr" rid="bib27">Chapman et al., 2011</xref>; <xref ref-type="bibr" rid="bib47">Flaherty et al., 2010</xref>).</p><p><italic>BRAF V600E</italic> mutation appears in up to 50% of melanoma cases, which results in the oncogenic activation of MAPK pathway (<xref ref-type="bibr" rid="bib2">Akbani et al., 2015</xref>; <xref ref-type="bibr" rid="bib176">Wan et al., 2004</xref>). Vemurafenib (PLX4032), a compound selectively inhibiting BRAF V600E, showed positive clinical effects in melanoma (<xref ref-type="bibr" rid="bib21">Bollag et al., 2012</xref>; <xref ref-type="bibr" rid="bib75">Joseph et al., 2010</xref>). Unfortunately, most of the patients develop resistance to vemurafenib treatment and progress (<xref ref-type="bibr" rid="bib27">Chapman et al., 2011</xref>). Multiple mechanisms underlying acquisition of resistance were described (<xref ref-type="bibr" rid="bib10">Arozarena and Wellbrock, 2019</xref>; <xref ref-type="bibr" rid="bib8">Arozarena and Wellbrock, 2017a</xref>; <xref ref-type="bibr" rid="bib74">Johnson et al., 2015</xref>; <xref ref-type="bibr" rid="bib101">Luebker and Koepsell, 2019</xref>; <xref ref-type="bibr" rid="bib150">Schmitt et al., 2019</xref>; <xref ref-type="bibr" rid="bib159">Su et al., 2020</xref>; <xref ref-type="bibr" rid="bib158">Su et al., 2017</xref>; <xref ref-type="bibr" rid="bib163">Talebi et al., 2018</xref>; <xref ref-type="bibr" rid="bib166">Tirosh et al., 2016</xref>). Among those mechanisms, WNT5A signaling has a prominent role – <italic>WNT5A</italic> expression was shown to positively correlate with vemurafenib resistance (<xref ref-type="bibr" rid="bib3">Anastas et al., 2014</xref>; <xref ref-type="bibr" rid="bib134">Prasad et al., 2015</xref>; <xref ref-type="bibr" rid="bib179">Webster et al., 2015</xref>) and WNT5A treatment decreased melanoma cells’ response to the vemurafenib (<xref ref-type="bibr" rid="bib3">Anastas et al., 2014</xref>; <xref ref-type="bibr" rid="bib127">O’Connell et al., 2013</xref>). Our finding that RNF43-controlled regulatory axis could completely block the development of resistance to BRAF and also MEK inhibition further highlights the importance of WNT5A signaling in this process and uncovers a mechanism that can be explored therapeutically.</p><p>Previous studies showed that melanoma displays remarkable phenotypic plasticity upon targeted therapy (<xref ref-type="bibr" rid="bib65">Hoek et al., 2006</xref>; <xref ref-type="bibr" rid="bib66">Hoek and Goding, 2010</xref>; <xref ref-type="bibr" rid="bib83">Kemper et al., 2014</xref>; <xref ref-type="bibr" rid="bib138">Rambow et al., 2018</xref>). This is also well demonstrated in our A2058 model where vemurafenib-resistant cells become melanotic (MITF<sup>high</sup>), whereas cobimetinib- and especially vemurafenib/cobimetinib-double-resistant cells have MITF<sup>low</sup>/WNT5A<sup>high</sup> phenotype that is characteristic for highly invasive melanoma with the dedifferentiated phenotype (<xref ref-type="bibr" rid="bib1">Ahn et al., 2017</xref>; <xref ref-type="bibr" rid="bib3">Anastas et al., 2014</xref>; <xref ref-type="bibr" rid="bib10">Arozarena and Wellbrock, 2019</xref>; <xref ref-type="bibr" rid="bib107">Massi et al., 2020</xref>; <xref ref-type="bibr" rid="bib179">Webster et al., 2015</xref>). Inhibition of the WNT5A pathway by RNF43 could block one of the trajectories of resistance acquisition by Darwinian selection of preexisting subpopulation (<xref ref-type="bibr" rid="bib29">Chisholm et al., 2015</xref>), thereby promoting less metastatic phenotype (<xref ref-type="bibr" rid="bib15">Bai et al., 2019</xref>). This is supported by our observation that vemurafenib-treated A2058 cells can partially overcome RNF43 OE by phenotypic switch to MITF<sup>high</sup> phenotype, which is not the case in cobimetinib-treated cells. From the other angle, the low <italic>RNF43</italic> expression might be explored as a marker of resistant melanoma phenotype. <italic>RNF43</italic> is a β-catenin target gene (<xref ref-type="bibr" rid="bib161">Takahashi et al., 2014</xref>), which could be a reason for the low <italic>RNF43</italic> levels in metastatic melanomas where Wnt/β-catenin signaling is inhibited (<xref ref-type="bibr" rid="bib7">Arozarena et al., 2011</xref>; <xref ref-type="bibr" rid="bib76">Kageshita et al., 2001</xref>; <xref ref-type="bibr" rid="bib171">Uka et al., 2020</xref>). Altogether, we provide evidence that RNF43 can act as a tumor suppressor and a negative regulator of the acquisition of the resistance to the targeted therapy.</p><p>The relevance of our findings is likely not limited to melanoma. Signaling cascade RSPO–LGR4/5–RNRF43/ZNRF3 has been shown to regulate a variety of biological processes. In light of our results, it is tempting to speculate that WNT5A-RNF43 axis regulates other developmental, physiological, and pathophysiological conditions. For example, <italic>WNT5A</italic> is overexpressed in gastric cancer where it positively correlates with the presence of lymph node metastasis, tumor depth, EMT induction, and poor prognosis (<xref ref-type="bibr" rid="bib13">Astudillo, 2020</xref>; <xref ref-type="bibr" rid="bib54">Hanaki et al., 2012</xref>; <xref ref-type="bibr" rid="bib79">Kanzawa et al., 2013</xref>; <xref ref-type="bibr" rid="bib93">Kurayoshi et al., 2006</xref>; <xref ref-type="bibr" rid="bib116">Nam et al., 2017</xref>; <xref ref-type="bibr" rid="bib146">Saitoh et al., 2002</xref>). Notably, reduced RNF43 function is a negative prognosis factor in gastric cancer patients (<xref ref-type="bibr" rid="bib49">Gao et al., 2017</xref>; <xref ref-type="bibr" rid="bib119">Neumeyer et al., 2019a</xref>; <xref ref-type="bibr" rid="bib121">Niu et al., 2015</xref>) and RNF43 loss-of-function type of mutation exacerbated <italic>Helicobacter pylori</italic>-induced gastric tumor carcinogenesis associated with the upregulation of <italic>WNT5A</italic> mRNA level (<xref ref-type="bibr" rid="bib80">Katoh, 2007</xref>; <xref ref-type="bibr" rid="bib97">Li et al., 2014</xref>; <xref ref-type="bibr" rid="bib120">Neumeyer et al., 2019b</xref>; <xref ref-type="bibr" rid="bib130">Peek and Crabtree, 2006</xref>). Further, in colorectal cancer, RNF43 mutations were found to associate with <italic>BRAF</italic> V600E mutation (<xref ref-type="bibr" rid="bib108">Matsumoto et al., 2020</xref>; <xref ref-type="bibr" rid="bib186">Yan et al., 2017</xref>). These results suggest the existence of a more universal functional WNT5A-RNF43 axis where RNF43 acts as a gatekeeper guarding the abnormal pro-cancerogenic noncanonical Wnt pathway activation.</p><p>Further exciting avenues relate to the importance of RSPO-RNF43/ZNRF3 module in the regulation of multiple developmental processes dependent on WNT5A. There are literature hints that suggest that indeed WNT5A signaling is fine-tuned by RNF43/ZNRF3 during convergent extension movements. The regulation of Rspo3 has been proven in <italic>Xenopus</italic> embryogenesis, where it regulates gastrulation movements and head cartilage morphogenesis in a manner involving Wnt5a and Syndecan-4 binding by R-spondin. Strikingly, <italic>Rspo3</italic> antisense morpholino caused a phenotype characteristic for the noncanonical Wnt signaling pathway – <italic>spina bifida</italic> (<xref ref-type="bibr" rid="bib122">Ohkawara et al., 2011</xref>). Similarly, overexpression of <italic>Znrf3</italic> in zebrafish embryos caused shortened body axis and abnormal shape of somites, phenotypes also recognized as typical for Wnt/PCP pathway perturbances (<xref ref-type="bibr" rid="bib56">Hao et al., 2012</xref>). And, finally in mammals, a fraction of <italic>Znrf3</italic> KO mice showed an open neural tube phenotype (<xref ref-type="bibr" rid="bib56">Hao et al., 2012</xref>), again reminiscent of defective Wnt/PCP signaling. Altogether, these observations, together with our data, suggest that RSPO-RNF43/ZNRF3 signaling represents an evolutionary conserved and widely used mechanism used to control the activation of noncanonical WNT signaling.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>1. Cell lines and treatments</title><p>T-REx-293 (R71007, Thermo Fisher Scientific), GFP labeled human melanoma A375 wild-type (A375) and its metastatic derivates A375 IV (<xref ref-type="bibr" rid="bib92">Kucerova et al., 2014</xref>), A2058 (ECACC 91100402), and MelJuso (<xref ref-type="bibr" rid="bib157">Štětková et al., 2020</xref>) (kindly gifted by Stjepan Uldrijan) cell lines were propagated in the Dulbecco’s modified Eagle’s medium (DMEM, 41966-029, Gibco, Life Technologies) supplemented with the 10% fetal bovine serum (FBS, 10270-106, Gibco, Life Technologies), 2 mM L-glutamine (25030024, Life Technologies), 1% penicillin-streptomycin (XC-A4122/100, Biosera) under 5% (vol/vol) CO<sub>2</sub> controlled atmosphere at 37°C. Routine checks for mycoplasma contamination were performed. For inhibition of endogenous Wnt ligands, cells were treated with the 0.5 μM Porcupine inhibitors C-59 (ab142216, Abcam) or 1 μM LGK-974 (1241454, PeproTech). The time points and doses have been chosen based on the purpose of the experiment. Changes in the phosphorylation of the WNT5A-downstream proteins in the noncanonical Wnt pathway transduction have been analyzed after 3 hr with the recombinant human WNT5A (645-WN, R&amp;D Systems) in doses 40–100 ng/ml as given in the figure legends. Longer stimulation (overnight and longer) has been used in the functional experiments. For canonical Wnt signaling activation, the recombinant human WNT3A (5036-WN, R&amp;D Systems) was used overnight in 40 ng/ml, 60 ng/ml, or 80 ng/ml concentrations. Co-treatment with the recombinant human R-Sponidin-1 (120-38, PeproTech) in 50 ng/ml dose was applied where indicated. Dansylcadaverine (D4008, Sigma-Aldrich) 50 µM treatment along with 3 hr tetracycline was applied to block clathrin-dependent endocytosis pathway (<xref ref-type="bibr" rid="bib20">Blitzer and Nusse, 2006</xref>).</p><p>For preparation of stable cell lines, antibiotic selection after plasmid DNA transfection was performed using 5 μg/ml blasticidin S (3513-03-9, Santa Cruz Biotechnology) or 200 μg/ml of hygromycin B (31282-04-9, Santa Cruz Biotechnology) for T-REx-293 cells and accordingly 400 μg/ml and 5 μg/ml in case of A375 melanoma cell line. As a result, tetracycline-inducible T-REx-293 RNF43 and RNF43 Mut1 TetON, T-REx-293 <italic>RNF43</italic>/<italic>ZNRF3</italic> dKO RNF43 TetON, A375+ RNF43, and A375 IV + RNF43 were obtained. A2058 RNF43 TetON, MelJuso RNF43 TetON A375 RNF43 TetON, and A375 TetON ctrl (not expressing exogenous RNF43) cells were obtained by lentiviral transduction of doxycycline-inducible pCW57-RNF43 (blast) plasmid encoding HA- and FLAG- tagged RNF43, using published protocol (<xref ref-type="bibr" rid="bib16">Barta et al., 2016</xref>), followed by 5 μg/ml blasticidin S selection and limiting dilution.</p><p>T-REx-293 <italic>DVL1</italic>/<italic>2</italic>/<italic>3</italic> tKO cells were described previously (<xref ref-type="bibr" rid="bib128">Paclíková et al., 2017</xref>). For transgene expression induction (TetON), T-REx-293 cells were treated with 1 μg/ml of tetracycline (60-54-8, Santa Cruz Biotechnology) for the indicated time (3 hr to overnight) and melanoma cells were induced overnight by 1 μg/ml doxycycline (HY-N0565B, MedChem Express). Lysosomal degradation pathway was blocked by the 10 μM chloroquine (C662, Sigma) treatment, whereas 10 μM MG-132 (C2211, Sigma) was used for the proteasome inhibition. Generation of the melanoma cells resistant to vemurafenib (HY-12057, MedChem Express) and cobimetinib (HY-13064, MedChem Express) was performed according to the published protocols (<xref ref-type="bibr" rid="bib3">Anastas et al., 2014</xref>). Resistant cells were cultured in the presence of 2 μM (A375) and 5 μM (A2058) of vemurafenib and 0.5 μM cobimetinib or their combination (A2058). For transient treatments (24 hr) of melanoma cell lines, 0.5 μM vemurafenib has been used (A375) or 2.5 μM of vemurafenib and 0.5 μM of cobimetinib (A2058).</p></sec><sec id="s4-2"><title>2. Plasmids/cloning</title><p>Backbone of the plasmid pcDNA4-TO-RNF43-2xHA-2xFLAG (kindly gifted by Bon-Kyoung Koo together with pcDNA4-TO-RNF43Mut1-2xHA-2xFLAG; <xref ref-type="bibr" rid="bib88">Koo et al., 2012</xref>) was used for further cloning. Briefly, for generation of the BioID-inducible pcDNA4-TO-RNF43-BirA*-HA plasmid, cDNA encoding RNF43 without stop codon was amplified by the PCR and cloned into the pcDNA3.1 MCS-BirA(R118G)-HA (Addgene plasmid #36047; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:Addgene_36047">Addgene_36047</ext-link>) using HpaI (ER1031, Thermo Fisher Scientific) and EcoRI (ER0271, Thermo Fisher Scientific) restriction enzymes to fuse it in frame with the BirA*-HA sequence. Then, RNF43-BirA*-HA cDNA was amplified and cloned by the In-Fusion cloning method (639690, Takara Bio) into linearized by HindIII (ER0501, Thermo Fisher Scientific) and XbaI (ER0681, Thermo Fisher Scientific) pcDNA4-TO plasmid. To eliminate BirA* enzyme-mediated potential false-positive results, pcDNA3-RNF43-HA was prepared by subcloning RNF43 PCR product containing HA encoding sequence in the reverse primer to the pcDNA3 backbone (Invitrogen). pCW57-RNF43 (blast) plasmid was obtained by RNF43-HA-FLAG cDNA cloning into the EcoRI site of the pCW57-MCS1-P2A-MCS2 (Blast) backbone (Addgene #80921; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:Addgene_80921">Addgene_80921</ext-link>) by the In-Fusion cloning method. All obtained plasmids were verified by the Sanger sequencing method.</p><p>Other plasmids used were described previously and included myc-Vangl1, GFP-Vangl2, GFP-Vangl2ΔN, GFP-Vangl2ΔC, GFP-Vangl2ΔNΔC (<xref ref-type="bibr" rid="bib17">Belotti et al., 2012</xref>), pLAMP1-mCherry (Addgene #45147), pEGFP-C1-Rab5a (<xref ref-type="bibr" rid="bib28">Chen et al., 2009</xref>), GFP-rab11 WT (Addgene #12674), His-ubiquitin (<xref ref-type="bibr" rid="bib164">Tauriello et al., 2010</xref>), pcDNA3-Flag-mDvl1 (<xref ref-type="bibr" rid="bib164">Tauriello et al., 2010</xref>), pCMV5-3xFlag Dvl2 (Addgene #24802), pCDNA3.1-Flag-hDvl3 (<xref ref-type="bibr" rid="bib6">Angers et al., 2006</xref>), pcDNA3.1-hROR1-V5-His (gifted by Kateřina Tmějová), pcDNA3-Ror2-Flag and pcDNA3-Ror2-dCRD-FLAG (<xref ref-type="bibr" rid="bib147">Sammar et al., 2004</xref>), pRRL2_ROR1ΔCYTO and pRRL2_ROR1ΔTail (<xref ref-type="bibr" rid="bib50">Gentile et al., 2011</xref>), hCas9 (Addgene #41815), gRNA_GFP-T1 (Addgene #41819), and PiggyBack-Hygro and Transposase coding plasmids (gifted by Bon-Kyoung Koo). Sequences of primers used for cloning are presented in <xref ref-type="table" rid="table1">Table 1</xref>.</p><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>Cloning and mutagenesis primers.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Primer</th><th align="left" valign="bottom">Sequence</th><th align="left" valign="bottom">Purpose</th></tr></thead><tbody><tr><td align="left" valign="bottom">RNF43 BirA*F</td><td align="left" valign="bottom"><italic><named-content content-type="sequence">ATGCAGTTAACATGAGTGGTGGCCACCAGCTG</named-content></italic></td><td align="left" rowspan="2" valign="bottom">RNF43 cDNA cloning into pcDNA3.1 MCS-BirA(R118G)-HA</td></tr><tr><td align="left" valign="bottom">RNF43 BirA*R</td><td align="left" valign="bottom"><italic><named-content content-type="sequence">ATGCAGAATTCCACAGCCTGTTCACACAGCTCCT</named-content></italic></td></tr><tr><td align="left" valign="bottom">RNF43 InFusion F</td><td align="left" valign="bottom"><italic><named-content content-type="sequence">GTTTAAACTTAAGCTTATGAGTGGTGGCCACCAG</named-content></italic></td><td align="left" rowspan="2" valign="bottom">RNF43-BirA(R118G)-HA into pcDNA4</td></tr><tr><td align="left" valign="bottom">RNF43 InFusion R</td><td align="left" valign="bottom"><italic><named-content content-type="sequence">AAACGGGCCCTCTAGACTATGCGTAATCCGGTACA</named-content></italic></td></tr><tr><td align="left" valign="bottom">RNF43-HA F</td><td align="left" valign="bottom"><italic><named-content content-type="sequence">TTAAAGCTTATGAGTGGTGGCCACCAG</named-content></italic></td><td align="left" rowspan="2" valign="bottom">RNF43-HA cloning into pcDNA3</td></tr><tr><td align="left" valign="bottom">RNF43-HA R</td><td align="left" valign="bottom"><named-content content-type="sequence">ATCGATATCTCAAGCGTAATCTGGAACATCGTATGGG</named-content><named-content content-type="sequence">TACACAGCCTGTTCACACAGCT</named-content></td></tr><tr><td align="left" valign="bottom">pCW57-RNF43 InFusion F</td><td align="left" valign="bottom"><italic><named-content content-type="sequence">ATTGGCTAGCGAATTATGAGTGGTGGCCACCAGC</named-content></italic></td><td align="left" rowspan="2" valign="bottom">pCW57-RNF43 generation</td></tr><tr><td align="left" valign="bottom">pCW57-RNF43 InFusion R</td><td align="left" valign="bottom"><italic><named-content content-type="sequence">CGGTGTCGACGAATTTCAGGCGTAGTCGGGCACG</named-content></italic></td></tr></tbody></table></table-wrap></sec><sec id="s4-3"><title>3. CRISPR/Cas9</title><p>For targeting <italic>RNF43</italic> and <italic>ZNRF3</italic> in the T-Rex-293, gRNAs <italic><named-content content-type="sequence">TGAGTTCCATCGTAACTGTG<underline>TGG</underline></named-content></italic> (<underline>PAM</underline>) and <named-content content-type="sequence">AGACCCGCTCAAGAGGCCGG<underline>TGG</underline></named-content> were cloned into gRNA_GFP-T1 backbone and transfected together with PiggyBack-Hygro and Transposase coding plasmids using polyethylenimine (PEI) in a way described below. For <italic>ROR1</italic> and <italic>WNT5A</italic> knockout cell lines generation, gRNA <italic><named-content content-type="sequence">CCATCTATGGCTCTCGGCTG<underline>CGG</underline></named-content></italic> (ROR1) and <named-content content-type="sequence">AGTATCAATTCCGACATCGA<underline>AGG</underline></named-content> (WNT5A) were used. Transfected cells were hygromycine B selected and seeded as single cells. Genomic DNA isolation was performed using DirectPCR Lysis Reagent (Cell) (Viagen Biotech), Proteinase K (EO0491, Thermo Fisher Scientific), and DreamTaq DNA Polymerase (EP0701, Thermo Fisher Scientific) according to the manufacturer’s instructions. PCR products were analyzed by restriction digestion using Taal (ER1361, Thermo Fisher Scientific) in case of <italic>RNF43</italic>, HpaII (ER0511, Thermo Fisher Scientific) – <italic>ZNRF3</italic>, TaqI (ER0671, Thermo Fisher Scientific) – <italic>WNT5A</italic> and TseI (R0591S, New England BioLabs) – <italic>ROR1</italic> for detection of Cas9-mediated disruptions in the recognition sites.</p><p>For targeting <italic>RNF43</italic>/<italic>ZNRF3</italic> in the A375 and in the A375 IV melanoma lines, gRNAs <italic><named-content content-type="sequence">AGTTACGATGGAACTCA<underline>TGG</underline></named-content></italic> (RNF43) and <named-content content-type="sequence">CTCCAGACAGATGGCACAGT<underline>CGG</underline></named-content> (ZNRF3) were accordingly cloned by described protocol into the pU6-(BbsI)CBh-Cas9-T2A-mCherry (Addgene #64324) and pSpCas9(BB)-2A-GFP (PX458) (Addgene #48138) backbones, transfected and sorted as single, GFP, and mCherry double-positive cells. These were then analyzed by restriction enzymes Hin1II (ER1831, Thermo Fisher Scientific) and Taal as described above. Finally, PCR products were sequenced using the Illumina platform and compared with the reference sequence (<xref ref-type="bibr" rid="bib104">Malcikova et al., 2015</xref>). Sequencing results are presented in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>.</p></sec><sec id="s4-4"><title>4. RNF43 BioID analysis</title><p>Data are available via ProteomeXchange (<xref ref-type="bibr" rid="bib39">Deutsch et al., 2020</xref>) with identifier PXD020478 in the PRIDE database (<xref ref-type="bibr" rid="bib132">Perez-Riverol et al., 2019</xref>). The analysis of the mass spectrometric RAW data files was carried out using the MaxQuant software (version 1.6.2.10) using default settings unless otherwise noted. MS/MS ion searches were done against modified cRAP database (based on <ext-link ext-link-type="uri" xlink:href="http://www.thegpm.org/crap">http://www.thegpm.org/crap</ext-link>) containing protein contaminants like keratin, trypsin, etc., and UniProtKB protein database for <italic>Homo sapiens</italic> (<ext-link ext-link-type="uri" xlink:href="ftp://ftp.uniprot.org/pub/databases/uniprot/current_release/knowledgebase/reference_proteomes/Eukaryota/UP000005640_9606.fasta.gz">ftp://ftp.uniprot.org/pub/databases/uniprot/current_release/knowledgebase/reference_proteomes/Eukaryota/UP000005640_9606.fasta.gz</ext-link>; downloaded 19.8.2018, version 2018/08, number of protein sequences 21,053). Oxidation of methionine and proline, deamidation (N, Q) and acetylation (protein N-terminus) as optional modification, carbamidomethylation (C) as fixed modification, and trypsin/P enzyme with two allowed miss cleavages was set. Peptides and proteins with FDR threshold &lt;0.01 and proteins having at least one unique or razor peptide were considered only. Match between runs was set among all analyzed samples. Protein abundance was assessed using protein intensities calculated by MaxQuant. Protein intensities reported in proteinGroups.txt file (output of MaxQuant) were further processed using the software container environment (<ext-link ext-link-type="uri" xlink:href="https://github.com/OmicsWorkflows">https://github.com/OmicsWorkflows</ext-link>, <xref ref-type="bibr" rid="bib91">Kristina, 2021</xref>), version 3.7.2 a. Processing workflow is available upon request. Briefly, it covered (1) removal of decoy hits and contaminant protein groups, (2) protein group intensities log2 transformation, (3) LoessF normalization, (4) imputation by the global minimum, and (5) differential expression using LIMMA statistical test. Prior to volcano plot plotting, suspected BirA* binders were filtered out (proteins identified by at least two peptides in both technical replicates of particular BirA* sample, and present in more than three samples). Volcano plot was created in R using ggplot2 and ggrepel R packages by R version 3.6.1. Proteins with an adjusted p-value &lt; 0.05 and log fold change &gt;1 were further subjected to gene ontology tools, considering only the first ID of majority protein IDs: g:Profiler online tool (<ext-link ext-link-type="uri" xlink:href="https://biit.cs.ut.ee/gprofiler/gost">https://biit.cs.ut.ee/gprofiler/gost</ext-link>, version e98_eg45_p14_ce5b097; <xref ref-type="bibr" rid="bib141">Raudvere et al., 2019</xref>) was used and selected GO terms were highlighted. RNF43 interactors from BioID assay are listed in <xref ref-type="supplementary-material" rid="fig1sdata1">Figure 1—source data 1</xref>, and the results obtained by g:Profiler are presented in <xref ref-type="supplementary-material" rid="fig1sdata2">Figure 1—source data 2</xref>.</p></sec><sec id="s4-5"><title>5. Transfection</title><p>T-REx-293 cells were transected using 1 μg/ml, pH 7.4 PEI, and plasmid DNA in a 4:1 ratio (<xref ref-type="bibr" rid="bib128">Paclíková et al., 2017</xref>). Plasmid DNA were in amount of 3 µg for 6 cm culture dish (ubiquitination assay) and 6 µg for 10 cm dish (co-immunoprecipitation or stable cell lines preparation). Approximately 1 × 10<sup>6</sup> of A375 and A375 IV cells were electroporated with 6 μg of plasmid DNA utilizing Neon Transfection System (Thermo Fisher Scientific) 1200 V, 40 ms, 1 pulse. Culture media were changed 6 hr post-transfection.</p></sec><sec id="s4-6"><title>6. His-ubiquitin pulldown assay</title><p>Cells were transfected with the plasmid encoding polyhistidine-tagged ubiquitin, RNF43-HA, or enzymatically inactive RNF43, protein of interest, and cultured overnight. Next, cells were treated with 0.2 µM epoxomicin (E3652, Sigma) for 4 hr and lysed in the buffer containing 6 M guanidine hydrochloride (G3272, Sigma), 0.1 M Na<sub>x</sub>H<sub>x</sub>PO<sub>4</sub> pH 8.0, and 10 mM imidazole (I5513, Sigma), sonicated, and boiled. Insoluble fraction was removed by the centrifugation (16,000 g, room temperature [RT], 10 min). For the pull down of tagged proteins, 10 µl of equilibrated in lysis buffer His Mag Sepharose beads Ni (GE28-9799-17, GE Healthcare) was added to each sample and kept on a roller overnight. Then, the beads were washed three times in the buffer containing 8 M urea (U5378, Sigma), 0.1 M Na<sub>x</sub>H<sub>x</sub>PO<sub>4</sub> pH 6.3, 0.01 M Tris, and 15 mM imidazole, resuspended in 100 μl of western blot sample buffer, boiled for 5 min, and loaded onto SDS-PAGE gel. Approximately 10% of cellular lysate was used as a transfection control after ethanol precipitation and resuspension in the western blot sample buffer.</p></sec><sec id="s4-7"><title>7. Western blotting and antibodies</title><p>Western blot analysis was performed as described before using samples with the same protein amount, measured by the DC Protein Assay (5000111, Bio-Rad), or lysed directly in the sample buffer (2% SDS, 10% glycerol, 5% β-mercaptoethanol, 0.002% bromophenol blue, and 0.06 M Tris HCl, pH 6.8) and protease inhibitor cocktail (11836145001, Roche) after PBS wash (<xref ref-type="bibr" rid="bib110">Mentink et al., 2018</xref>). Protein extraction from mouse tissues was done by homogenizing in the 1% SDS, 100 mM NaCl, 100 mM Tris, pH 7.4 buffer, sonication, clarification by centrifugation (16,000 g, 4°C, 15 min), and protein concentration measurement. Next, volumes of samples containing the same protein amounts were mixed with western blot sampling buffer and loaded onto SDS-PAGE gels. Briefly, after electrophoretic separation, proteins were transferred onto Immobilon-P PVDF Membrane (IPVH00010, Millipore) and detected using primary and corresponding HRP-conjugated secondary antibodies on Fusion SL imaging system (Vibler) using Immobilon Western Chemiluminescent HRP Substrate (Merck, WBKLS0500). Molecular size of the bands is marked in each panel (kDa). A list of used antibodies is presented in Appendix 1—key resources table. Shifts of ROR1, ROR2, DVL2, DVL3, VANGL1, and VANGL2 are marked by arrowheads. Empty arrowhead marks phosphorylation-dependent shift. Densitometric analysis of western blot signals was performed using ImageJ software. Activation level of DVL2 and DVL3 (<xref ref-type="bibr" rid="bib23">Bryja et al., 2007a</xref>) is presented as the ratio of intensities of upper band; representing active – phosphorylated protein fraction and lower band (black arrowhead; unphosphorylated). Total DVL2 and DVL3 levels were quantified as the sum of two bands intensities.</p></sec><sec id="s4-8"><title>8. Immunofluorescence and confocal microscopy</title><p>Cells growing on the glass were fixed in 4% paraformaldehyde (PFA) in PBS. Fixed cells were permeabilized by 0.1% Triton X-100 in PBS and blocked in 1% solution of bovine serum albumin (BSA) in PBS. Then, samples were incubated overnight at 4°C with primary antibodies diluted in 1% BSA in PBS and washed. Corresponding Alexa Fluor secondary antibodies (Invitrogen) were incubated with samples for 1 hr at RT, along with 1 µg/ml Hoechst 33342 (H1399, Thermo Fisher Scientific) for nuclei staining. After PBS washes, the samples were mounted in the DAKO mounting medium (S3023, DAKO). Images were taken on the confocal laser scanning microscopy platform Leica TCS SP8 (Leica). For co-localization analysis, histograms for each channel were prepared in LAS X Life Science (Leica) software and plotted in GraphPad Prism 8. Co-localization is marked by arrowheads.</p></sec><sec id="s4-9"><title>9. Immunoprecipitation</title><p>T-REx-293 cells were transfected with the proper plasmid DNA and cultured for 24 hr. Then, cells were washed two times with PBS and lysed for 15 min in the buffer containing 50 mM Tris pH7.6, 200 mM NaCl, 1 mM EDTA, 0.5% NP40, fresh 0.1 mM DTT (E3876, Sigma) and protease inhibitor cocktail (04693159001, Roche). Insoluble fraction was removed by centrifugation (16,000 g, RT, 15 min), 10% of total cell lysate was kept as western blot control. Lysates were incubated with 1 μg of antibody for 16 hr at 4°C on the head-over-tail rotator. Next, 20 μl of protein G-Sepharose beads (17-0618-05; GE Healthcare) equilibrated in complete lysis buffer were added to each sample and incubated for 4 hr at 4°C, following six washes using lysis buffer and resuspension in 100 μl of western blot sample buffer. Immunoprecipitation experiments were analyzed by the western blot.</p></sec><sec id="s4-10"><title>10. Flow cytometric determination of ROR1 surface expression</title><p>Determination of the ROR1 surface expression of T-REx-293 and its derivates was done using anti-ROR1-APC (#130-119-860, Miltenyi Biotec) and Accuri C6 (BD Biosciences) (<italic>RNF43</italic>/<italic>ZNRF3</italic> dKO cells) or using BD FACSVerse Flow Cytometer (BD Biosciences) (TetON cells). Cells were harvested in 0.5 mM EDTA/PBS, washed in PBS, and incubated in 2% FBS in PBS with anti-ROR1-APC antibody (1:25, #130-119-860, Miltenyi Biotec) on ice for 30 min. The cells were washed and resuspended in PBS, and incubated with propidium iodide (10 ng/ml, #81845, Sigma-Aldrich) for 5 min to exclude dead cells from analysis. For the detection of ROR1 surface expression in HA-positive cells, ROR1-APC-stained cells were washed in PBS, fixed in 4% PFA at RT for 15 min, permeabilized in 0.02% Triton X-100 at RT for 15 min, and incubated with anti-HA antibody (1:1000, #9110, Abcam) in staining buffer at RT for 30 min. After two washes, cells were incubated with secondary antibody ALEXA Fluor 488 Donkey anti-Rabbit (#A21206, Invitrogen) at RT for 20 min, washed, and measured using FACS Verse (BD Biosciences). Data were analyzed using NovoExpress Software (ACEA Biosciences).</p></sec><sec id="s4-11"><title>11. Quantitative polymerase chain reaction (qPCR)</title><p>Messenger RNA was isolated using the RNeasy Mini Kit (74106; Qiagen) according to the manufacturer’s instructions. 1 μg of mRNA was transcribed to cDNA by the RevertAid Reverse Transcriptase (EP0442, Thermo Fisher Scientific) and analyzed by use of LightCycler 480 SYBR Green I Master (04887352001, Roche) and LightCycler LC480 (Roche). Results are presented as 2<sup>−ΔΔ<italic>CT</italic></sup> and compared by unpaired Student’s t-test. Mean expression of <italic>B2M</italic> and <italic>GAPDH</italic> or <italic>HSPCB</italic> and <italic>RPS13</italic> (A375 VR cells) was used as reference. Primers are listed in Appendix 1—key resources table.</p></sec><sec id="s4-12"><title>12. Databases</title><p>RNF43, VANGL1, and DVL3 gene expression in different melanoma stages was analyzed through Oncomine (RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_007834">SCR_007834</ext-link>; <xref ref-type="bibr" rid="bib142">Rhodes et al., 2004</xref>) database in the different datasets (<xref ref-type="bibr" rid="bib162">Talantov et al., 2005</xref>, <xref ref-type="bibr" rid="bib185">Xu et al., 2008</xref>, <xref ref-type="bibr" rid="bib58">Haqq et al., 2005</xref>). OncoLnc (<xref ref-type="bibr" rid="bib4">Anaya, 2016</xref>) database was employed to elucidate whether the expression of the <italic>RNF43</italic>, <italic>ZNRF3</italic>, <italic>VANGL1,</italic> and <italic>DVL3</italic> gene expression has a significant impact on the melanoma patients’ overall survival. RNF43 BioID data are available via ProteomeXchange (RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_004055">SCR_004055</ext-link>; <xref ref-type="bibr" rid="bib39">Deutsch et al., 2020</xref>) in the PRIDE database (PXD020478) (RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_003411">SCR_003411</ext-link>; <xref ref-type="bibr" rid="bib132">Perez-Riverol et al., 2019</xref>).</p></sec><sec id="s4-13"><title>13. Wound healing assay, Matrigel invasion assay, fluorescent gelatin degradation assay, invadopodia formation assay, and collagen I hydrogel 3D invasion assay</title><p>For the determination of cellular motility and invasive properties in vitro wound healing (<xref ref-type="bibr" rid="bib124">O’Connell et al., 2008</xref>), Matrigel invasion towards 20% FBS as chemoattractant followed by crystal violet staining of invaded cells, fluorescent gelatin degradation in the presence of 5% FBS after overnight starvation, and invadopodia formation assays were prepared according to the established protocols (<xref ref-type="bibr" rid="bib103">Makowiecka et al., 2016</xref>). The wound gap was photographed using the Olympus ix51 inverted fluorescence microscope after 48 hr from scratch. Percentage of the cell-free surface was measured by ImageJ software. For the fluorescent gelatin degradation assay purpose, 80 ng/ml of rhWNT5A was used during 16 hr of cells’ incubation on the coverslips coated with gelatin-Oregon Green conjugate (G13186, Thermo Fisher Scientific). Alexa Fluor 594 phalloidin (A12381, Thermo Fisher Scientific) and TO-PRO-3 Iodide (642/661) were employed for the cells’ visualization on confocal microscopy platform Leica TCS SP8. For the invadopodia formation assay, an immunofluorescence imaging protocol employing phalloidin and anti-cortactin antibody was performed. Invadopodia – as structures double positive for F-actin and cortactin staining – was quantified for tested cell lines and conditions and presented as the number of invadopodia per one cell. Two independent repetitions were performed.</p><p>Collagen I hydrogel 3D invasion assay is a modification of the inverted vertical invasion assay (<xref ref-type="bibr" rid="bib109">McArdle et al., 2016</xref>). Cells were plated on the µ-Slide 8 Well glass bottom coverslips (80827, Ibidi). At 80% confluence, the full medium was replaced with one containing 0.5% FBS for proliferation suppression. Doxycycline for RNF43 induction was applied at this step when needed. Next day, a solution of rat tail collagen type I in final concentration 1.5 mg/ml prepared accordingly to the manufacturer’s protocol was overlaid over the cells and left for polymerization for 30 min at 37°C, 5% CO<sub>2</sub>. Then medium with final FBS concentration 10% and 100 ng/ml CXCL12 (350-NS, R&amp;D Systems) or 100 ng/ml CCL21 (366-6C, R&amp;D Systems) was added to the wells. After 24 hr, cells were PFA fixed, permeabilized, and stained with Hoechst 33342 (H1399, Thermo Fisher Scientific) and Alexa Fluor 594 phalloidin. Corresponding photos at the coverslip level and at 50 μm (A375 and A2058) or 70 μm (A375 IV) were taken using a confocal laser scanning microscopy platform Leica TCS SP8 (Leica). Invasion index was calculated as the ratio of invaded cells at a specified height to the number of noninvasive ones.</p></sec><sec id="s4-14"><title>14. Colony formation assay</title><p>To assess the ability of colony formation in the presence of 0.3 μM vemurafenib, 300 of the melanoma cells were plated onto 24-well plate and were subsequently cultured for 7 days. After that time, the medium was removed and colonies were washed in PBS, fixed in the ice-cold methanol for 30 min, and stained with 0.5% crystal violet in 25% methanol. After washing and drying, bound crystal violate was eluted with 10% acetic acid and absorbance at 590 nm was measured on Tecan Sunrise plate reader. Results were normalized to the nontreated A375 wild-type results.</p></sec><sec id="s4-15"><title>15. Animal studies</title><p>Animal experiments were approved by the Academy of Sciences of the Czech Republic (AVCR 85/2018), supervised by the local ethical committee, and performed by certified individuals (Karel Souček, Markéta Pícková, Ráchel Víchová).</p><p>A375 ctrl and A375 RNF43 TetON cells were implanted as a suspension of 50,000 cells in 50 μl saline intradermally into 9-week-old males of NOD-Rag1<sup>null</sup> IL2rg<sup>null</sup> strain, obtained from Jackson Laboratory. Animals were checked daily, and weight and tumors sizes were measured weekly along perpendicular axes using an external caliper. Tumor volumes were calculated using the equation volume = ½ (length × width<sup>2</sup>). Upon tumor establishment, animals were divided into five cohorts based on administered cells and treatment: (I) A375 ctrl + vemurafenib (N = 5); (II) A375 RNF43 TetON Dox - (N = 3); (III) A375 RNF43 TetON Dox + (N = 4); (IV) A375 RNF43 TetON VEMURAFENIB Dox - (N = 5); and (V) A375 RNF43 TetON VEMURAFENIB Dox + (N = 4). Doxycycline supplemented for RNF43 expression induction was administrated in drinking water, 0.2 mg/ml in 0.1% weight:volume sucrose. Control cohort obtained drinking water with 0.1% sucrose. Vemurafenib was supplemented daily by oral gavage in concentration of 25 mg/kg/day as freshly prepared formulation in 25% Kolliphor ELP (61791-12-6, Sigma-Aldrich) with 2.5% DMSO. Animals not treated with vemurafenib received the same formulation without inhibitor. Mice were sacrificed when tumors reached approximately 1000 mm<sup>3</sup>. Tumor samples were analyzed by western blot, and the times to reach the experimental end point was compared.</p></sec><sec id="s4-16"><title>16. Software and statistics</title><p>Statistical significance was confirmed by two-tailed paired or unpaired Student’s t-tests. Survival was analyzed by Mantel–Cox test. Correlation between RNF43(HA) protein level and its targets in the in vivo experiments was tested by one-tailed Spearman correlation test. Statistical significance levels were defined as *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, ****p&lt;0.0001. All statistical details including the number of biological or technical replicates can be found in each figure legend. Statistical analysis and data visualization were performed in GraphPad Prism 8.0 software. Graphs are presented with error bars as ± SD if not stated differently in the figure legends.</p></sec></sec></body><back><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Formal analysis, Investigation, Methodology, Validation, Visualization, Writing - original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con2"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con3"><p>Data curation, Formal analysis, Investigation, Methodology, Software, Visualization</p></fn><fn fn-type="con" id="con4"><p>Investigation, Methodology, Visualization</p></fn><fn fn-type="con" id="con5"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con6"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con7"><p>Investigation</p></fn><fn fn-type="con" id="con8"><p>Investigation</p></fn><fn fn-type="con" id="con9"><p>Investigation, Resources</p></fn><fn fn-type="con" id="con10"><p>Investigation</p></fn><fn fn-type="con" id="con11"><p>Resources, Supervision</p></fn><fn fn-type="con" id="con12"><p>Dr. Tomáš Bárta performed experiments applied in the revised submission. Authors agree with their inclusion and place in the author list, Investigation</p></fn><fn fn-type="con" id="con13"><p>Data curation, Investigation, Methodology, Supervision</p></fn><fn fn-type="con" id="con14"><p>Resources, Supervision</p></fn><fn fn-type="con" id="con15"><p>Investigation, Methodology, Supervision</p></fn><fn fn-type="con" id="con16"><p>Conceptualization, Funding acquisition, Supervision, Validation, Writing - original draft, Writing - review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experiments were approved by the Academy of Sciences of the Czech Republic (AVCR 85/2018), supervised by the local ethical committee, and performed by certified individuals.</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="transrepform"><label>Transparent reporting form</label><media mime-subtype="docx" mimetype="application" xlink:href="elife-65759-transrepform1-v1.docx"/></supplementary-material><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Sequencing of the CRISPR/Cas9 derived cell lines.</title></caption><media mime-subtype="pptx" mimetype="application" xlink:href="elife-65759-supp1-v1.pptx"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>All data generated or analysed during this study are included in the manuscript and supporting files. Source data files are also provided.</p><p>The following previously published datasets were used:</p><p><element-citation id="dataset1" publication-type="data" specific-use="references"><person-group person-group-type="author"><name><surname>Spit</surname><given-names>M</given-names></name><name><surname>Fenderico</surname><given-names>N</given-names></name><name><surname>Jordens</surname><given-names>I</given-names></name><name><surname>Radaszkiewicz</surname><given-names>T</given-names></name><name><surname>Lindeboom</surname><given-names>RG</given-names></name><name><surname>Bugter</surname><given-names>JM</given-names></name><name><surname>Cristobal</surname><given-names>A</given-names></name><name><surname>Ootes</surname><given-names>L</given-names></name><name><surname>van Osch</surname><given-names>M</given-names></name><name><surname>Janssen</surname><given-names>E</given-names></name><name><surname>Boonekamp</surname><given-names>KE</given-names></name><name><surname>Hanakova</surname><given-names>K</given-names></name><name><surname>Potesil</surname><given-names>D</given-names></name><name><surname>Zdrahal</surname><given-names>Z</given-names></name><name><surname>Boj</surname><given-names>SF</given-names></name><name><surname>Medema</surname><given-names>JP</given-names></name><name><surname>Bryja</surname><given-names>V</given-names></name><name><surname>Koo</surname><given-names>BK</given-names></name><name><surname>Vermeulen</surname><given-names>M</given-names></name><name><surname>Maurice</surname><given-names>MM</given-names></name></person-group><year iso-8601-date="2020">2020</year><data-title>RNF43 truncations trap CK1 to drive niche-independent self-renewal in cancer</data-title><source>ProteomeXchange</source><pub-id pub-id-type="accession" xlink:href="http://proteomecentral.proteomexchange.org/cgi/GetDataset?ID=PXD020478">PXD020478</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>We thank Lucie Nesvadbová, Lenka Bryjová, Pavlína Žofka Mrhálková, Lenka Doubková, and Naďa Bílá for excellent assistance. We also would like to express our gratitude to Adrienne A Boire and Jan Remsik (Memorial Sloan Kettering Cancer Center) and to Stjepan Uldrijan (Masaryk University) for their help with study models.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahn</surname><given-names>A</given-names></name><name><surname>Chatterjee</surname><given-names>A</given-names></name><name><surname>Eccles</surname><given-names>MR</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>The Slow Cycling Phenotype: A Growing Problem for Treatment Resistance in Melanoma</article-title><source>Molecular Cancer Therapeutics</source><volume>16</volume><fpage>1002</fpage><lpage>1009</lpage><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-16-0535</pub-id><pub-id pub-id-type="pmid">28576947</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akbani</surname><given-names>R</given-names></name><name><surname>Akdemir KC</surname><given-names>KC</given-names></name><name><surname>Aksoy BA</surname><given-names>BA</given-names></name><name><surname>Albert M</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Genomic classification of cutaneous melanoma</article-title><source>Cell</source><volume>161</volume><fpage>1681</fpage><lpage>1696</lpage><pub-id pub-id-type="doi">10.1016/J.CELL.2015.05.044</pub-id><pub-id pub-id-type="pmid">26091043</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anastas</surname><given-names>JN</given-names></name><name><surname>Kulikauskas</surname><given-names>RM</given-names></name><name><surname>Tamir</surname><given-names>T</given-names></name><name><surname>Rizos</surname><given-names>H</given-names></name><name><surname>Long</surname><given-names>GV</given-names></name><name><surname>von Euw</surname><given-names>EM</given-names></name><name><surname>Yang</surname><given-names>PT</given-names></name><name><surname>Chen</surname><given-names>HW</given-names></name><name><surname>Haydu</surname><given-names>L</given-names></name><name><surname>Toroni</surname><given-names>RA</given-names></name><name><surname>Lucero</surname><given-names>OM</given-names></name><name><surname>Chien</surname><given-names>AJ</given-names></name><name><surname>Moon</surname><given-names>RT</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>WNT5A enhances resistance of melanoma cells to targeted BRAF inhibitors</article-title><source>The Journal of Clinical Investigation</source><volume>124</volume><fpage>2877</fpage><lpage>2890</lpage><pub-id pub-id-type="doi">10.1172/JCI70156</pub-id><pub-id pub-id-type="pmid">24865425</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anaya</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>OncoLnc: linking TCGA survival data to mRNAs, miRNAs, and lncRNAs</article-title><source>PeerJ Computer Science</source><volume>2</volume><elocation-id>e67</elocation-id><pub-id pub-id-type="doi">10.7717/peerj-cs.67</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andre</surname><given-names>P</given-names></name><name><surname>Song</surname><given-names>H</given-names></name><name><surname>Kim</surname><given-names>W</given-names></name><name><surname>Kispert</surname><given-names>A</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Wnt5a and Wnt11 regulate mammalian anterior-posterior axis elongation</article-title><source>Development</source><volume>142</volume><fpage>1516</fpage><lpage>1527</lpage><pub-id pub-id-type="doi">10.1242/dev.119065</pub-id><pub-id pub-id-type="pmid">25813538</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Angers</surname><given-names>S</given-names></name><name><surname>Thorpe</surname><given-names>CJ</given-names></name><name><surname>Biechele</surname><given-names>TL</given-names></name><name><surname>Goldenberg</surname><given-names>SJ</given-names></name><name><surname>Zheng</surname><given-names>N</given-names></name><name><surname>MacCoss</surname><given-names>MJ</given-names></name><name><surname>Moon</surname><given-names>RT</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>The KLHL12–Cullin-3 ubiquitin ligase negatively regulates the Wnt–β-catenin pathway by targeting Dishevelled for degradation</article-title><source>Nature Cell Biology</source><volume>8</volume><fpage>348</fpage><lpage>357</lpage><pub-id pub-id-type="doi">10.1038/ncb1381</pub-id><pub-id pub-id-type="pmid">16547521</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arozarena</surname><given-names>I</given-names></name><name><surname>Bischof</surname><given-names>H</given-names></name><name><surname>Gilby</surname><given-names>D</given-names></name><name><surname>Belloni</surname><given-names>B</given-names></name><name><surname>Dummer</surname><given-names>R</given-names></name><name><surname>Wellbrock</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>In melanoma, beta-catenin is a suppressor of invasion</article-title><source>Oncogene</source><volume>30</volume><fpage>4531</fpage><lpage>4543</lpage><pub-id pub-id-type="doi">10.1038/onc.2011.162</pub-id><pub-id pub-id-type="pmid">21577209</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arozarena</surname><given-names>I</given-names></name><name><surname>Wellbrock</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2017">2017a</year><article-title>Overcoming resistance to BRAF inhibitors</article-title><source>Annals of Translational Medicine</source><volume>5</volume><elocation-id>387</elocation-id><pub-id pub-id-type="doi">10.21037/atm.2017.06.09</pub-id><pub-id pub-id-type="pmid">29114545</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arozarena</surname><given-names>I</given-names></name><name><surname>Wellbrock</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2017">2017b</year><article-title>Targeting invasive properties of melanoma cells</article-title><source>The FEBS Journal</source><volume>284</volume><fpage>2148</fpage><lpage>2162</lpage><pub-id pub-id-type="doi">10.1111/febs.14040</pub-id><pub-id pub-id-type="pmid">28196297</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arozarena</surname><given-names>I</given-names></name><name><surname>Wellbrock</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Phenotype plasticity as enabler of melanoma progression and therapy resistance</article-title><source>Nature Reviews. Cancer</source><volume>19</volume><fpage>377</fpage><lpage>391</lpage><pub-id pub-id-type="doi">10.1038/s41568-019-0154-4</pub-id><pub-id pub-id-type="pmid">31209265</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ascierto</surname><given-names>PA</given-names></name><name><surname>McArthur</surname><given-names>GA</given-names></name><name><surname>Dréno</surname><given-names>B</given-names></name><name><surname>Atkinson</surname><given-names>V</given-names></name><name><surname>Liszkay</surname><given-names>G</given-names></name><name><surname>Di Giacomo</surname><given-names>AM</given-names></name><name><surname>Mandalà</surname><given-names>M</given-names></name><name><surname>Demidov</surname><given-names>L</given-names></name><name><surname>Stroyakovskiy</surname><given-names>D</given-names></name><name><surname>Thomas</surname><given-names>L</given-names></name><name><surname>de la Cruz-Merino</surname><given-names>L</given-names></name><name><surname>Dutriaux</surname><given-names>C</given-names></name><name><surname>Garbe</surname><given-names>C</given-names></name><name><surname>Yan</surname><given-names>Y</given-names></name><name><surname>Wongchenko</surname><given-names>M</given-names></name><name><surname>Chang</surname><given-names>I</given-names></name><name><surname>Hsu</surname><given-names>JJ</given-names></name><name><surname>Koralek</surname><given-names>DO</given-names></name><name><surname>Rooney</surname><given-names>I</given-names></name><name><surname>Ribas</surname><given-names>A</given-names></name><name><surname>Larkin</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial</article-title><source>The Lancet. Oncology</source><volume>17</volume><fpage>1248</fpage><lpage>1260</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(16)30122-X</pub-id><pub-id pub-id-type="pmid">27480103</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Asem</surname><given-names>MS</given-names></name><name><surname>Buechler</surname><given-names>S</given-names></name><name><surname>Wates</surname><given-names>RB</given-names></name><name><surname>Miller</surname><given-names>DL</given-names></name><name><surname>Stack</surname><given-names>MS</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>WNT5A signaling in cancer</article-title><source>Cancers</source><volume>8</volume><elocation-id>E79</elocation-id><pub-id pub-id-type="doi">10.3390/cancers8090079</pub-id><pub-id pub-id-type="pmid">27571105</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Astudillo</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>WNT5A signaling in gastric cancer</article-title><source>Frontiers in Cell and Developmental Biology</source><volume>8</volume><elocation-id>110</elocation-id><pub-id pub-id-type="doi">10.3389/fcell.2020.00110</pub-id><pub-id pub-id-type="pmid">32195251</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bache</surname><given-names>KG</given-names></name><name><surname>Raiborg</surname><given-names>C</given-names></name><name><surname>Mehlum</surname><given-names>A</given-names></name><name><surname>Stenmark</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Stam and hrs are subunits of a multivalent ubiquitin-binding complex on early endosomes</article-title><source>The Journal of Biological Chemistry</source><volume>278</volume><fpage>12513</fpage><lpage>12521</lpage><pub-id pub-id-type="doi">10.1074/jbc.M210843200</pub-id><pub-id pub-id-type="pmid">12551915</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bai</surname><given-names>X</given-names></name><name><surname>Fisher</surname><given-names>DE</given-names></name><name><surname>Flaherty</surname><given-names>KT</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Cell-state dynamics and therapeutic resistance in melanoma from the perspective of MITF and IFNΓ pathways</article-title><source>Nature Reviews. Clinical Oncology</source><volume>16</volume><fpage>549</fpage><lpage>562</lpage><pub-id pub-id-type="doi">10.1038/S41571-019-0204-6</pub-id><pub-id pub-id-type="pmid">30967646</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barta</surname><given-names>T</given-names></name><name><surname>Peskova</surname><given-names>L</given-names></name><name><surname>Hampl</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Mirnasong: A web-based tool for generation and testing of mirna sponge constructs in silico</article-title><source>Scientific Reports</source><volume>6</volume><elocation-id>36625</elocation-id><pub-id pub-id-type="doi">10.1038/srep36625</pub-id><pub-id pub-id-type="pmid">27857164</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Belotti</surname><given-names>E</given-names></name><name><surname>Puvirajesinghe</surname><given-names>TM</given-names></name><name><surname>Audebert</surname><given-names>S</given-names></name><name><surname>Baudelet</surname><given-names>E</given-names></name><name><surname>Camoin</surname><given-names>L</given-names></name><name><surname>Pierres</surname><given-names>M</given-names></name><name><surname>Lasvaux</surname><given-names>L</given-names></name><name><surname>Ferracci</surname><given-names>G</given-names></name><name><surname>Montcouquiol</surname><given-names>M</given-names></name><name><surname>Borg</surname><given-names>JP</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Molecular characterisation of endogenous Vangl2/vangl1 heteromeric protein complexes</article-title><source>PLOS ONE</source><volume>7</volume><elocation-id>e46213</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0046213</pub-id><pub-id pub-id-type="pmid">23029439</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Binnerts</surname><given-names>ME</given-names></name><name><surname>Kim</surname><given-names>KA</given-names></name><name><surname>Bright</surname><given-names>JM</given-names></name><name><surname>Patel</surname><given-names>SM</given-names></name><name><surname>Tran</surname><given-names>K</given-names></name><name><surname>Zhou</surname><given-names>M</given-names></name><name><surname>Leung</surname><given-names>JM</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Lomas</surname><given-names>WE</given-names></name><name><surname>Dixon</surname><given-names>M</given-names></name><name><surname>Hazell</surname><given-names>SA</given-names></name><name><surname>Wagle</surname><given-names>M</given-names></name><name><surname>Nie</surname><given-names>WS</given-names></name><name><surname>Tomasevic</surname><given-names>N</given-names></name><name><surname>Williams</surname><given-names>J</given-names></name><name><surname>Zhan</surname><given-names>X</given-names></name><name><surname>Levy</surname><given-names>MD</given-names></name><name><surname>Funk</surname><given-names>WD</given-names></name><name><surname>Abo</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>R-SPONDIN1 regulates wnt signaling by inhibiting internalization of lrp6</article-title><source>PNAS</source><volume>104</volume><fpage>14700</fpage><lpage>14705</lpage><pub-id pub-id-type="doi">10.1073/pnas.0702305104</pub-id><pub-id pub-id-type="pmid">17804805</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Birkeland</surname><given-names>E</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Poduval</surname><given-names>D</given-names></name><name><surname>Geisler</surname><given-names>J</given-names></name><name><surname>Nakken</surname><given-names>S</given-names></name><name><surname>Vodak</surname><given-names>D</given-names></name><name><surname>Meza-Zepeda</surname><given-names>LA</given-names></name><name><surname>Hovig</surname><given-names>E</given-names></name><name><surname>Myklebost</surname><given-names>O</given-names></name><name><surname>Knappskog</surname><given-names>S</given-names></name><name><surname>Lønning</surname><given-names>PE</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Patterns of genomic evolution in advanced melanoma</article-title><source>Nature Communications</source><volume>9</volume><elocation-id>2665</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-018-05063-1</pub-id><pub-id pub-id-type="pmid">29991680</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blitzer</surname><given-names>JT</given-names></name><name><surname>Nusse</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>A critical role for endocytosis in Wnt signaling</article-title><source>BMC Cell Biology</source><volume>7</volume><elocation-id>28</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2121-7-28</pub-id><pub-id pub-id-type="pmid">16824228</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bollag</surname><given-names>G</given-names></name><name><surname>Tsai</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Ibrahim</surname><given-names>P</given-names></name><name><surname>Nolop</surname><given-names>K</given-names></name><name><surname>Hirth</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>VEMURAFENIB: The first drug approved for braf-mutant cancer</article-title><source>Nature Reviews. Drug Discovery</source><volume>11</volume><fpage>873</fpage><lpage>886</lpage><pub-id pub-id-type="doi">10.1038/nrd3847</pub-id><pub-id pub-id-type="pmid">23060265</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bond</surname><given-names>CE</given-names></name><name><surname>McKeone</surname><given-names>DM</given-names></name><name><surname>Kalimutho</surname><given-names>M</given-names></name><name><surname>Bettington</surname><given-names>ML</given-names></name><name><surname>Pearson</surname><given-names>SA</given-names></name><name><surname>Dumenil</surname><given-names>TD</given-names></name><name><surname>Wockner</surname><given-names>LF</given-names></name><name><surname>Burge</surname><given-names>M</given-names></name><name><surname>Leggett</surname><given-names>BA</given-names></name><name><surname>Whitehall</surname><given-names>VLJ</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>RNF43 and znrf3 are commonly altered in serrated pathway colorectal tumorigenesis</article-title><source>Oncotarget</source><volume>7</volume><fpage>70589</fpage><lpage>70600</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.12130</pub-id><pub-id pub-id-type="pmid">27661107</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bryja</surname><given-names>V</given-names></name><name><surname>Schulte</surname><given-names>G</given-names></name><name><surname>Arenas</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2007">2007a</year><article-title>Wnt-3a utilizes a novel low dose and rapid pathway that does not require casein kinase 1-mediated phosphorylation of Dvl to activate beta-catenin</article-title><source>Cellular Signalling</source><volume>19</volume><fpage>610</fpage><lpage>616</lpage><pub-id pub-id-type="doi">10.1016/j.cellsig.2006.08.011</pub-id><pub-id pub-id-type="pmid">17027228</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bryja</surname><given-names>V</given-names></name><name><surname>Schulte</surname><given-names>G</given-names></name><name><surname>Rawal</surname><given-names>N</given-names></name><name><surname>Grahn</surname><given-names>A</given-names></name><name><surname>Arenas</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2007">2007b</year><article-title>Wnt-5a induces dishevelled phosphorylation and dopaminergic differentiation via a ck1-dependent mechanism</article-title><source>Journal of Cell Science</source><volume>120</volume><fpage>586</fpage><lpage>595</lpage><pub-id pub-id-type="doi">10.1242/jcs.03368</pub-id><pub-id pub-id-type="pmid">17244647</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bucci</surname><given-names>C</given-names></name><name><surname>Parton</surname><given-names>RG</given-names></name><name><surname>Mather</surname><given-names>IH</given-names></name><name><surname>Stunnenberg</surname><given-names>H</given-names></name><name><surname>Simons</surname><given-names>K</given-names></name><name><surname>Hoflack</surname><given-names>B</given-names></name><name><surname>Zerial</surname><given-names>M</given-names></name></person-group><year iso-8601-date="1992">1992</year><article-title>The small gtpase rab5 functions as a regulatory factor in the early endocytic pathway</article-title><source>Cell</source><volume>70</volume><fpage>715</fpage><lpage>728</lpage><pub-id pub-id-type="doi">10.1016/0092-8674(92)90306-W</pub-id><pub-id pub-id-type="pmid">1516130</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carmon</surname><given-names>KS</given-names></name><name><surname>Gong</surname><given-names>X</given-names></name><name><surname>Lin</surname><given-names>Q</given-names></name><name><surname>Thomas</surname><given-names>A</given-names></name><name><surname>Liu</surname><given-names>Q</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>R-spondins function as ligands of the orphan receptors LGR4 and LGR5 to regulate Wnt/beta-catenin signaling</article-title><source>PNAS</source><volume>108</volume><fpage>11452</fpage><lpage>11457</lpage><pub-id pub-id-type="doi">10.1073/pnas.1106083108</pub-id><pub-id pub-id-type="pmid">21693646</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chapman</surname><given-names>PB</given-names></name><name><surname>Hauschild</surname><given-names>A</given-names></name><name><surname>Robert</surname><given-names>C</given-names></name><name><surname>Haanen</surname><given-names>JB</given-names></name><name><surname>Ascierto</surname><given-names>P</given-names></name><name><surname>Larkin</surname><given-names>J</given-names></name><name><surname>Dummer</surname><given-names>R</given-names></name><name><surname>Garbe</surname><given-names>C</given-names></name><name><surname>Testori</surname><given-names>A</given-names></name><name><surname>Maio</surname><given-names>M</given-names></name><name><surname>Hogg</surname><given-names>D</given-names></name><name><surname>Lorigan</surname><given-names>P</given-names></name><name><surname>Lebbe</surname><given-names>C</given-names></name><name><surname>Jouary</surname><given-names>T</given-names></name><name><surname>Schadendorf</surname><given-names>D</given-names></name><name><surname>Ribas</surname><given-names>A</given-names></name><name><surname>O’Day</surname><given-names>SJ</given-names></name><name><surname>Sosman</surname><given-names>JA</given-names></name><name><surname>Kirkwood</surname><given-names>JM</given-names></name><name><surname>Eggermont</surname><given-names>AMM</given-names></name><name><surname>Dreno</surname><given-names>B</given-names></name><name><surname>Nolop</surname><given-names>K</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Nelson</surname><given-names>B</given-names></name><name><surname>Hou</surname><given-names>J</given-names></name><name><surname>Lee</surname><given-names>RJ</given-names></name><name><surname>Flaherty</surname><given-names>KT</given-names></name><name><surname>McArthur</surname><given-names>GA</given-names></name><collab>BRIM-3 Study Group</collab></person-group><year iso-8601-date="2011">2011</year><article-title>Improved survival with Vemurafenib in melanoma with BRAF V600E mutation</article-title><source>The New England Journal of Medicine</source><volume>364</volume><fpage>2507</fpage><lpage>2516</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1103782</pub-id><pub-id pub-id-type="pmid">21639808</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>PI</given-names></name><name><surname>Kong</surname><given-names>C</given-names></name><name><surname>Su</surname><given-names>X</given-names></name><name><surname>Stahl</surname><given-names>PD</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>RAB5 isoforms differentially regulate the trafficking and degradation of epidermal growth factor receptors</article-title><source>The Journal of Biological Chemistry</source><volume>284</volume><fpage>30328</fpage><lpage>30338</lpage><pub-id pub-id-type="doi">10.1074/jbc.M109.034546</pub-id><pub-id pub-id-type="pmid">19723633</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chisholm</surname><given-names>RH</given-names></name><name><surname>Lorenzi</surname><given-names>T</given-names></name><name><surname>Lorz</surname><given-names>A</given-names></name><name><surname>Larsen</surname><given-names>AK</given-names></name><name><surname>de Almeida</surname><given-names>LN</given-names></name><name><surname>Escargueil</surname><given-names>A</given-names></name><name><surname>Clairambault</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Emergence of drug tolerance in cancer cell populations: An evolutionary outcome of selection, nongenetic instability, and stress-induced adaptation</article-title><source>Cancer Research</source><volume>75</volume><fpage>930</fpage><lpage>939</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-14-2103</pub-id><pub-id pub-id-type="pmid">25627977</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choudhury</surname><given-names>A</given-names></name><name><surname>Dominguez</surname><given-names>M</given-names></name><name><surname>Puri</surname><given-names>V</given-names></name><name><surname>Sharma</surname><given-names>DK</given-names></name><name><surname>Narita</surname><given-names>K</given-names></name><name><surname>Wheatley</surname><given-names>CL</given-names></name><name><surname>Marks</surname><given-names>DL</given-names></name><name><surname>Pagano</surname><given-names>RE</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Rab proteins mediate golgi transport of caveola-internalized glycosphingolipids and correct lipid trafficking in Niemann-pick C cells</article-title><source>The Journal of Clinical Investigation</source><volume>109</volume><fpage>1541</fpage><lpage>1550</lpage><pub-id pub-id-type="doi">10.1172/jci15420</pub-id><pub-id pub-id-type="pmid">12070301</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chu</surname><given-names>VT</given-names></name><name><surname>Weber</surname><given-names>T</given-names></name><name><surname>Wefers</surname><given-names>B</given-names></name><name><surname>Wurst</surname><given-names>W</given-names></name><name><surname>Sander</surname><given-names>S</given-names></name><name><surname>Rajewsky</surname><given-names>K</given-names></name><name><surname>Kühn</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Increasing the efficiency of homology-directed repair for crispr-cas9-induced precise gene editing in mammalian cells</article-title><source>Nature Biotechnology</source><volume>33</volume><fpage>543</fpage><lpage>548</lpage><pub-id pub-id-type="doi">10.1038/nbt.3198</pub-id><pub-id pub-id-type="pmid">25803306</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Connacher</surname><given-names>MK</given-names></name><name><surname>Tay</surname><given-names>JW</given-names></name><name><surname>Ahn</surname><given-names>NG</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Rear-polarized Wnt5a-receptor-actin-myosin-polarity (WRAMP) structures promote the speed and persistence of directional cell migration</article-title><source>Molecular Biology of the Cell</source><volume>28</volume><fpage>1924</fpage><lpage>1936</lpage><pub-id pub-id-type="doi">10.1091/mbc.E16-12-0875</pub-id><pub-id pub-id-type="pmid">28592632</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coyaud</surname><given-names>E</given-names></name><name><surname>Mis</surname><given-names>M</given-names></name><name><surname>Laurent</surname><given-names>EMN</given-names></name><name><surname>Dunham</surname><given-names>WH</given-names></name><name><surname>Couzens</surname><given-names>AL</given-names></name><name><surname>Robitaille</surname><given-names>M</given-names></name><name><surname>Gingras</surname><given-names>AC</given-names></name><name><surname>Angers</surname><given-names>S</given-names></name><name><surname>Raught</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>BioID-based identification of skp cullin F-box (SCF)β-TrCP1/2 E3 ligase substrates</article-title><source>Molecular &amp; Cellular Proteomics</source><volume>14</volume><fpage>1781</fpage><lpage>1795</lpage><pub-id pub-id-type="doi">10.1074/mcp.M114.045658</pub-id><pub-id pub-id-type="pmid">25900982</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cullis</surname><given-names>DN</given-names></name><name><surname>Philip</surname><given-names>B</given-names></name><name><surname>Baleja</surname><given-names>JD</given-names></name><name><surname>Feig</surname><given-names>LA</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Rab11-fip2, an adaptor protein connecting cellular components involved in internalization and recycling of epidermal growth factor receptors</article-title><source>The Journal of Biological Chemistry</source><volume>277</volume><fpage>49158</fpage><lpage>49166</lpage><pub-id pub-id-type="doi">10.1074/jbc.M206316200</pub-id><pub-id pub-id-type="pmid">12364336</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Da Forno</surname><given-names>PD</given-names></name><name><surname>Pringle</surname><given-names>JH</given-names></name><name><surname>Hutchinson</surname><given-names>P</given-names></name><name><surname>Osborn</surname><given-names>J</given-names></name><name><surname>Huang</surname><given-names>Q</given-names></name><name><surname>Potter</surname><given-names>L</given-names></name><name><surname>Hancox</surname><given-names>RA</given-names></name><name><surname>Fletcher</surname><given-names>A</given-names></name><name><surname>Saldanha</surname><given-names>GS</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>WNT5A expression increases during melanoma progression and correlates with outcome</article-title><source>Clinical Cancer Research</source><volume>14</volume><fpage>5825</fpage><lpage>5832</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-07-5104</pub-id><pub-id pub-id-type="pmid">18794093</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davies</surname><given-names>H</given-names></name><name><surname>Bignell</surname><given-names>GR</given-names></name><name><surname>Cox</surname><given-names>C</given-names></name><name><surname>Stephens</surname><given-names>P</given-names></name><name><surname>Edkins</surname><given-names>S</given-names></name><name><surname>Clegg</surname><given-names>S</given-names></name><name><surname>Teague</surname><given-names>J</given-names></name><name><surname>Woffendin</surname><given-names>H</given-names></name><name><surname>Garnett</surname><given-names>MJ</given-names></name><name><surname>Bottomley</surname><given-names>W</given-names></name><name><surname>Davis</surname><given-names>N</given-names></name><name><surname>Dicks</surname><given-names>E</given-names></name><name><surname>Ewing</surname><given-names>R</given-names></name><name><surname>Floyd</surname><given-names>Y</given-names></name><name><surname>Gray</surname><given-names>K</given-names></name><name><surname>Hall</surname><given-names>S</given-names></name><name><surname>Hawes</surname><given-names>R</given-names></name><name><surname>Hughes</surname><given-names>J</given-names></name><name><surname>Kosmidou</surname><given-names>V</given-names></name><name><surname>Menzies</surname><given-names>A</given-names></name><name><surname>Mould</surname><given-names>C</given-names></name><name><surname>Parker</surname><given-names>A</given-names></name><name><surname>Stevens</surname><given-names>C</given-names></name><name><surname>Watt</surname><given-names>S</given-names></name><name><surname>Hooper</surname><given-names>S</given-names></name><name><surname>Wilson</surname><given-names>R</given-names></name><name><surname>Jayatilake</surname><given-names>H</given-names></name><name><surname>Gusterson</surname><given-names>BA</given-names></name><name><surname>Cooper</surname><given-names>C</given-names></name><name><surname>Shipley</surname><given-names>J</given-names></name><name><surname>Hargrave</surname><given-names>D</given-names></name><name><surname>Pritchard-Jones</surname><given-names>K</given-names></name><name><surname>Maitland</surname><given-names>N</given-names></name><name><surname>Chenevix-Trench</surname><given-names>G</given-names></name><name><surname>Riggins</surname><given-names>GJ</given-names></name><name><surname>Bigner</surname><given-names>DD</given-names></name><name><surname>Palmieri</surname><given-names>G</given-names></name><name><surname>Cossu</surname><given-names>A</given-names></name><name><surname>Flanagan</surname><given-names>A</given-names></name><name><surname>Nicholson</surname><given-names>A</given-names></name><name><surname>Ho</surname><given-names>JWC</given-names></name><name><surname>Leung</surname><given-names>SY</given-names></name><name><surname>Yuen</surname><given-names>ST</given-names></name><name><surname>Weber</surname><given-names>BL</given-names></name><name><surname>Seigler</surname><given-names>HF</given-names></name><name><surname>Darrow</surname><given-names>TL</given-names></name><name><surname>Paterson</surname><given-names>H</given-names></name><name><surname>Marais</surname><given-names>R</given-names></name><name><surname>Marshall</surname><given-names>CJ</given-names></name><name><surname>Wooster</surname><given-names>R</given-names></name><name><surname>Stratton</surname><given-names>MR</given-names></name><name><surname>Futreal</surname><given-names>PA</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Mutations of the BRAF gene in human cancer</article-title><source>Nature</source><volume>417</volume><fpage>949</fpage><lpage>954</lpage><pub-id pub-id-type="doi">10.1038/nature00766</pub-id><pub-id pub-id-type="pmid">12068308</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Lau</surname><given-names>W</given-names></name><name><surname>Barker</surname><given-names>N</given-names></name><name><surname>Low</surname><given-names>TY</given-names></name><name><surname>Koo</surname><given-names>B-K</given-names></name><name><surname>Li</surname><given-names>VSW</given-names></name><name><surname>Teunissen</surname><given-names>H</given-names></name><name><surname>Kujala</surname><given-names>P</given-names></name><name><surname>Haegebarth</surname><given-names>A</given-names></name><name><surname>Peters</surname><given-names>PJ</given-names></name><name><surname>van de Wetering</surname><given-names>M</given-names></name><name><surname>Stange</surname><given-names>DE</given-names></name><name><surname>van Es</surname><given-names>JE</given-names></name><name><surname>Guardavaccaro</surname><given-names>D</given-names></name><name><surname>Schasfoort</surname><given-names>RBM</given-names></name><name><surname>Mohri</surname><given-names>Y</given-names></name><name><surname>Nishimori</surname><given-names>K</given-names></name><name><surname>Mohammed</surname><given-names>S</given-names></name><name><surname>Heck</surname><given-names>AJR</given-names></name><name><surname>Clevers</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Lgr5 homologues associate with Wnt receptors and mediate r-spondin signalling</article-title><source>Nature</source><volume>476</volume><fpage>293</fpage><lpage>297</lpage><pub-id pub-id-type="doi">10.1038/nature10337</pub-id><pub-id pub-id-type="pmid">21727895</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deshar</surname><given-names>R</given-names></name><name><surname>Moon</surname><given-names>S</given-names></name><name><surname>Yoo</surname><given-names>W</given-names></name><name><surname>Cho</surname><given-names>EB</given-names></name><name><surname>Yoon</surname><given-names>SK</given-names></name><name><surname>Yoon</surname><given-names>JB</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>RNF167 targets ARL8B for degradation to regulate lysosome positioning and endocytic trafficking</article-title><source>The FEBS Journal</source><volume>283</volume><fpage>4583</fpage><lpage>4599</lpage><pub-id pub-id-type="doi">10.1111/febs.13947</pub-id><pub-id pub-id-type="pmid">27808481</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deutsch</surname><given-names>EW</given-names></name><name><surname>Bandeira</surname><given-names>N</given-names></name><name><surname>Sharma</surname><given-names>V</given-names></name><name><surname>Perez-Riverol</surname><given-names>Y</given-names></name><name><surname>Carver</surname><given-names>JJ</given-names></name><name><surname>Kundu</surname><given-names>DJ</given-names></name><name><surname>García-Seisdedos</surname><given-names>D</given-names></name><name><surname>Jarnuczak</surname><given-names>AF</given-names></name><name><surname>Hewapathirana</surname><given-names>S</given-names></name><name><surname>Pullman</surname><given-names>BS</given-names></name><name><surname>Wertz</surname><given-names>J</given-names></name><name><surname>Sun</surname><given-names>Z</given-names></name><name><surname>Kawano</surname><given-names>S</given-names></name><name><surname>Okuda</surname><given-names>S</given-names></name><name><surname>Watanabe</surname><given-names>Y</given-names></name><name><surname>Hermjakob</surname><given-names>H</given-names></name><name><surname>MacLean</surname><given-names>B</given-names></name><name><surname>MacCoss</surname><given-names>MJ</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Ishihama</surname><given-names>Y</given-names></name><name><surname>Vizcaíno</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The ProteomeXchange consortium in 2020: enabling “big data” approaches in proteomics</article-title><source>Nucleic Acids Research</source><volume>48</volume><fpage>D1145</fpage><lpage>D1152</lpage><pub-id pub-id-type="doi">10.1093/nar/gkz984</pub-id><pub-id pub-id-type="pmid">31686107</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dissanayake</surname><given-names>SK</given-names></name><name><surname>Wade</surname><given-names>M</given-names></name><name><surname>Johnson</surname><given-names>CE</given-names></name><name><surname>O’Connell</surname><given-names>MP</given-names></name><name><surname>Leotlela</surname><given-names>PD</given-names></name><name><surname>French</surname><given-names>AD</given-names></name><name><surname>Shah</surname><given-names>KV</given-names></name><name><surname>Hewitt</surname><given-names>KJ</given-names></name><name><surname>Rosenthal</surname><given-names>DT</given-names></name><name><surname>Indig</surname><given-names>FE</given-names></name><name><surname>Jiang</surname><given-names>Y</given-names></name><name><surname>Nickoloff</surname><given-names>BJ</given-names></name><name><surname>Taub</surname><given-names>DD</given-names></name><name><surname>Trent</surname><given-names>JM</given-names></name><name><surname>Moon</surname><given-names>RT</given-names></name><name><surname>Bittner</surname><given-names>M</given-names></name><name><surname>Weeraratna</surname><given-names>AT</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>The Wnt5a/protein kinase C pathway mediates motility in melanoma cells via the inhibition of metastasis suppressors and initiation of an epithelial to mesenchymal transition</article-title><source>The Journal of Biological Chemistry</source><volume>282</volume><fpage>17259</fpage><lpage>17271</lpage><pub-id pub-id-type="doi">10.1074/jbc.M700075200</pub-id><pub-id pub-id-type="pmid">17426020</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dissanayake</surname><given-names>SK</given-names></name><name><surname>Olkhanud</surname><given-names>PB</given-names></name><name><surname>O’Connell</surname><given-names>MP</given-names></name><name><surname>Carter</surname><given-names>A</given-names></name><name><surname>French</surname><given-names>AD</given-names></name><name><surname>Camilli</surname><given-names>TC</given-names></name><name><surname>Emeche</surname><given-names>CD</given-names></name><name><surname>Hewitt</surname><given-names>KJ</given-names></name><name><surname>Rosenthal</surname><given-names>DT</given-names></name><name><surname>Leotlela</surname><given-names>PD</given-names></name><name><surname>Wade</surname><given-names>MS</given-names></name><name><surname>Yang</surname><given-names>SW</given-names></name><name><surname>Brant</surname><given-names>L</given-names></name><name><surname>Nickoloff</surname><given-names>BJ</given-names></name><name><surname>Messina</surname><given-names>JL</given-names></name><name><surname>Biragyn</surname><given-names>A</given-names></name><name><surname>Hoek</surname><given-names>KS</given-names></name><name><surname>Taub</surname><given-names>DD</given-names></name><name><surname>Longo</surname><given-names>DL</given-names></name><name><surname>Sondak</surname><given-names>VK</given-names></name><name><surname>Hewitt</surname><given-names>SM</given-names></name><name><surname>Weeraratna</surname><given-names>AT</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>WNT5A regulates expression of tumor-associated antigens in melanoma via changes in signal transducers and activators of transcription 3 phosphorylation</article-title><source>Cancer Research</source><volume>68</volume><fpage>10205</fpage><lpage>10214</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-08-2149</pub-id><pub-id pub-id-type="pmid">19074888</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eddy</surname><given-names>RJ</given-names></name><name><surname>Weidmann</surname><given-names>MD</given-names></name><name><surname>Sharma</surname><given-names>VP</given-names></name><name><surname>Condeelis</surname><given-names>JS</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Tumor cell invadopodia: Invasive protrusions that orchestrate metastasis</article-title><source>Trends in Cell Biology</source><volume>27</volume><fpage>595</fpage><lpage>607</lpage><pub-id pub-id-type="doi">10.1016/j.tcb.2017.03.003</pub-id><pub-id pub-id-type="pmid">28412099</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ekström</surname><given-names>EJ</given-names></name><name><surname>Bergenfelz</surname><given-names>C</given-names></name><name><surname>von Bülow</surname><given-names>V</given-names></name><name><surname>Serifler</surname><given-names>F</given-names></name><name><surname>Carlemalm</surname><given-names>E</given-names></name><name><surname>Jönsson</surname><given-names>G</given-names></name><name><surname>Andersson</surname><given-names>T</given-names></name><name><surname>Leandersson</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>WNT5A induces release of exosomes containing pro-angiogenic and immunosuppressive factors from malignant melanoma cells</article-title><source>Molecular Cancer</source><volume>13</volume><elocation-id>88</elocation-id><pub-id pub-id-type="doi">10.1186/1476-4598-13-88</pub-id><pub-id pub-id-type="pmid">24766647</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eto</surname><given-names>T</given-names></name><name><surname>Miyake</surname><given-names>K</given-names></name><name><surname>Nosho</surname><given-names>K</given-names></name><name><surname>Ohmuraya</surname><given-names>M</given-names></name><name><surname>Imamura</surname><given-names>Y</given-names></name><name><surname>Arima</surname><given-names>K</given-names></name><name><surname>Kanno</surname><given-names>S</given-names></name><name><surname>Fu</surname><given-names>L</given-names></name><name><surname>Kiyozumi</surname><given-names>Y</given-names></name><name><surname>Izumi</surname><given-names>D</given-names></name><name><surname>Sugihara</surname><given-names>H</given-names></name><name><surname>Hiyoshi</surname><given-names>Y</given-names></name><name><surname>Miyamoto</surname><given-names>Y</given-names></name><name><surname>Sawayama</surname><given-names>H</given-names></name><name><surname>Iwatsuki</surname><given-names>M</given-names></name><name><surname>Baba</surname><given-names>Y</given-names></name><name><surname>Yoshida</surname><given-names>N</given-names></name><name><surname>Furukawa</surname><given-names>T</given-names></name><name><surname>Araki</surname><given-names>K</given-names></name><name><surname>Baba</surname><given-names>H</given-names></name><name><surname>Ishimoto</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Impact of loss-of-function mutations at the RNF43 locus on colorectal cancer development and progression</article-title><source>The Journal of Pathology</source><volume>245</volume><fpage>445</fpage><lpage>455</lpage><pub-id pub-id-type="doi">10.1002/path.5098</pub-id><pub-id pub-id-type="pmid">29756208</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feng</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Lin</surname><given-names>X</given-names></name><name><surname>Zha</surname><given-names>F</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Ma</surname><given-names>L</given-names></name><name><surname>Choi</surname><given-names>NT</given-names></name><name><surname>Mii</surname><given-names>Y</given-names></name><name><surname>Takada</surname><given-names>S</given-names></name><name><surname>Huen</surname><given-names>MSY</given-names></name><name><surname>Guo</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Gao</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Regulation of Wnt/PCP signaling through p97/VCP-KBTBD7-mediated Vangl ubiquitination and endoplasmic reticulum-associated degradation</article-title><source>Science Advances</source><volume>7</volume><elocation-id>eabg2099</elocation-id><pub-id pub-id-type="doi">10.1126/sciadv.abg2099</pub-id><pub-id pub-id-type="pmid">33990333</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fernández</surname><given-names>NB</given-names></name><name><surname>Lorenzo</surname><given-names>D</given-names></name><name><surname>Picco</surname><given-names>ME</given-names></name><name><surname>Barbero</surname><given-names>G</given-names></name><name><surname>Dergan-Dylon</surname><given-names>LS</given-names></name><name><surname>Marks</surname><given-names>MP</given-names></name><name><surname>García-Rivello</surname><given-names>H</given-names></name><name><surname>Gimenez</surname><given-names>L</given-names></name><name><surname>Labovsky</surname><given-names>V</given-names></name><name><surname>Grumolato</surname><given-names>L</given-names></name><name><surname>Lopez-Bergami</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>ROR1 contributes to melanoma cell growth and migration by regulating n-cadherin expression via the PI3K/AKT pathway</article-title><source>Molecular Carcinogenesis</source><volume>55</volume><fpage>1772</fpage><lpage>1785</lpage><pub-id pub-id-type="doi">10.1002/mc.22426</pub-id><pub-id pub-id-type="pmid">26509654</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flaherty</surname><given-names>KT</given-names></name><name><surname>Puzanov</surname><given-names>I</given-names></name><name><surname>Kim</surname><given-names>KB</given-names></name><name><surname>Ribas</surname><given-names>A</given-names></name><name><surname>McArthur</surname><given-names>GA</given-names></name><name><surname>Sosman</surname><given-names>JA</given-names></name><name><surname>O’Dwyer</surname><given-names>PJ</given-names></name><name><surname>Lee</surname><given-names>RJ</given-names></name><name><surname>Grippo</surname><given-names>JF</given-names></name><name><surname>Nolop</surname><given-names>K</given-names></name><name><surname>Chapman</surname><given-names>PB</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Inhibition of mutated, activated BRAF in metastatic melanoma</article-title><source>The New England Journal of Medicine</source><volume>363</volume><fpage>809</fpage><lpage>819</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1002011</pub-id><pub-id pub-id-type="pmid">20818844</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>B</given-names></name><name><surname>Song</surname><given-names>H</given-names></name><name><surname>Bishop</surname><given-names>K</given-names></name><name><surname>Elliot</surname><given-names>G</given-names></name><name><surname>Garrett</surname><given-names>L</given-names></name><name><surname>English</surname><given-names>MA</given-names></name><name><surname>Andre</surname><given-names>P</given-names></name><name><surname>Robinson</surname><given-names>J</given-names></name><name><surname>Sood</surname><given-names>R</given-names></name><name><surname>Minami</surname><given-names>Y</given-names></name><name><surname>Economides</surname><given-names>AN</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Wnt signaling gradients establish planar cell polarity by inducing vangl2 phosphorylation through ror2</article-title><source>Developmental Cell</source><volume>20</volume><fpage>163</fpage><lpage>176</lpage><pub-id pub-id-type="doi">10.1016/J.DEVCEL.2011.01.001</pub-id><pub-id pub-id-type="pmid">21316585</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>Y</given-names></name><name><surname>Cai</surname><given-names>A</given-names></name><name><surname>Xi</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>K</given-names></name><name><surname>Cui</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Wei</surname><given-names>B</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Ring finger protein 43 associates with gastric cancer progression and attenuates the stemness of gastric cancer stem-like cells via the wnt-β/catenin signaling pathway</article-title><source>Stem Cell Research &amp; Therapy</source><volume>8</volume><elocation-id>98</elocation-id><pub-id pub-id-type="doi">10.1186/s13287-017-0548-8</pub-id><pub-id pub-id-type="pmid">28446252</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gentile</surname><given-names>A</given-names></name><name><surname>Lazzari</surname><given-names>L</given-names></name><name><surname>Benvenuti</surname><given-names>S</given-names></name><name><surname>Trusolino</surname><given-names>L</given-names></name><name><surname>Comoglio</surname><given-names>PM</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Ror1 is a pseudokinase that is crucial for met-driven tumorigenesis</article-title><source>Cancer Research</source><volume>71</volume><fpage>3132</fpage><lpage>3141</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-10-2662</pub-id><pub-id pub-id-type="pmid">21487037</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giannakis</surname><given-names>M</given-names></name><name><surname>Hodis</surname><given-names>E</given-names></name><name><surname>Jasmine Mu</surname><given-names>X</given-names></name><name><surname>Yamauchi</surname><given-names>M</given-names></name><name><surname>Rosenbluh</surname><given-names>J</given-names></name><name><surname>Cibulskis</surname><given-names>K</given-names></name><name><surname>Saksena</surname><given-names>G</given-names></name><name><surname>Lawrence</surname><given-names>MS</given-names></name><name><surname>Qian</surname><given-names>ZR</given-names></name><name><surname>Nishihara</surname><given-names>R</given-names></name><name><surname>Van Allen</surname><given-names>EM</given-names></name><name><surname>Hahn</surname><given-names>WC</given-names></name><name><surname>Gabriel</surname><given-names>SB</given-names></name><name><surname>Lander</surname><given-names>ES</given-names></name><name><surname>Getz</surname><given-names>G</given-names></name><name><surname>Ogino</surname><given-names>S</given-names></name><name><surname>Fuchs</surname><given-names>CS</given-names></name><name><surname>Garraway</surname><given-names>LA</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>RNF43 is frequently mutated in colorectal and endometrial cancers</article-title><source>Nature Genetics</source><volume>46</volume><fpage>1264</fpage><lpage>1266</lpage><pub-id pub-id-type="doi">10.1038/ng.3127</pub-id><pub-id pub-id-type="pmid">25344691</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glinka</surname><given-names>A</given-names></name><name><surname>Dolde</surname><given-names>C</given-names></name><name><surname>Kirsch</surname><given-names>N</given-names></name><name><surname>Huang</surname><given-names>YL</given-names></name><name><surname>Kazanskaya</surname><given-names>O</given-names></name><name><surname>Ingelfinger</surname><given-names>D</given-names></name><name><surname>Boutros</surname><given-names>M</given-names></name><name><surname>Cruciat</surname><given-names>CM</given-names></name><name><surname>Niehrs</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>LGR4 and lgr5 are r-spondin receptors mediating wnt/β-catenin and Wnt/pcp signalling</article-title><source>EMBO Reports</source><volume>12</volume><fpage>1055</fpage><lpage>1061</lpage><pub-id pub-id-type="doi">10.1038/embor.2011.175</pub-id><pub-id pub-id-type="pmid">21909076</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>Y</given-names></name><name><surname>Zanetti</surname><given-names>G</given-names></name><name><surname>Schekman</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>A novel gtp-binding protein-adaptor protein complex responsible for export of vangl2 from the trans GOLGI network</article-title><source>eLife</source><volume>2</volume><elocation-id>e00160</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.00160</pub-id><pub-id pub-id-type="pmid">23326640</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanaki</surname><given-names>H</given-names></name><name><surname>Yamamoto</surname><given-names>H</given-names></name><name><surname>Sakane</surname><given-names>H</given-names></name><name><surname>Matsumoto</surname><given-names>S</given-names></name><name><surname>Ohdan</surname><given-names>H</given-names></name><name><surname>Sato</surname><given-names>A</given-names></name><name><surname>Kikuchi</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>An anti-wnt5A antibody suppresses metastasis of gastric cancer cells in vivo by inhibiting receptor-mediated endocytosis</article-title><source>Molecular Cancer Therapeutics</source><volume>11</volume><fpage>298</fpage><lpage>307</lpage><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-11-0682</pub-id><pub-id pub-id-type="pmid">22101459</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanáková</surname><given-names>K</given-names></name><name><surname>Bernatík</surname><given-names>O</given-names></name><name><surname>Kravec</surname><given-names>M</given-names></name><name><surname>Micka</surname><given-names>M</given-names></name><name><surname>Kumar</surname><given-names>J</given-names></name><name><surname>Harnoš</surname><given-names>J</given-names></name><name><surname>Ovesná</surname><given-names>P</given-names></name><name><surname>Paclíková</surname><given-names>P</given-names></name><name><surname>Rádsetoulal</surname><given-names>M</given-names></name><name><surname>Potěšil</surname><given-names>D</given-names></name><name><surname>Tripsianes</surname><given-names>K</given-names></name><name><surname>Čajánek</surname><given-names>L</given-names></name><name><surname>Zdráhal</surname><given-names>Z</given-names></name><name><surname>Bryja</surname><given-names>V</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Comparative phosphorylation map of Dishevelled 3 links phospho-signatures to biological outputs</article-title><source>Cell Communication and Signaling</source><volume>17</volume><elocation-id>170</elocation-id><pub-id pub-id-type="doi">10.1186/s12964-019-0470-z</pub-id><pub-id pub-id-type="pmid">31870452</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hao</surname><given-names>HX</given-names></name><name><surname>Xie</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Charlat</surname><given-names>O</given-names></name><name><surname>Oster</surname><given-names>E</given-names></name><name><surname>Avello</surname><given-names>M</given-names></name><name><surname>Lei</surname><given-names>H</given-names></name><name><surname>Mickanin</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>D</given-names></name><name><surname>Ruffner</surname><given-names>H</given-names></name><name><surname>Mao</surname><given-names>X</given-names></name><name><surname>Ma</surname><given-names>Q</given-names></name><name><surname>Zamponi</surname><given-names>R</given-names></name><name><surname>Bouwmeester</surname><given-names>T</given-names></name><name><surname>Finan</surname><given-names>PM</given-names></name><name><surname>Kirschner</surname><given-names>MW</given-names></name><name><surname>Porter</surname><given-names>JA</given-names></name><name><surname>Serluca</surname><given-names>FC</given-names></name><name><surname>Cong</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>ZNRF3 promotes wnt receptor turnover in an r-spondin-sensitive manner</article-title><source>Nature</source><volume>485</volume><fpage>195</fpage><lpage>200</lpage><pub-id pub-id-type="doi">10.1038/nature11019</pub-id><pub-id pub-id-type="pmid">22575959</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hao</surname><given-names>HX</given-names></name><name><surname>Jiang</surname><given-names>X</given-names></name><name><surname>Cong</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Control of wnt receptor turnover by r-spondin-znrf3/rnf43 signaling module and its dysregulation in cancer</article-title><source>Cancers</source><volume>8</volume><elocation-id>E54</elocation-id><pub-id pub-id-type="doi">10.3390/cancers8060054</pub-id><pub-id pub-id-type="pmid">27338477</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haqq</surname><given-names>C</given-names></name><name><surname>Nosrati</surname><given-names>M</given-names></name><name><surname>Sudilovsky</surname><given-names>D</given-names></name><name><surname>Crothers</surname><given-names>J</given-names></name><name><surname>Khodabakhsh</surname><given-names>D</given-names></name><name><surname>Pulliam</surname><given-names>BL</given-names></name><name><surname>Federman</surname><given-names>S</given-names></name><name><surname>Miller</surname><given-names>JR</given-names></name><name><surname>Allen</surname><given-names>RE</given-names></name><name><surname>Singer</surname><given-names>MI</given-names></name><name><surname>Leong</surname><given-names>SPL</given-names></name><name><surname>Ljung</surname><given-names>BM</given-names></name><name><surname>Sagebiel</surname><given-names>RW</given-names></name><name><surname>Kashani-Sabet</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>The gene expression signatures of melanoma progression</article-title><source>PNAS</source><volume>102</volume><fpage>6092</fpage><lpage>6097</lpage><pub-id pub-id-type="doi">10.1073/pnas.0501564102</pub-id><pub-id pub-id-type="pmid">15833814</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harnoš</surname><given-names>J</given-names></name><name><surname>Cañizal</surname><given-names>MCA</given-names></name><name><surname>Jurásek</surname><given-names>M</given-names></name><name><surname>Kumar</surname><given-names>J</given-names></name><name><surname>Holler</surname><given-names>C</given-names></name><name><surname>Schambony</surname><given-names>A</given-names></name><name><surname>Hanáková</surname><given-names>K</given-names></name><name><surname>Bernatík</surname><given-names>O</given-names></name><name><surname>Zdráhal</surname><given-names>Z</given-names></name><name><surname>Gömöryová</surname><given-names>K</given-names></name><name><surname>Gybeľ</surname><given-names>T</given-names></name><name><surname>Radaszkiewicz</surname><given-names>TW</given-names></name><name><surname>Kravec</surname><given-names>M</given-names></name><name><surname>Trantírek</surname><given-names>L</given-names></name><name><surname>Ryneš</surname><given-names>J</given-names></name><name><surname>Dave</surname><given-names>Z</given-names></name><name><surname>Fernández-Llamazares</surname><given-names>AI</given-names></name><name><surname>Vácha</surname><given-names>R</given-names></name><name><surname>Tripsianes</surname><given-names>K</given-names></name><name><surname>Hoffmann</surname><given-names>C</given-names></name><name><surname>Bryja</surname><given-names>V</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Dishevelled-3 conformation dynamics analyzed by fret-based biosensors reveals a key role of casein kinase 1</article-title><source>Nature Communications</source><volume>10</volume><elocation-id>1804</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-019-09651-7</pub-id><pub-id pub-id-type="pmid">31000703</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harris</surname><given-names>A</given-names></name><name><surname>Siggers</surname><given-names>P</given-names></name><name><surname>Corrochano</surname><given-names>S</given-names></name><name><surname>Warr</surname><given-names>N</given-names></name><name><surname>Sagar</surname><given-names>D</given-names></name><name><surname>Grimes</surname><given-names>DT</given-names></name><name><surname>Suzuki</surname><given-names>M</given-names></name><name><surname>Burdine</surname><given-names>RD</given-names></name><name><surname>Cong</surname><given-names>F</given-names></name><name><surname>Koo</surname><given-names>B-K</given-names></name><name><surname>Clevers</surname><given-names>H</given-names></name><name><surname>Stévant</surname><given-names>I</given-names></name><name><surname>Nef</surname><given-names>S</given-names></name><name><surname>Wells</surname><given-names>S</given-names></name><name><surname>Brauner</surname><given-names>R</given-names></name><name><surname>Ben Rhouma</surname><given-names>B</given-names></name><name><surname>Belguith</surname><given-names>N</given-names></name><name><surname>Eozenou</surname><given-names>C</given-names></name><name><surname>Bignon-Topalovic</surname><given-names>J</given-names></name><name><surname>Bashamboo</surname><given-names>A</given-names></name><name><surname>McElreavey</surname><given-names>K</given-names></name><name><surname>Greenfield</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>ZNRF3 functions in mammalian sex determination by inhibiting canonical WNT signaling</article-title><source>PNAS</source><volume>115</volume><fpage>5474</fpage><lpage>5479</lpage><pub-id pub-id-type="doi">10.1073/pnas.1801223115</pub-id><pub-id pub-id-type="pmid">29735715</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hershko</surname><given-names>A</given-names></name><name><surname>Ciechanover</surname><given-names>A</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>The UBIQUITIN SYSTEM</article-title><source>Annual Review of Biochemistry</source><volume>67</volume><fpage>425</fpage><lpage>479</lpage><pub-id pub-id-type="doi">10.1146/annurev.biochem.67.1.425</pub-id><pub-id pub-id-type="pmid">9759494</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hirst</surname><given-names>J</given-names></name><name><surname>Irving</surname><given-names>C</given-names></name><name><surname>Borner</surname><given-names>GHH</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Adaptor Protein Complexes AP-4 and AP-5: New Players in Endosomal Trafficking and Progressive Spastic Paraplegia</article-title><source>Traffic</source><volume>14</volume><fpage>153</fpage><lpage>164</lpage><pub-id pub-id-type="doi">10.1111/tra.12028</pub-id><pub-id pub-id-type="pmid">23167973</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ho</surname><given-names>HYH</given-names></name><name><surname>Susman</surname><given-names>MW</given-names></name><name><surname>Bikoff</surname><given-names>JB</given-names></name><name><surname>Ryu</surname><given-names>YK</given-names></name><name><surname>Jonas</surname><given-names>AM</given-names></name><name><surname>Hu</surname><given-names>L</given-names></name><name><surname>Kuruvilla</surname><given-names>R</given-names></name><name><surname>Greenberg</surname><given-names>ME</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Wnt5a-Ror-Dishevelled signaling constitutes a core developmental pathway that controls tissue morphogenesis</article-title><source>PNAS</source><volume>109</volume><fpage>4044</fpage><lpage>4051</lpage><pub-id pub-id-type="doi">10.1073/pnas.1200421109</pub-id><pub-id pub-id-type="pmid">22343533</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hodis</surname><given-names>E</given-names></name><name><surname>Watson</surname><given-names>IR</given-names></name><name><surname>Kryukov</surname><given-names>G</given-names></name><name><surname>Arold</surname><given-names>ST</given-names></name><name><surname>Imielinski</surname><given-names>M</given-names></name><name><surname>Theurillat</surname><given-names>JP</given-names></name><name><surname>Nickerson</surname><given-names>E</given-names></name><name><surname>Auclair</surname><given-names>D</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Place</surname><given-names>C</given-names></name><name><surname>Dicara</surname><given-names>D</given-names></name><name><surname>Ramos</surname><given-names>AH</given-names></name><name><surname>Lawrence</surname><given-names>MS</given-names></name><name><surname>Cibulskis</surname><given-names>K</given-names></name><name><surname>Sivachenko</surname><given-names>A</given-names></name><name><surname>Voet</surname><given-names>D</given-names></name><name><surname>Saksena</surname><given-names>G</given-names></name><name><surname>Stransky</surname><given-names>N</given-names></name><name><surname>Onofrio</surname><given-names>RC</given-names></name><name><surname>Winckler</surname><given-names>W</given-names></name><name><surname>Ardlie</surname><given-names>K</given-names></name><name><surname>Wagle</surname><given-names>N</given-names></name><name><surname>Wargo</surname><given-names>J</given-names></name><name><surname>Chong</surname><given-names>K</given-names></name><name><surname>Morton</surname><given-names>DL</given-names></name><name><surname>Stemke-Hale</surname><given-names>K</given-names></name><name><surname>Chen</surname><given-names>G</given-names></name><name><surname>Noble</surname><given-names>M</given-names></name><name><surname>Meyerson</surname><given-names>M</given-names></name><name><surname>Ladbury</surname><given-names>JE</given-names></name><name><surname>Davies</surname><given-names>MA</given-names></name><name><surname>Gershenwald</surname><given-names>JE</given-names></name><name><surname>Wagner</surname><given-names>SN</given-names></name><name><surname>Hoon</surname><given-names>DSB</given-names></name><name><surname>Schadendorf</surname><given-names>D</given-names></name><name><surname>Lander</surname><given-names>ES</given-names></name><name><surname>Gabriel</surname><given-names>SB</given-names></name><name><surname>Getz</surname><given-names>G</given-names></name><name><surname>Garraway</surname><given-names>LA</given-names></name><name><surname>Chin</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>A landscape of driver mutations in melanoma</article-title><source>Cell</source><volume>150</volume><fpage>251</fpage><lpage>263</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2012.06.024</pub-id><pub-id pub-id-type="pmid">22817889</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoek</surname><given-names>KS</given-names></name><name><surname>Schlegel</surname><given-names>NC</given-names></name><name><surname>Brafford</surname><given-names>P</given-names></name><name><surname>Sucker</surname><given-names>A</given-names></name><name><surname>Ugurel</surname><given-names>S</given-names></name><name><surname>Kumar</surname><given-names>R</given-names></name><name><surname>Weber</surname><given-names>BL</given-names></name><name><surname>Nathanson</surname><given-names>KL</given-names></name><name><surname>Phillips</surname><given-names>DJ</given-names></name><name><surname>Herlyn</surname><given-names>M</given-names></name><name><surname>Schadendorf</surname><given-names>D</given-names></name><name><surname>Dummer</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature</article-title><source>Pigment Cell Research</source><volume>19</volume><fpage>290</fpage><lpage>302</lpage><pub-id pub-id-type="doi">10.1111/j.1600-0749.2006.00322.x</pub-id><pub-id pub-id-type="pmid">16827748</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoek</surname><given-names>KS</given-names></name><name><surname>Goding</surname><given-names>CR</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Cancer stem cells versus phenotype-switching in melanoma</article-title><source>Pigment Cell &amp; Melanoma Research</source><volume>23</volume><fpage>746</fpage><lpage>759</lpage><pub-id pub-id-type="doi">10.1111/J.1755-148X.2010.00757.X</pub-id><pub-id pub-id-type="pmid">20726948</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Humphries</surname><given-names>AC</given-names></name><name><surname>Mlodzik</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>From instruction to output: Wnt/pcp signaling in development and cancer</article-title><source>Current Opinion in Cell Biology</source><volume>51</volume><fpage>110</fpage><lpage>116</lpage><pub-id pub-id-type="doi">10.1016/J.CEB.2017.12.005</pub-id><pub-id pub-id-type="pmid">29289896</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jacquelot</surname><given-names>N</given-names></name><name><surname>Duong</surname><given-names>CPM</given-names></name><name><surname>Belz</surname><given-names>GT</given-names></name><name><surname>Zitvogel</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Targeting Chemokines and Chemokine Receptors in Melanoma and Other Cancers</article-title><source>Frontiers in Immunology</source><volume>9</volume><elocation-id>2480</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2018.02480</pub-id><pub-id pub-id-type="pmid">30420855</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Janovská</surname><given-names>P</given-names></name><name><surname>Bryja</surname><given-names>V</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Wnt signalling pathways in chronic lymphocytic leukaemia and B-cell lymphomas</article-title><source>British Journal of Pharmacology</source><volume>174</volume><fpage>4701</fpage><lpage>4715</lpage><pub-id pub-id-type="doi">10.1111/bph.13949</pub-id><pub-id pub-id-type="pmid">28703283</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ji</surname><given-names>Z</given-names></name><name><surname>Erin Chen</surname><given-names>Y</given-names></name><name><surname>Kumar</surname><given-names>R</given-names></name><name><surname>Taylor</surname><given-names>M</given-names></name><name><surname>Jenny Njauw</surname><given-names>CN</given-names></name><name><surname>Miao</surname><given-names>B</given-names></name><name><surname>Frederick</surname><given-names>DT</given-names></name><name><surname>Wargo</surname><given-names>JA</given-names></name><name><surname>Flaherty</surname><given-names>KT</given-names></name><name><surname>Jönsson</surname><given-names>G</given-names></name><name><surname>Tsao</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>MITF Modulates Therapeutic Resistance through EGFR Signaling</article-title><source>The Journal of Investigative Dermatology</source><volume>135</volume><fpage>1863</fpage><lpage>1872</lpage><pub-id pub-id-type="doi">10.1038/JID.2015.105</pub-id><pub-id pub-id-type="pmid">25789707</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>X</given-names></name><name><surname>Hao</surname><given-names>HX</given-names></name><name><surname>Growney</surname><given-names>JD</given-names></name><name><surname>Woolfenden</surname><given-names>S</given-names></name><name><surname>Bottiglio</surname><given-names>C</given-names></name><name><surname>Ng</surname><given-names>N</given-names></name><name><surname>Lu</surname><given-names>B</given-names></name><name><surname>Hsieh</surname><given-names>MH</given-names></name><name><surname>Bagdasarian</surname><given-names>L</given-names></name><name><surname>Meyer</surname><given-names>R</given-names></name><name><surname>Smith</surname><given-names>TR</given-names></name><name><surname>Avello</surname><given-names>M</given-names></name><name><surname>Charlat</surname><given-names>O</given-names></name><name><surname>Xie</surname><given-names>Y</given-names></name><name><surname>Porter</surname><given-names>JA</given-names></name><name><surname>Pan</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>McLaughlin</surname><given-names>ME</given-names></name><name><surname>Cong</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Inactivating mutations of RNF43 confer Wnt dependency in pancreatic ductal adenocarcinoma</article-title><source>PNAS</source><volume>110</volume><fpage>12649</fpage><lpage>12654</lpage><pub-id pub-id-type="doi">10.1073/PNAS.1307218110</pub-id><pub-id pub-id-type="pmid">23847203</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>X</given-names></name><name><surname>Charlat</surname><given-names>O</given-names></name><name><surname>Zamponi</surname><given-names>R</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Cong</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Dishevelled Promotes Wnt Receptor Degradation through Recruitment of ZNRF3/RNF43 E3 Ubiquitin Ligases</article-title><source>Molecular Cell</source><volume>58</volume><fpage>522</fpage><lpage>533</lpage><pub-id pub-id-type="doi">10.1016/J.MOLCEL.2015.03.015</pub-id><pub-id pub-id-type="pmid">25891077</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jo</surname><given-names>YS</given-names></name><name><surname>Kim</surname><given-names>MS</given-names></name><name><surname>Lee</surname><given-names>JH</given-names></name><name><surname>Lee</surname><given-names>SH</given-names></name><name><surname>An</surname><given-names>CH</given-names></name><name><surname>Yoo</surname><given-names>NJ</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Frequent frameshift mutations in 2 mononucleotide repeats of rnf43 gene and its regional heterogeneity in gastric and colorectal cancers</article-title><source>Human Pathology</source><volume>46</volume><fpage>1640</fpage><lpage>1646</lpage><pub-id pub-id-type="doi">10.1016/J.HUMPATH.2015.07.004</pub-id><pub-id pub-id-type="pmid">26297255</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>DB</given-names></name><name><surname>Menzies</surname><given-names>AM</given-names></name><name><surname>Zimmer</surname><given-names>L</given-names></name><name><surname>Eroglu</surname><given-names>Z</given-names></name><name><surname>Ye</surname><given-names>F</given-names></name><name><surname>Zhao</surname><given-names>S</given-names></name><name><surname>Rizos</surname><given-names>H</given-names></name><name><surname>Sucker</surname><given-names>A</given-names></name><name><surname>Scolyer</surname><given-names>RA</given-names></name><name><surname>Gutzmer</surname><given-names>R</given-names></name><name><surname>Gogas</surname><given-names>H</given-names></name><name><surname>Kefford</surname><given-names>RF</given-names></name><name><surname>Thompson</surname><given-names>JF</given-names></name><name><surname>Becker</surname><given-names>JC</given-names></name><name><surname>Berking</surname><given-names>C</given-names></name><name><surname>Egberts</surname><given-names>F</given-names></name><name><surname>Loquai</surname><given-names>C</given-names></name><name><surname>Goldinger</surname><given-names>SM</given-names></name><name><surname>Pupo</surname><given-names>GM</given-names></name><name><surname>Hugo</surname><given-names>W</given-names></name><name><surname>Kong</surname><given-names>X</given-names></name><name><surname>Garraway</surname><given-names>LA</given-names></name><name><surname>Sosman</surname><given-names>JA</given-names></name><name><surname>Ribas</surname><given-names>A</given-names></name><name><surname>Lo</surname><given-names>RS</given-names></name><name><surname>Long</surname><given-names>G</given-names></name><name><surname>Schadendorf</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms</article-title><source>European Journal of Cancer</source><volume>51</volume><fpage>2792</fpage><lpage>2799</lpage><pub-id pub-id-type="doi">10.1016/J.EJCA.2015.08.022</pub-id><pub-id pub-id-type="pmid">26608120</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joseph</surname><given-names>EW</given-names></name><name><surname>Pratilas</surname><given-names>CA</given-names></name><name><surname>Poulikakos</surname><given-names>PI</given-names></name><name><surname>Tadi</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Taylor</surname><given-names>BS</given-names></name><name><surname>Halilovic</surname><given-names>E</given-names></name><name><surname>Persaud</surname><given-names>Y</given-names></name><name><surname>Xing</surname><given-names>F</given-names></name><name><surname>Viale</surname><given-names>A</given-names></name><name><surname>Tsai</surname><given-names>J</given-names></name><name><surname>Chapman</surname><given-names>PB</given-names></name><name><surname>Bollag</surname><given-names>G</given-names></name><name><surname>Solit</surname><given-names>DB</given-names></name><name><surname>Rosen</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner</article-title><source>PNAS</source><volume>107</volume><fpage>14903</fpage><lpage>14908</lpage><pub-id pub-id-type="doi">10.1073/pnas.1008990107</pub-id><pub-id pub-id-type="pmid">20668238</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kageshita</surname><given-names>T</given-names></name><name><surname>Hamby</surname><given-names>CV</given-names></name><name><surname>Ishihara</surname><given-names>T</given-names></name><name><surname>Matsumoto</surname><given-names>K</given-names></name><name><surname>Saida</surname><given-names>T</given-names></name><name><surname>Ono</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Loss of beta-catenin expression associated with disease progression in malignant melanoma</article-title><source>The British Journal of Dermatology</source><volume>145</volume><fpage>210</fpage><lpage>216</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2133.2001.04336.x</pub-id><pub-id pub-id-type="pmid">11531781</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaiser</surname><given-names>K</given-names></name><name><surname>Gyllborg</surname><given-names>D</given-names></name><name><surname>Procházka</surname><given-names>J</given-names></name><name><surname>Salašová</surname><given-names>A</given-names></name><name><surname>Kompaníková</surname><given-names>P</given-names></name><name><surname>Molina</surname><given-names>FL</given-names></name><name><surname>Laguna-Goya</surname><given-names>R</given-names></name><name><surname>Radaszkiewicz</surname><given-names>T</given-names></name><name><surname>Harnoš</surname><given-names>J</given-names></name><name><surname>Procházková</surname><given-names>M</given-names></name><name><surname>Potěšil</surname><given-names>D</given-names></name><name><surname>Barker</surname><given-names>RA</given-names></name><name><surname>Casado</surname><given-names>ÁG</given-names></name><name><surname>Zdráhal</surname><given-names>Z</given-names></name><name><surname>Sedláček</surname><given-names>R</given-names></name><name><surname>Arenas</surname><given-names>E</given-names></name><name><surname>Villaescusa</surname><given-names>JC</given-names></name><name><surname>Bryja</surname><given-names>V</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>WNT5A is transported via lipoprotein particles in the cerebrospinal fluid to regulate hindbrain morphogenesis</article-title><source>Nature Communications</source><volume>10</volume><elocation-id>1498</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-019-09298-4</pub-id><pub-id pub-id-type="pmid">30940800</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Kaiser</surname><given-names>K</given-names></name><name><surname>Jang</surname><given-names>A</given-names></name><name><surname>Lun</surname><given-names>MP</given-names></name><name><surname>Procházka</surname><given-names>J</given-names></name><name><surname>Machon</surname><given-names>O</given-names></name><name><surname>Procházková</surname><given-names>M</given-names></name><name><surname>Laurent</surname><given-names>B</given-names></name><name><surname>Gyllborg</surname><given-names>D</given-names></name><name><surname>van Amerongen</surname><given-names>R</given-names></name><name><surname>Kompaníková</surname><given-names>P</given-names></name><name><surname>Wu</surname><given-names>F</given-names></name><name><surname>Barker</surname><given-names>RA</given-names></name><name><surname>Uramová</surname><given-names>I</given-names></name><name><surname>Sedláček</surname><given-names>R</given-names></name><name><surname>Kozmík</surname><given-names>Z</given-names></name><name><surname>Arenas</surname><given-names>E</given-names></name><name><surname>Lehtinen</surname><given-names>MK</given-names></name><name><surname>Bryja</surname><given-names>V</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>2020. MEIS-WNT5A Axis Regulates Development of 4th Ventricle Choroid Plexus</article-title><source>bioRxiv</source><pub-id pub-id-type="doi">10.1101/2020.05.07.082370</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanzawa</surname><given-names>M</given-names></name><name><surname>Semba</surname><given-names>S</given-names></name><name><surname>Hara</surname><given-names>S</given-names></name><name><surname>Itoh</surname><given-names>T</given-names></name><name><surname>Yokozaki</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>WNT5A is a key regulator of the epithelial-mesenchymal transition and cancer stem cell properties in human gastric carcinoma cells</article-title><source>Pathobiology</source><volume>80</volume><fpage>235</fpage><lpage>244</lpage><pub-id pub-id-type="doi">10.1159/000346843</pub-id><pub-id pub-id-type="pmid">23615002</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Katoh</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Networking of WNT, FGF, notch, BMP, and hedgehog signaling pathways during carcinogenesis</article-title><source>Stem Cell Reviews</source><volume>3</volume><fpage>30</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1007/s12015-007-0006-6</pub-id><pub-id pub-id-type="pmid">17873379</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaucká</surname><given-names>M</given-names></name><name><surname>Petersen</surname><given-names>J</given-names></name><name><surname>Janovská</surname><given-names>P</given-names></name><name><surname>Radaszkiewicz</surname><given-names>T</given-names></name><name><surname>Smyčková</surname><given-names>L</given-names></name><name><surname>Daulat</surname><given-names>AM</given-names></name><name><surname>Borg</surname><given-names>J-P</given-names></name><name><surname>Schulte</surname><given-names>G</given-names></name><name><surname>Bryja</surname><given-names>V</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Asymmetry of VANGL2 in migrating lymphocytes as a tool to monitor activity of the mammalian wnt/planar cell polarity pathway</article-title><source>Cell Communication and Signaling</source><volume>13</volume><elocation-id>2</elocation-id><pub-id pub-id-type="doi">10.1186/s12964-014-0079-1</pub-id><pub-id pub-id-type="pmid">25627785</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kazanskaya</surname><given-names>O</given-names></name><name><surname>Glinka</surname><given-names>A</given-names></name><name><surname>del Barco Barrantes</surname><given-names>I</given-names></name><name><surname>Stannek</surname><given-names>P</given-names></name><name><surname>Niehrs</surname><given-names>C</given-names></name><name><surname>Wu</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>R-Spondin2 is a secreted activator of Wnt/beta-catenin signaling and is required for <italic>Xenopus</italic> myogenesis</article-title><source>Developmental Cell</source><volume>7</volume><fpage>525</fpage><lpage>534</lpage><pub-id pub-id-type="doi">10.1016/j.devcel.2004.07.019</pub-id><pub-id pub-id-type="pmid">15469841</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kemper</surname><given-names>K</given-names></name><name><surname>de Goeje</surname><given-names>PL</given-names></name><name><surname>Peeper</surname><given-names>DS</given-names></name><name><surname>van Amerongen</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Phenotype switching: Tumor cell plasticity as a resistance mechanism and target for therapy</article-title><source>Cancer Research</source><volume>74</volume><fpage>5937</fpage><lpage>5941</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-14-1174</pub-id><pub-id pub-id-type="pmid">25320006</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>KA</given-names></name><name><surname>Kakitani</surname><given-names>M</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Oshima</surname><given-names>T</given-names></name><name><surname>Tang</surname><given-names>T</given-names></name><name><surname>Binnerts</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Boyle</surname><given-names>B</given-names></name><name><surname>Park</surname><given-names>E</given-names></name><name><surname>Emtage</surname><given-names>P</given-names></name><name><surname>Funk</surname><given-names>WD</given-names></name><name><surname>Tomizuka</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Mitogenic influence of human R-spondin1 on the intestinal epithelium</article-title><source>Science</source><volume>309</volume><fpage>1256</fpage><lpage>1259</lpage><pub-id pub-id-type="doi">10.1126/science.1112521</pub-id><pub-id pub-id-type="pmid">16109882</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>KA</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Andarmani</surname><given-names>S</given-names></name><name><surname>Kakitani</surname><given-names>M</given-names></name><name><surname>Oshima</surname><given-names>T</given-names></name><name><surname>Binnerts</surname><given-names>ME</given-names></name><name><surname>Abo</surname><given-names>A</given-names></name><name><surname>Tomizuka</surname><given-names>K</given-names></name><name><surname>Funk</surname><given-names>WD</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>R-Spondin proteins: a novel link to beta-catenin activation</article-title><source>Cell Cycle</source><volume>5</volume><fpage>23</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.4161/cc.5.1.2305</pub-id><pub-id pub-id-type="pmid">16357527</pub-id></element-citation></ref><ref id="bib86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>KA</given-names></name><name><surname>Wagle</surname><given-names>M</given-names></name><name><surname>Tran</surname><given-names>K</given-names></name><name><surname>Zhan</surname><given-names>X</given-names></name><name><surname>Dixon</surname><given-names>MA</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Gros</surname><given-names>D</given-names></name><name><surname>Korver</surname><given-names>W</given-names></name><name><surname>Yonkovich</surname><given-names>S</given-names></name><name><surname>Tomasevic</surname><given-names>N</given-names></name><name><surname>Binnerts</surname><given-names>M</given-names></name><name><surname>Abo</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>R-spondin family members regulate the WNT pathway by a common mechanism</article-title><source>Molecular Biology of the Cell</source><volume>19</volume><fpage>2588</fpage><lpage>2596</lpage><pub-id pub-id-type="doi">10.1091/mbc.e08-02-0187</pub-id><pub-id pub-id-type="pmid">18400942</pub-id></element-citation></ref><ref id="bib87"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>IS</given-names></name><name><surname>Heilmann</surname><given-names>S</given-names></name><name><surname>Kansler</surname><given-names>ER</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Zimmer</surname><given-names>M</given-names></name><name><surname>Ratnakumar</surname><given-names>K</given-names></name><name><surname>Bowman</surname><given-names>RL</given-names></name><name><surname>Simon-Vermot</surname><given-names>T</given-names></name><name><surname>Fennell</surname><given-names>M</given-names></name><name><surname>Garippa</surname><given-names>R</given-names></name><name><surname>Lu</surname><given-names>L</given-names></name><name><surname>Lee</surname><given-names>W</given-names></name><name><surname>Hollmann</surname><given-names>T</given-names></name><name><surname>Xavier</surname><given-names>JB</given-names></name><name><surname>White</surname><given-names>RM</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Microenvironment-derived factors driving metastatic plasticity in melanoma</article-title><source>Nature Communications</source><volume>8</volume><elocation-id>14343</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms14343</pub-id><pub-id pub-id-type="pmid">28181494</pub-id></element-citation></ref><ref id="bib88"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koo</surname><given-names>BK</given-names></name><name><surname>Spit</surname><given-names>M</given-names></name><name><surname>Jordens</surname><given-names>I</given-names></name><name><surname>Low</surname><given-names>TY</given-names></name><name><surname>Stange</surname><given-names>DE</given-names></name><name><surname>van de Wetering</surname><given-names>M</given-names></name><name><surname>van Es</surname><given-names>JH</given-names></name><name><surname>Mohammed</surname><given-names>S</given-names></name><name><surname>Heck</surname><given-names>AJR</given-names></name><name><surname>Maurice</surname><given-names>MM</given-names></name><name><surname>Clevers</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Tumour suppressor rnf43 is a stem-cell e3 ligase that induces endocytosis of WNT receptors</article-title><source>Nature</source><volume>488</volume><fpage>665</fpage><lpage>669</lpage><pub-id pub-id-type="doi">10.1038/nature11308</pub-id><pub-id pub-id-type="pmid">22895187</pub-id></element-citation></ref><ref id="bib89"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kotašková</surname><given-names>J</given-names></name><name><surname>Pavlová</surname><given-names>Š</given-names></name><name><surname>Greif</surname><given-names>I</given-names></name><name><surname>Stehlíková</surname><given-names>O</given-names></name><name><surname>Plevová</surname><given-names>K</given-names></name><name><surname>Janovská</surname><given-names>P</given-names></name><name><surname>Brychtová</surname><given-names>Y</given-names></name><name><surname>Doubek</surname><given-names>M</given-names></name><name><surname>Pospíšilová</surname><given-names>Š</given-names></name><name><surname>Bryja</surname><given-names>V</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Ror1-based immunomagnetic protocol allows efficient separation of CLL and healthy B cells</article-title><source>British Journal of Haematology</source><volume>175</volume><fpage>339</fpage><lpage>342</lpage><pub-id pub-id-type="doi">10.1111/bjh.13848</pub-id><pub-id pub-id-type="pmid">26567475</pub-id></element-citation></ref><ref id="bib90"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kotrbová</surname><given-names>A</given-names></name><name><surname>Ovesná</surname><given-names>P</given-names></name><name><surname>Gybel’</surname><given-names>T</given-names></name><name><surname>Radaszkiewicz</surname><given-names>T</given-names></name><name><surname>Bednaříková</surname><given-names>M</given-names></name><name><surname>Hausnerová</surname><given-names>J</given-names></name><name><surname>Jandáková</surname><given-names>E</given-names></name><name><surname>Minář</surname><given-names>L</given-names></name><name><surname>Crha</surname><given-names>I</given-names></name><name><surname>Weinberger</surname><given-names>V</given-names></name><name><surname>Záveský</surname><given-names>L</given-names></name><name><surname>Bryja</surname><given-names>V</given-names></name><name><surname>Pospíchalová</surname><given-names>V</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>WNT signaling inducing activity in ascites predicts poor outcome in ovarian cancer</article-title><source>Theranostics</source><volume>10</volume><fpage>537</fpage><lpage>552</lpage><pub-id pub-id-type="doi">10.7150/thno.37423</pub-id><pub-id pub-id-type="pmid">31903136</pub-id></element-citation></ref><ref id="bib91"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Kristina</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2021">2021</year><data-title>OmicsWorkflows</data-title><source>GitHub</source><ext-link ext-link-type="uri" xlink:href="https://github.com/OmicsWorkflows">https://github.com/OmicsWorkflows</ext-link></element-citation></ref><ref id="bib92"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kucerova</surname><given-names>L</given-names></name><name><surname>Skolekova</surname><given-names>S</given-names></name><name><surname>Demkova</surname><given-names>L</given-names></name><name><surname>Bohovic</surname><given-names>R</given-names></name><name><surname>Matuskova</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Long-term efficiency of mesenchymal stromal cell-mediated CD-MSC/5FC therapy in human melanoma xenograft model</article-title><source>Gene Therapy</source><volume>21</volume><fpage>874</fpage><lpage>887</lpage><pub-id pub-id-type="doi">10.1038/gt.2014.66</pub-id><pub-id pub-id-type="pmid">25056607</pub-id></element-citation></ref><ref id="bib93"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kurayoshi</surname><given-names>M</given-names></name><name><surname>Oue</surname><given-names>N</given-names></name><name><surname>Yamamoto</surname><given-names>H</given-names></name><name><surname>Kishida</surname><given-names>M</given-names></name><name><surname>Inoue</surname><given-names>A</given-names></name><name><surname>Asahara</surname><given-names>T</given-names></name><name><surname>Yasui</surname><given-names>W</given-names></name><name><surname>Kikuchi</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Expression of Wnt-5a is correlated with aggressiveness of gastric cancer by stimulating cell migration and invasion</article-title><source>Cancer Research</source><volume>66</volume><fpage>10439</fpage><lpage>10448</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-06-2359</pub-id><pub-id pub-id-type="pmid">17079465</pub-id></element-citation></ref><ref id="bib94"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lai</surname><given-names>SS</given-names></name><name><surname>Xue</surname><given-names>B</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Zhao</surname><given-names>L</given-names></name><name><surname>Chu</surname><given-names>CS</given-names></name><name><surname>Hao</surname><given-names>JY</given-names></name><name><surname>Wen</surname><given-names>CJ</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Ror2-src signaling in metastasis of mouse melanoma cells is inhibited by NRAGE</article-title><source>Cancer Genetics</source><volume>205</volume><fpage>552</fpage><lpage>562</lpage><pub-id pub-id-type="doi">10.1016/J.CANCERGEN.2012.09.002</pub-id><pub-id pub-id-type="pmid">23142633</pub-id></element-citation></ref><ref id="bib95"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lavelle</surname><given-names>TJ</given-names></name><name><surname>Alver</surname><given-names>TN</given-names></name><name><surname>Heintz</surname><given-names>KM</given-names></name><name><surname>Wernhoff</surname><given-names>P</given-names></name><name><surname>Nygaard</surname><given-names>V</given-names></name><name><surname>Nakken</surname><given-names>S</given-names></name><name><surname>Øy</surname><given-names>GF</given-names></name><name><surname>Bøe</surname><given-names>SL</given-names></name><name><surname>Urbanucci</surname><given-names>A</given-names></name><name><surname>Hovig</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Dysregulation of MITF leads to transformation in mc1r-defective melanocytes</article-title><source>Cancers</source><volume>12</volume><fpage>1</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.3390/cancers12071719</pub-id><pub-id pub-id-type="pmid">32605315</pub-id></element-citation></ref><ref id="bib96"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lebensohn</surname><given-names>AM</given-names></name><name><surname>Rohatgi</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>R-spondins can potentiate WNT signaling without LGRS</article-title><source>eLife</source><volume>7</volume><elocation-id>e33126</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.33126</pub-id><pub-id pub-id-type="pmid">29405118</pub-id></element-citation></ref><ref id="bib97"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>N</given-names></name><name><surname>Ma</surname><given-names>T</given-names></name><name><surname>Zhao</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Il-1β mediates mcp-1 induction by WNT5A in gastric cancer cells</article-title><source>BMC Cancer</source><volume>14</volume><elocation-id>480</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2407-14-480</pub-id><pub-id pub-id-type="pmid">24993819</pub-id></element-citation></ref><ref id="bib98"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lim</surname><given-names>X</given-names></name><name><surname>Nusse</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>WNT signaling in skin development, homeostasis, and disease</article-title><source>Cold Spring Harbor Perspectives in Biology</source><volume>5</volume><elocation-id>a008029</elocation-id><pub-id pub-id-type="doi">10.1101/cshperspect.a008029</pub-id><pub-id pub-id-type="pmid">23209129</pub-id></element-citation></ref><ref id="bib99"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Linnskog</surname><given-names>R</given-names></name><name><surname>Mohapatra</surname><given-names>P</given-names></name><name><surname>Moradi</surname><given-names>F</given-names></name><name><surname>Prasad</surname><given-names>CP</given-names></name><name><surname>Andersson</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Demonstration of a wnt5a-il-6 positive feedback loop in melanoma cells: Dual interference of this loop more effectively impairs melanoma cell invasion</article-title><source>Oncotarget</source><volume>7</volume><fpage>37790</fpage><lpage>37802</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.9332</pub-id><pub-id pub-id-type="pmid">27191257</pub-id></element-citation></ref><ref id="bib100"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Q</given-names></name><name><surname>Zhu</surname><given-names>H</given-names></name><name><surname>Tiruthani</surname><given-names>K</given-names></name><name><surname>Shen</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>F</given-names></name><name><surname>Gao</surname><given-names>K</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Hou</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Liu</surname><given-names>R</given-names></name><name><surname>Huang</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Nanoparticle-mediated trapping of Wnt family member 5A in tumor microenvironments enhances immunotherapy for B-RAF proto-oncogene mutant melanoma</article-title><source>ACS Nano</source><volume>12</volume><fpage>1250</fpage><lpage>1261</lpage><pub-id pub-id-type="doi">10.1021/acsnano.7b07384</pub-id><pub-id pub-id-type="pmid">29370526</pub-id></element-citation></ref><ref id="bib101"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luebker</surname><given-names>SA</given-names></name><name><surname>Koepsell</surname><given-names>SA</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Diverse mechanisms of BRAF inhibitor resistance in melanoma identified in clinical and preclinical studies</article-title><source>Frontiers in Oncology</source><volume>9</volume><elocation-id>268</elocation-id><pub-id pub-id-type="doi">10.3389/fonc.2019.00268</pub-id><pub-id pub-id-type="pmid">31058079</pub-id></element-citation></ref><ref id="bib102"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname><given-names>C</given-names></name><name><surname>Balsa</surname><given-names>E</given-names></name><name><surname>Perry</surname><given-names>EA</given-names></name><name><surname>Liang</surname><given-names>J</given-names></name><name><surname>Tavares</surname><given-names>CD</given-names></name><name><surname>Vazquez</surname><given-names>F</given-names></name><name><surname>Widlund</surname><given-names>HR</given-names></name><name><surname>Puigserver</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>H3k27me3-mediated pgc1α gene silencing promotes melanoma invasion through wnt5a and YAP</article-title><source>The Journal of Clinical Investigation</source><volume>130</volume><fpage>853</fpage><lpage>862</lpage><pub-id pub-id-type="doi">10.1172/JCI130038</pub-id><pub-id pub-id-type="pmid">31929186</pub-id></element-citation></ref><ref id="bib103"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Makowiecka</surname><given-names>A</given-names></name><name><surname>Simiczyjew</surname><given-names>A</given-names></name><name><surname>Nowak</surname><given-names>D</given-names></name><name><surname>Mazur</surname><given-names>AJ</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Varying effects of EGF, HGF and tgfβ on formation of invadopodia and invasiveness of melanoma cell lines of different origin</article-title><source>European Journal of Histochemistry</source><volume>60</volume><elocation-id>2728</elocation-id><pub-id pub-id-type="doi">10.4081/ejh.2016.2728</pub-id><pub-id pub-id-type="pmid">28076931</pub-id></element-citation></ref><ref id="bib104"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malcikova</surname><given-names>J</given-names></name><name><surname>Stano-Kozubik</surname><given-names>K</given-names></name><name><surname>Tichy</surname><given-names>B</given-names></name><name><surname>Kantorova</surname><given-names>B</given-names></name><name><surname>Pavlova</surname><given-names>S</given-names></name><name><surname>Tom</surname><given-names>N</given-names></name><name><surname>Radova</surname><given-names>L</given-names></name><name><surname>Smardova</surname><given-names>J</given-names></name><name><surname>Pardy</surname><given-names>F</given-names></name><name><surname>Doubek</surname><given-names>M</given-names></name><name><surname>Brychtova</surname><given-names>Y</given-names></name><name><surname>Mraz</surname><given-names>M</given-names></name><name><surname>Plevova</surname><given-names>K</given-names></name><name><surname>Diviskova</surname><given-names>E</given-names></name><name><surname>Oltova</surname><given-names>A</given-names></name><name><surname>Mayer</surname><given-names>J</given-names></name><name><surname>Pospisilova</surname><given-names>S</given-names></name><name><surname>Trbusek</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Detailed analysis of therapy-driven clonal evolution of tp53 mutations in chronic lymphocytic leukemia</article-title><source>Leukemia</source><volume>29</volume><fpage>877</fpage><lpage>885</lpage><pub-id pub-id-type="doi">10.1038/leu.2014.297</pub-id><pub-id pub-id-type="pmid">25287991</pub-id></element-citation></ref><ref id="bib105"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mali</surname><given-names>P</given-names></name><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Esvelt</surname><given-names>KM</given-names></name><name><surname>Aach</surname><given-names>J</given-names></name><name><surname>Guell</surname><given-names>M</given-names></name><name><surname>DiCarlo</surname><given-names>JE</given-names></name><name><surname>Norville</surname><given-names>JE</given-names></name><name><surname>Church</surname><given-names>GM</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>RNA-guided human genome engineering via cas9</article-title><source>Science</source><volume>339</volume><fpage>823</fpage><lpage>826</lpage><pub-id pub-id-type="doi">10.1126/science.1232033</pub-id><pub-id pub-id-type="pmid">23287722</pub-id></element-citation></ref><ref id="bib106"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Masi</surname><given-names>I</given-names></name><name><surname>Caprara</surname><given-names>V</given-names></name><name><surname>Bagnato</surname><given-names>A</given-names></name><name><surname>Rosanò</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Tumor cellular and microenvironmental cues controlling invadopodia formation</article-title><source>Frontiers in Cell and Developmental Biology</source><volume>8</volume><elocation-id>584181</elocation-id><pub-id pub-id-type="doi">10.3389/fcell.2020.584181</pub-id><pub-id pub-id-type="pmid">33178698</pub-id></element-citation></ref><ref id="bib107"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Massi</surname><given-names>D</given-names></name><name><surname>Mihic-Probst</surname><given-names>D</given-names></name><name><surname>Schadendorf</surname><given-names>D</given-names></name><name><surname>Dummer</surname><given-names>R</given-names></name><name><surname>Mandalà</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Dedifferentiated melanomas: Morpho-phenotypic profile, genetic reprogramming and clinical implications</article-title><source>Cancer Treatment Reviews</source><volume>88</volume><pub-id pub-id-type="doi">10.1016/j.ctrv.2020.102060</pub-id></element-citation></ref><ref id="bib108"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsumoto</surname><given-names>A</given-names></name><name><surname>Shimada</surname><given-names>Y</given-names></name><name><surname>Nakano</surname><given-names>M</given-names></name><name><surname>Oyanagi</surname><given-names>H</given-names></name><name><surname>Tajima</surname><given-names>Y</given-names></name><name><surname>Nakano</surname><given-names>M</given-names></name><name><surname>Kameyama</surname><given-names>H</given-names></name><name><surname>Hirose</surname><given-names>Y</given-names></name><name><surname>Ichikawa</surname><given-names>H</given-names></name><name><surname>Nagahashi</surname><given-names>M</given-names></name><name><surname>Nogami</surname><given-names>H</given-names></name><name><surname>Maruyama</surname><given-names>S</given-names></name><name><surname>Takii</surname><given-names>Y</given-names></name><name><surname>Ling</surname><given-names>Y</given-names></name><name><surname>Okuda</surname><given-names>S</given-names></name><name><surname>Wakai</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>RNF43 mutation is associated with aggressive tumor biology along with BRAF V600E mutation in right-sided colorectal cancer</article-title><source>Oncology Reports</source><volume>43</volume><fpage>1853</fpage><lpage>1862</lpage><pub-id pub-id-type="doi">10.3892/or.2020.7561</pub-id><pub-id pub-id-type="pmid">32236609</pub-id></element-citation></ref><ref id="bib109"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McArdle</surname><given-names>TJ</given-names></name><name><surname>Ogle</surname><given-names>BM</given-names></name><name><surname>Noubissi</surname><given-names>FK</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>An in vitro inverted vertical invasion assay to avoid manipulation of rare or sensitive cell types</article-title><source>Journal of Cancer</source><volume>7</volume><fpage>2333</fpage><lpage>2340</lpage><pub-id pub-id-type="doi">10.7150/jca.15812</pub-id><pub-id pub-id-type="pmid">27994672</pub-id></element-citation></ref><ref id="bib110"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mentink</surname><given-names>RA</given-names></name><name><surname>Rella</surname><given-names>L</given-names></name><name><surname>Radaszkiewicz</surname><given-names>TW</given-names></name><name><surname>Gybel</surname><given-names>T</given-names></name><name><surname>Betist</surname><given-names>MC</given-names></name><name><surname>Bryja</surname><given-names>V</given-names></name><name><surname>Korswagen</surname><given-names>HC</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The planar cell polarity protein Vang-1/vangl negatively regulates wnt/β-catenin signaling through a DVL dependent mechanism</article-title><source>PLOS Genetics</source><volume>14</volume><elocation-id>e1007840</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pgen.1007840</pub-id><pub-id pub-id-type="pmid">30532125</pub-id></element-citation></ref><ref id="bib111"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moffat</surname><given-names>LL</given-names></name><name><surname>Robinson</surname><given-names>RE</given-names></name><name><surname>Bakoulis</surname><given-names>A</given-names></name><name><surname>Clark</surname><given-names>SG</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>The conserved transmembrane ring finger protein PLR-1 downregulates wnt signaling by reducing Frizzled, ROR and ryk cell-surface levels in <italic>C. elegans</italic></article-title><source>Development</source><volume>141</volume><fpage>617</fpage><lpage>628</lpage><pub-id pub-id-type="doi">10.1242/dev.101600</pub-id><pub-id pub-id-type="pmid">24401370</pub-id></element-citation></ref><ref id="bib112"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mohapatra</surname><given-names>P</given-names></name><name><surname>Prasad</surname><given-names>CP</given-names></name><name><surname>Andersson</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Combination therapy targeting the elevated interleukin-6 level reduces invasive migration of BRAF inhibitor-resistant melanoma cells</article-title><source>Molecular Oncology</source><volume>13</volume><fpage>480</fpage><lpage>494</lpage><pub-id pub-id-type="doi">10.1002/1878-0261.12433</pub-id><pub-id pub-id-type="pmid">30582770</pub-id></element-citation></ref><ref id="bib113"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Müller</surname><given-names>J</given-names></name><name><surname>Krijgsman</surname><given-names>O</given-names></name><name><surname>Tsoi</surname><given-names>J</given-names></name><name><surname>Robert</surname><given-names>L</given-names></name><name><surname>Hugo</surname><given-names>W</given-names></name><name><surname>Song</surname><given-names>C</given-names></name><name><surname>Kong</surname><given-names>X</given-names></name><name><surname>Possik</surname><given-names>PA</given-names></name><name><surname>Cornelissen-Steijger</surname><given-names>PDM</given-names></name><name><surname>Geukes Foppen</surname><given-names>MH</given-names></name><name><surname>Kemper</surname><given-names>K</given-names></name><name><surname>Goding</surname><given-names>CR</given-names></name><name><surname>McDermott</surname><given-names>U</given-names></name><name><surname>Blank</surname><given-names>C</given-names></name><name><surname>Haanen</surname><given-names>J</given-names></name><name><surname>Graeber</surname><given-names>TG</given-names></name><name><surname>Ribas</surname><given-names>A</given-names></name><name><surname>Lo</surname><given-names>RS</given-names></name><name><surname>Peeper</surname><given-names>DS</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma</article-title><source>Nature Communications</source><volume>5</volume><fpage>1</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1038/ncomms6712</pub-id><pub-id pub-id-type="pmid">25502142</pub-id></element-citation></ref><ref id="bib114"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nam</surname><given-names>JS</given-names></name><name><surname>Turcotte</surname><given-names>TJ</given-names></name><name><surname>Smith</surname><given-names>PF</given-names></name><name><surname>Choi</surname><given-names>S</given-names></name><name><surname>Yoon</surname><given-names>JK</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Mouse cristin/R-spondin family proteins are novel ligands for the Frizzled 8 and LRP6 receptors and activate beta-catenin-dependent gene expression</article-title><source>The Journal of Biological Chemistry</source><volume>281</volume><fpage>13247</fpage><lpage>13257</lpage><pub-id pub-id-type="doi">10.1074/jbc.M508324200</pub-id><pub-id pub-id-type="pmid">16543246</pub-id></element-citation></ref><ref id="bib115"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nam</surname><given-names>JS</given-names></name><name><surname>Turcotte</surname><given-names>TJ</given-names></name><name><surname>Yoon</surname><given-names>JK</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Dynamic expression of R-spondin family genes in mouse development</article-title><source>Gene Expression Patterns</source><volume>7</volume><fpage>306</fpage><lpage>312</lpage><pub-id pub-id-type="doi">10.1016/j.modgep.2006.08.006</pub-id><pub-id pub-id-type="pmid">17035101</pub-id></element-citation></ref><ref id="bib116"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nam</surname><given-names>S</given-names></name><name><surname>Chung</surname><given-names>JW</given-names></name><name><surname>Yang</surname><given-names>JY</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>WNT5A correlates with clinicopathological characteristics in gastric cancer: A meta-analysis</article-title><source>Cellular Physiology and Biochemistry</source><volume>41</volume><fpage>33</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1159/000455934</pub-id></element-citation></ref><ref id="bib117"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Narimatsu</surname><given-names>M</given-names></name><name><surname>Bose</surname><given-names>R</given-names></name><name><surname>Pye</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Miller</surname><given-names>B</given-names></name><name><surname>Ching</surname><given-names>P</given-names></name><name><surname>Sakuma</surname><given-names>R</given-names></name><name><surname>Luga</surname><given-names>V</given-names></name><name><surname>Roncari</surname><given-names>L</given-names></name><name><surname>Attisano</surname><given-names>L</given-names></name><name><surname>Wrana</surname><given-names>JL</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Regulation of planar cell polarity by Smurf ubiquitin ligases</article-title><source>Cell</source><volume>137</volume><fpage>295</fpage><lpage>307</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2009.02.025</pub-id><pub-id pub-id-type="pmid">19379695</pub-id></element-citation></ref><ref id="bib118"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nazarian</surname><given-names>R</given-names></name><name><surname>Shi</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Kong</surname><given-names>X</given-names></name><name><surname>Koya</surname><given-names>RC</given-names></name><name><surname>Lee</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Lee</surname><given-names>M-K</given-names></name><name><surname>Attar</surname><given-names>N</given-names></name><name><surname>Sazegar</surname><given-names>H</given-names></name><name><surname>Chodon</surname><given-names>T</given-names></name><name><surname>Nelson</surname><given-names>SF</given-names></name><name><surname>McArthur</surname><given-names>G</given-names></name><name><surname>Sosman</surname><given-names>JA</given-names></name><name><surname>Ribas</surname><given-names>A</given-names></name><name><surname>Lo</surname><given-names>RS</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation</article-title><source>Nature</source><volume>468</volume><fpage>973</fpage><lpage>977</lpage><pub-id pub-id-type="doi">10.1038/nature09626</pub-id><pub-id pub-id-type="pmid">21107323</pub-id></element-citation></ref><ref id="bib119"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neumeyer</surname><given-names>V</given-names></name><name><surname>Grandl</surname><given-names>M</given-names></name><name><surname>Dietl</surname><given-names>A</given-names></name><name><surname>Brutau-Abia</surname><given-names>A</given-names></name><name><surname>Allgäuer</surname><given-names>M</given-names></name><name><surname>Kalali</surname><given-names>B</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Pan</surname><given-names>KF</given-names></name><name><surname>Steiger</surname><given-names>K</given-names></name><name><surname>Vieth</surname><given-names>M</given-names></name><name><surname>Anton</surname><given-names>M</given-names></name><name><surname>Mejías-Luque</surname><given-names>R</given-names></name><name><surname>Gerhard</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2019">2019a</year><article-title>Loss of endogenous RNF43 function enhances proliferation and tumour growth of intestinal and gastric cells</article-title><source>Carcinogenesis</source><volume>40</volume><fpage>551</fpage><lpage>559</lpage><pub-id pub-id-type="doi">10.1093/carcin/bgy152</pub-id><pub-id pub-id-type="pmid">30380024</pub-id></element-citation></ref><ref id="bib120"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neumeyer</surname><given-names>V</given-names></name><name><surname>Vieth</surname><given-names>M</given-names></name><name><surname>Gerhard</surname><given-names>M</given-names></name><name><surname>Mejías-Luque</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2019">2019b</year><article-title>Mutated RNF43 aggravates helicobacter pylori-induced gastric pathology</article-title><source>Cancers</source><volume>11</volume><elocation-id>E372</elocation-id><pub-id pub-id-type="doi">10.3390/cancers11030372</pub-id><pub-id pub-id-type="pmid">30884828</pub-id></element-citation></ref><ref id="bib121"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Niu</surname><given-names>L</given-names></name><name><surname>Qin</surname><given-names>H-Z</given-names></name><name><surname>Xi</surname><given-names>H-Q</given-names></name><name><surname>Wei</surname><given-names>B</given-names></name><name><surname>Xia</surname><given-names>S-Y</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>RNF43 inhibits cancer cell proliferation and could be a potential prognostic factor for human gastric carcinoma</article-title><source>Cellular Physiology and Biochemistry</source><volume>36</volume><fpage>1835</fpage><lpage>1846</lpage><pub-id pub-id-type="doi">10.1159/000430154</pub-id><pub-id pub-id-type="pmid">26184844</pub-id></element-citation></ref><ref id="bib122"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ohkawara</surname><given-names>B</given-names></name><name><surname>Glinka</surname><given-names>A</given-names></name><name><surname>Niehrs</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>RSPO3 binds syndecan 4 and induces Wnt/pcp signaling via clathrin-mediated endocytosis to promote morphogenesis</article-title><source>Developmental Cell</source><volume>20</volume><fpage>303</fpage><lpage>314</lpage><pub-id pub-id-type="doi">10.1016/J.DEVCEL.2011.01.006</pub-id><pub-id pub-id-type="pmid">21397842</pub-id></element-citation></ref><ref id="bib123"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ozeki</surname><given-names>N</given-names></name><name><surname>Mogi</surname><given-names>M</given-names></name><name><surname>Hase</surname><given-names>N</given-names></name><name><surname>Hiyama</surname><given-names>T</given-names></name><name><surname>Yamaguchi</surname><given-names>H</given-names></name><name><surname>Kawai</surname><given-names>R</given-names></name><name><surname>Kondo</surname><given-names>A</given-names></name><name><surname>Nakata</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Wnt16 signaling is required for il-1β-induced matrix metalloproteinase-13-regulated proliferation of human stem cell-derived osteoblastic cells</article-title><source>International Journal of Molecular Sciences</source><volume>17</volume><elocation-id>E221</elocation-id><pub-id pub-id-type="doi">10.3390/ijms17020221</pub-id><pub-id pub-id-type="pmid">26861315</pub-id></element-citation></ref><ref id="bib124"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O’Connell</surname><given-names>MP</given-names></name><name><surname>French</surname><given-names>AD</given-names></name><name><surname>Leotlela</surname><given-names>PD</given-names></name><name><surname>Weeraratna</surname><given-names>AT</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Assaying Wnt5a-Mediated Invasion in Melanoma Cells</article-title><source>Methods in Molecular Biology</source><volume>468</volume><elocation-id>243</elocation-id><pub-id pub-id-type="doi">10.1007/978-1-59745-249-6_19</pub-id></element-citation></ref><ref id="bib125"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O’Connell</surname><given-names>MP</given-names></name><name><surname>Weeraratna</surname><given-names>AT</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Hear the Wnt ROR: How melanoma cells adjust to changes in Wnt</article-title><source>Pigment Cell &amp; Melanoma Research</source><volume>22</volume><fpage>724</fpage><lpage>739</lpage><pub-id pub-id-type="doi">10.1111/j.1755-148X.2009.00627.x</pub-id><pub-id pub-id-type="pmid">19708915</pub-id></element-citation></ref><ref id="bib126"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O’Connell</surname><given-names>MP</given-names></name><name><surname>Fiori</surname><given-names>JL</given-names></name><name><surname>Xu</surname><given-names>M</given-names></name><name><surname>Carter</surname><given-names>AD</given-names></name><name><surname>Frank</surname><given-names>BP</given-names></name><name><surname>Camilli</surname><given-names>TC</given-names></name><name><surname>French</surname><given-names>AD</given-names></name><name><surname>Dissanayake</surname><given-names>SK</given-names></name><name><surname>Indig</surname><given-names>FE</given-names></name><name><surname>Bernier</surname><given-names>M</given-names></name><name><surname>Taub</surname><given-names>DD</given-names></name><name><surname>Hewitt</surname><given-names>SM</given-names></name><name><surname>Weeraratna</surname><given-names>AT</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>The orphan tyrosine kinase receptor, ror2, mediates wnt5a signaling in metastatic melanoma</article-title><source>Oncogene</source><volume>29</volume><fpage>34</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1038/onc.2009.305</pub-id><pub-id pub-id-type="pmid">19802008</pub-id></element-citation></ref><ref id="bib127"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O’Connell</surname><given-names>MP</given-names></name><name><surname>Marchbank</surname><given-names>K</given-names></name><name><surname>Webster</surname><given-names>MR</given-names></name><name><surname>Valiga</surname><given-names>AA</given-names></name><name><surname>Kaur</surname><given-names>A</given-names></name><name><surname>Vultur</surname><given-names>A</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Herlyn</surname><given-names>M</given-names></name><name><surname>Villanueva</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>Q</given-names></name><name><surname>Yin</surname><given-names>X</given-names></name><name><surname>Widura</surname><given-names>S</given-names></name><name><surname>Nelson</surname><given-names>J</given-names></name><name><surname>Ruiz</surname><given-names>N</given-names></name><name><surname>Camilli</surname><given-names>TC</given-names></name><name><surname>Indig</surname><given-names>FE</given-names></name><name><surname>Flaherty</surname><given-names>KT</given-names></name><name><surname>Wargo</surname><given-names>JA</given-names></name><name><surname>Frederick</surname><given-names>DT</given-names></name><name><surname>Cooper</surname><given-names>ZA</given-names></name><name><surname>Nair</surname><given-names>S</given-names></name><name><surname>Amaravadi</surname><given-names>RK</given-names></name><name><surname>Schuchter</surname><given-names>LM</given-names></name><name><surname>Karakousis</surname><given-names>GC</given-names></name><name><surname>Xu</surname><given-names>W</given-names></name><name><surname>Xu</surname><given-names>X</given-names></name><name><surname>Weeraratna</surname><given-names>AT</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Hypoxia induces phenotypic plasticity and therapy resistance in melanoma via the tyrosine kinase receptors ror1 and ror2</article-title><source>Cancer Discovery</source><volume>3</volume><fpage>1378</fpage><lpage>1393</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-13-0005</pub-id><pub-id pub-id-type="pmid">24104062</pub-id></element-citation></ref><ref id="bib128"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paclíková</surname><given-names>P</given-names></name><name><surname>Bernatík</surname><given-names>O</given-names></name><name><surname>Radaszkiewicz</surname><given-names>TW</given-names></name><name><surname>Bryja</surname><given-names>V</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>The N-terminal part of the Dishevelled DEP domain is required for Wnt/β- catenin signaling in mammalian cells</article-title><source>Molecular and Cellular Biology</source><volume>37</volume><elocation-id>e00145-17</elocation-id><pub-id pub-id-type="doi">10.1128/MCB.00145-17</pub-id><pub-id pub-id-type="pmid">28674183</pub-id></element-citation></ref><ref id="bib129"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pandur</surname><given-names>P</given-names></name><name><surname>Maurus</surname><given-names>D</given-names></name><name><surname>Kühl</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Increasingly complex: New players enter the Wnt signaling network</article-title><source>BioEssays</source><volume>24</volume><fpage>881</fpage><lpage>884</lpage><pub-id pub-id-type="doi">10.1002/bies.10164</pub-id><pub-id pub-id-type="pmid">12325120</pub-id></element-citation></ref><ref id="bib130"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peek</surname><given-names>RMJ</given-names></name><name><surname>Crabtree</surname><given-names>JE</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Helicobacter infection and gastric neoplasia</article-title><source>The Journal of Pathology</source><volume>208</volume><fpage>233</fpage><lpage>248</lpage><pub-id pub-id-type="doi">10.1002/path.1868</pub-id><pub-id pub-id-type="pmid">16362989</pub-id></element-citation></ref><ref id="bib131"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peng</surname><given-names>WC</given-names></name><name><surname>de Lau</surname><given-names>W</given-names></name><name><surname>Madoori</surname><given-names>PK</given-names></name><name><surname>Forneris</surname><given-names>F</given-names></name><name><surname>Granneman</surname><given-names>JCM</given-names></name><name><surname>Clevers</surname><given-names>H</given-names></name><name><surname>Gros</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Structures of wnt-antagonist ZNRF3 and its complex with R-spondin 1 and implications for signaling</article-title><source>PLOS ONE</source><volume>8</volume><elocation-id>e83110</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0083110</pub-id><pub-id pub-id-type="pmid">24349440</pub-id></element-citation></ref><ref id="bib132"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perez-Riverol</surname><given-names>Y</given-names></name><name><surname>Csordas</surname><given-names>A</given-names></name><name><surname>Bai</surname><given-names>J</given-names></name><name><surname>Bernal-Llinares</surname><given-names>M</given-names></name><name><surname>Hewapathirana</surname><given-names>S</given-names></name><name><surname>Kundu</surname><given-names>DJ</given-names></name><name><surname>Inuganti</surname><given-names>A</given-names></name><name><surname>Griss</surname><given-names>J</given-names></name><name><surname>Mayer</surname><given-names>G</given-names></name><name><surname>Eisenacher</surname><given-names>M</given-names></name><name><surname>Pérez</surname><given-names>E</given-names></name><name><surname>Uszkoreit</surname><given-names>J</given-names></name><name><surname>Pfeuffer</surname><given-names>J</given-names></name><name><surname>Sachsenberg</surname><given-names>T</given-names></name><name><surname>Yilmaz</surname><given-names>S</given-names></name><name><surname>Tiwary</surname><given-names>S</given-names></name><name><surname>Cox</surname><given-names>J</given-names></name><name><surname>Audain</surname><given-names>E</given-names></name><name><surname>Walzer</surname><given-names>M</given-names></name><name><surname>Jarnuczak</surname><given-names>AF</given-names></name><name><surname>Ternent</surname><given-names>T</given-names></name><name><surname>Brazma</surname><given-names>A</given-names></name><name><surname>Vizcaíno</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>The PRIDE database and related tools and resources in 2019: improving support for quantification data</article-title><source>Nucleic Acids Research</source><volume>47</volume><fpage>D442</fpage><lpage>D450</lpage><pub-id pub-id-type="doi">10.1093/nar/gky1106</pub-id><pub-id pub-id-type="pmid">30395289</pub-id></element-citation></ref><ref id="bib133"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Planas-Paz</surname><given-names>L</given-names></name><name><surname>Orsini</surname><given-names>V</given-names></name><name><surname>Boulter</surname><given-names>L</given-names></name><name><surname>Calabrese</surname><given-names>D</given-names></name><name><surname>Pikiolek</surname><given-names>M</given-names></name><name><surname>Nigsch</surname><given-names>F</given-names></name><name><surname>Xie</surname><given-names>Y</given-names></name><name><surname>Roma</surname><given-names>G</given-names></name><name><surname>Donovan</surname><given-names>A</given-names></name><name><surname>Marti</surname><given-names>P</given-names></name><name><surname>Beckmann</surname><given-names>N</given-names></name><name><surname>Dill</surname><given-names>MT</given-names></name><name><surname>Carbone</surname><given-names>W</given-names></name><name><surname>Bergling</surname><given-names>S</given-names></name><name><surname>Isken</surname><given-names>A</given-names></name><name><surname>Mueller</surname><given-names>M</given-names></name><name><surname>Kinzel</surname><given-names>B</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Mao</surname><given-names>X</given-names></name><name><surname>Nicholson</surname><given-names>TB</given-names></name><name><surname>Zamponi</surname><given-names>R</given-names></name><name><surname>Capodieci</surname><given-names>P</given-names></name><name><surname>Valdez</surname><given-names>R</given-names></name><name><surname>Rivera</surname><given-names>D</given-names></name><name><surname>Loew</surname><given-names>A</given-names></name><name><surname>Ukomadu</surname><given-names>C</given-names></name><name><surname>Terracciano</surname><given-names>LM</given-names></name><name><surname>Bouwmeester</surname><given-names>T</given-names></name><name><surname>Cong</surname><given-names>F</given-names></name><name><surname>Heim</surname><given-names>MH</given-names></name><name><surname>Forbes</surname><given-names>SJ</given-names></name><name><surname>Ruffner</surname><given-names>H</given-names></name><name><surname>Tchorz</surname><given-names>JS</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>The RSPO-LGR4/5-ZNRF3/RNF43 module controls liver zonation and size</article-title><source>Nature Cell Biology</source><volume>18</volume><fpage>467</fpage><lpage>479</lpage><pub-id pub-id-type="doi">10.1038/ncb3337</pub-id><pub-id pub-id-type="pmid">27088858</pub-id></element-citation></ref><ref id="bib134"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prasad</surname><given-names>C</given-names></name><name><surname>Mohapatra</surname><given-names>P</given-names></name><name><surname>Andersson</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Therapy for BRAFi-Resistant Melanomas: Is WNT5A the Answer</article-title><source>Cancers</source><volume>7</volume><fpage>1900</fpage><lpage>1924</lpage><pub-id pub-id-type="doi">10.3390/cancers7030868</pub-id><pub-id pub-id-type="pmid">26393652</pub-id></element-citation></ref><ref id="bib135"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Radaszkiewicz</surname><given-names>KA</given-names></name><name><surname>Beckerová</surname><given-names>D</given-names></name><name><surname>Woloszczuková</surname><given-names>L</given-names></name><name><surname>Radaszkiewicz</surname><given-names>TW</given-names></name><name><surname>Lesáková</surname><given-names>P</given-names></name><name><surname>Blanářová</surname><given-names>OV</given-names></name><name><surname>Kubala</surname><given-names>L</given-names></name><name><surname>Humpolíček</surname><given-names>P</given-names></name><name><surname>Pachernik</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>12-o-tetradecanoylphorbol-13-acetate increases cardiomyogenesis through PKC/ERK signaling</article-title><source>Scientific Reports</source><volume>10</volume><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1038/s41598-020-73074-4</pub-id><pub-id pub-id-type="pmid">32985604</pub-id></element-citation></ref><ref id="bib136"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Radaszkiewicz</surname><given-names>T</given-names></name><name><surname>Bryja</surname><given-names>V</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Protease associated domain of RNF43 is not necessary for the suppression of wnt/β-catenin signaling in human cells</article-title><source>Cell Communication and Signaling</source><volume>18</volume><elocation-id>91</elocation-id><pub-id pub-id-type="doi">10.1186/s12964-020-00559-0</pub-id><pub-id pub-id-type="pmid">32527265</pub-id></element-citation></ref><ref id="bib137"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raiborg</surname><given-names>C</given-names></name><name><surname>Bache</surname><given-names>KG</given-names></name><name><surname>Mehlum</surname><given-names>A</given-names></name><name><surname>Stang</surname><given-names>E</given-names></name><name><surname>Stenmark</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Hrs recruits clathrin to early endosomes</article-title><source>The EMBO Journal</source><volume>20</volume><fpage>5008</fpage><lpage>5021</lpage><pub-id pub-id-type="doi">10.1093/emboj/20.17.5008</pub-id><pub-id pub-id-type="pmid">11532964</pub-id></element-citation></ref><ref id="bib138"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rambow</surname><given-names>F</given-names></name><name><surname>Rogiers</surname><given-names>A</given-names></name><name><surname>Marin-Bejar</surname><given-names>O</given-names></name><name><surname>Aibar</surname><given-names>S</given-names></name><name><surname>Femel</surname><given-names>J</given-names></name><name><surname>Dewaele</surname><given-names>M</given-names></name><name><surname>Karras</surname><given-names>P</given-names></name><name><surname>Brown</surname><given-names>D</given-names></name><name><surname>Chang</surname><given-names>YH</given-names></name><name><surname>Debiec-Rychter</surname><given-names>M</given-names></name><name><surname>Adriaens</surname><given-names>C</given-names></name><name><surname>Radaelli</surname><given-names>E</given-names></name><name><surname>Wolter</surname><given-names>P</given-names></name><name><surname>Bechter</surname><given-names>O</given-names></name><name><surname>Dummer</surname><given-names>R</given-names></name><name><surname>Levesque</surname><given-names>M</given-names></name><name><surname>Piris</surname><given-names>A</given-names></name><name><surname>Frederick</surname><given-names>DT</given-names></name><name><surname>Boland</surname><given-names>G</given-names></name><name><surname>Flaherty</surname><given-names>KT</given-names></name><name><surname>van den Oord</surname><given-names>J</given-names></name><name><surname>Voet</surname><given-names>T</given-names></name><name><surname>Aerts</surname><given-names>S</given-names></name><name><surname>Lund</surname><given-names>AW</given-names></name><name><surname>Marine</surname><given-names>JC</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Toward minimal residual disease-directed therapy in melanoma</article-title><source>Cell</source><volume>174</volume><fpage>843</fpage><lpage>855</lpage><pub-id pub-id-type="doi">10.1016/J.CELL.2018.06.025</pub-id><pub-id pub-id-type="pmid">30017245</pub-id></element-citation></ref><ref id="bib139"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ran</surname><given-names>FA</given-names></name><name><surname>Hsu</surname><given-names>PD</given-names></name><name><surname>Wright</surname><given-names>J</given-names></name><name><surname>Agarwala</surname><given-names>V</given-names></name><name><surname>Scott</surname><given-names>DA</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Genome engineering using the crispr-cas9 system</article-title><source>Nature Protocols</source><volume>8</volume><fpage>2281</fpage><lpage>2308</lpage><pub-id pub-id-type="doi">10.1038/nprot.2013.143</pub-id><pub-id pub-id-type="pmid">24157548</pub-id></element-citation></ref><ref id="bib140"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rape</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Post-translational modifications: Ubiquitylation at the crossroads of development and disease</article-title><source>Nature Reviews Molecular Cell Biology</source><volume>7</volume><elocation-id>128</elocation-id><pub-id pub-id-type="doi">10.1038/nrm.2017.83</pub-id></element-citation></ref><ref id="bib141"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raudvere</surname><given-names>U</given-names></name><name><surname>Kolberg</surname><given-names>L</given-names></name><name><surname>Kuzmin</surname><given-names>I</given-names></name><name><surname>Arak</surname><given-names>T</given-names></name><name><surname>Adler</surname><given-names>P</given-names></name><name><surname>Peterson</surname><given-names>H</given-names></name><name><surname>Vilo</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>g:Profiler: a web server for functional enrichment analysis and conversions of gene lists (2019 update</article-title><source>Nucleic Acids Research</source><volume>47</volume><fpage>W191</fpage><lpage>W198</lpage><pub-id pub-id-type="doi">10.1093/nar/gkz369</pub-id><pub-id pub-id-type="pmid">31066453</pub-id></element-citation></ref><ref id="bib142"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rhodes</surname><given-names>DR</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Shanker</surname><given-names>K</given-names></name><name><surname>Deshpande</surname><given-names>N</given-names></name><name><surname>Varambally</surname><given-names>R</given-names></name><name><surname>Ghosh</surname><given-names>D</given-names></name><name><surname>Barrette</surname><given-names>T</given-names></name><name><surname>Pandey</surname><given-names>A</given-names></name><name><surname>Chinnaiyan</surname><given-names>AM</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>ONCOMINE: A cancer microarray database and integrated data-mining platform</article-title><source>Neoplasia</source><volume>6</volume><fpage>1</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1016/s1476-5586(04)80047-2</pub-id><pub-id pub-id-type="pmid">15068665</pub-id></element-citation></ref><ref id="bib143"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roux</surname><given-names>KJ</given-names></name><name><surname>Kim</surname><given-names>DI</given-names></name><name><surname>Raida</surname><given-names>M</given-names></name><name><surname>Burke</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>A promiscuous biotin ligase fusion protein identifies proximal and interacting proteins in mammalian cells</article-title><source>The Journal of Cell Biology</source><volume>196</volume><fpage>801</fpage><lpage>810</lpage><pub-id pub-id-type="doi">10.1083/jcb.201112098</pub-id><pub-id pub-id-type="pmid">22412018</pub-id></element-citation></ref><ref id="bib144"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ryland</surname><given-names>GL</given-names></name><name><surname>Hunter</surname><given-names>SM</given-names></name><name><surname>Doyle</surname><given-names>MA</given-names></name><name><surname>Rowley</surname><given-names>SM</given-names></name><name><surname>Christie</surname><given-names>M</given-names></name><name><surname>Allan</surname><given-names>PE</given-names></name><name><surname>Bowtell</surname><given-names>DDL</given-names></name><collab>Australian Ovarian Cancer Study Group</collab><name><surname>Gorringe</surname><given-names>KL</given-names></name><name><surname>Campbell</surname><given-names>IG</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>RNF43 is a tumour suppressor gene mutated in mucinous tumours of the ovary</article-title><source>The Journal of Pathology</source><volume>229</volume><fpage>469</fpage><lpage>476</lpage><pub-id pub-id-type="doi">10.1002/path.4134</pub-id><pub-id pub-id-type="pmid">23096461</pub-id></element-citation></ref><ref id="bib145"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sadeghi</surname><given-names>RS</given-names></name><name><surname>Kulej</surname><given-names>K</given-names></name><name><surname>Kathayat</surname><given-names>RS</given-names></name><name><surname>Garcia</surname><given-names>BA</given-names></name><name><surname>Dickinson</surname><given-names>BC</given-names></name><name><surname>Brady</surname><given-names>DC</given-names></name><name><surname>Witze</surname><given-names>ES</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Wnt5a signaling induced phosphorylation increases apt1 activity and promotes melanoma metastatic behavior</article-title><source>eLife</source><volume>7</volume><elocation-id>e34362</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.34362</pub-id><pub-id pub-id-type="pmid">29648538</pub-id></element-citation></ref><ref id="bib146"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saitoh</surname><given-names>T</given-names></name><name><surname>Mine</surname><given-names>T</given-names></name><name><surname>Katoh</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Frequent up-regulation of WNT5A mrna in primary gastric cancer</article-title><source>International Journal of Molecular Medicine</source><volume>9</volume><fpage>515</fpage><lpage>519</lpage><pub-id pub-id-type="doi">10.3892/ijmm.9.5.515</pub-id><pub-id pub-id-type="pmid">11956659</pub-id></element-citation></ref><ref id="bib147"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sammar</surname><given-names>M</given-names></name><name><surname>Stricker</surname><given-names>S</given-names></name><name><surname>Schwabe</surname><given-names>GC</given-names></name><name><surname>Sieber</surname><given-names>C</given-names></name><name><surname>Hartung</surname><given-names>A</given-names></name><name><surname>Hanke</surname><given-names>M</given-names></name><name><surname>Oishi</surname><given-names>I</given-names></name><name><surname>Pohl</surname><given-names>J</given-names></name><name><surname>Minami</surname><given-names>Y</given-names></name><name><surname>Sebald</surname><given-names>W</given-names></name><name><surname>Mundlos</surname><given-names>S</given-names></name><name><surname>Knaus</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Modulation of GDF5/BRI-B signalling through interaction with the tyrosine kinase receptor ROR2</article-title><source>Genes to Cells</source><volume>9</volume><fpage>1227</fpage><lpage>1238</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2443.2004.00799.x</pub-id><pub-id pub-id-type="pmid">15569154</pub-id></element-citation></ref><ref id="bib148"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sandru</surname><given-names>A</given-names></name><name><surname>Voinea</surname><given-names>S</given-names></name><name><surname>Panaitescu</surname><given-names>E</given-names></name><name><surname>Blidaru</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Survival rates of patients with metastatic malignant melanoma</article-title><source>Journal of Medicine and Life</source><volume>7</volume><fpage>572</fpage><lpage>576</lpage><pub-id pub-id-type="pmid">25713625</pub-id></element-citation></ref><ref id="bib149"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Santolini</surname><given-names>E</given-names></name><name><surname>Puri</surname><given-names>C</given-names></name><name><surname>Salcini</surname><given-names>AE</given-names></name><name><surname>Gagliani</surname><given-names>MC</given-names></name><name><surname>Pelicci</surname><given-names>PG</given-names></name><name><surname>Tacchetti</surname><given-names>C</given-names></name><name><surname>Di Fiore</surname><given-names>PP</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Numb is an endocytic protein</article-title><source>The Journal of Cell Biology</source><volume>151</volume><fpage>1345</fpage><lpage>1352</lpage><pub-id pub-id-type="doi">10.1083/jcb.151.6.1345</pub-id><pub-id pub-id-type="pmid">11121447</pub-id></element-citation></ref><ref id="bib150"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmitt</surname><given-names>M</given-names></name><name><surname>Sinnberg</surname><given-names>T</given-names></name><name><surname>Nalpas</surname><given-names>NC</given-names></name><name><surname>Maass</surname><given-names>A</given-names></name><name><surname>Schittek</surname><given-names>B</given-names></name><name><surname>Macek</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Quantitative proteomics links the intermediate filament nestin to resistance to targeted braf inhibition in melanoma cells</article-title><source>Molecular &amp; Cellular Proteomics</source><volume>18</volume><fpage>1096</fpage><lpage>1109</lpage><pub-id pub-id-type="doi">10.1074/mcp.RA119.001302</pub-id><pub-id pub-id-type="pmid">30890564</pub-id></element-citation></ref><ref id="bib151"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seet</surname><given-names>LF</given-names></name><name><surname>Hong</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Endofin recruits clathrin to early endosomes via tom1</article-title><source>Journal of Cell Science</source><volume>118</volume><fpage>575</fpage><lpage>587</lpage><pub-id pub-id-type="doi">10.1242/jcs.01628</pub-id><pub-id pub-id-type="pmid">15657082</pub-id></element-citation></ref><ref id="bib152"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sensi</surname><given-names>M</given-names></name><name><surname>Catani</surname><given-names>M</given-names></name><name><surname>Castellano</surname><given-names>G</given-names></name><name><surname>Nicolini</surname><given-names>G</given-names></name><name><surname>Alciato</surname><given-names>F</given-names></name><name><surname>Tragni</surname><given-names>G</given-names></name><name><surname>De Santis</surname><given-names>G</given-names></name><name><surname>Bersani</surname><given-names>I</given-names></name><name><surname>Avanzi</surname><given-names>G</given-names></name><name><surname>Tomassetti</surname><given-names>A</given-names></name><name><surname>Canevari</surname><given-names>S</given-names></name><name><surname>Anichini</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Human cutaneous melanomas lacking MITF and melanocyte differentiation antigens express a functional AXL receptor kinase</article-title><source>The Journal of Investigative Dermatology</source><volume>131</volume><fpage>2448</fpage><lpage>2457</lpage><pub-id pub-id-type="doi">10.1038/JID.2011.218</pub-id><pub-id pub-id-type="pmid">21796150</pub-id></element-citation></ref><ref id="bib153"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seo</surname><given-names>HS</given-names></name><name><surname>Habas</surname><given-names>R</given-names></name><name><surname>Chang</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Bimodal regulation of dishevelled function by vangl2 during morphogenesis</article-title><source>Human Molecular Genetics</source><volume>26</volume><fpage>2053</fpage><lpage>2061</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddx095</pub-id><pub-id pub-id-type="pmid">28334810</pub-id></element-citation></ref><ref id="bib154"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shain</surname><given-names>AH</given-names></name><name><surname>Yeh</surname><given-names>I</given-names></name><name><surname>Kovalyshyn</surname><given-names>I</given-names></name><name><surname>Sriharan</surname><given-names>A</given-names></name><name><surname>Talevich</surname><given-names>E</given-names></name><name><surname>Gagnon</surname><given-names>A</given-names></name><name><surname>Dummer</surname><given-names>R</given-names></name><name><surname>North</surname><given-names>J</given-names></name><name><surname>Pincus</surname><given-names>L</given-names></name><name><surname>Ruben</surname><given-names>B</given-names></name><name><surname>Rickaby</surname><given-names>W</given-names></name><name><surname>D’Arrigo</surname><given-names>C</given-names></name><name><surname>Robson</surname><given-names>A</given-names></name><name><surname>Bastian</surname><given-names>BC</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The genetic evolution of melanoma from precursor lesions</article-title><source>The New England Journal of Medicine</source><volume>373</volume><fpage>1926</fpage><lpage>1936</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1502583</pub-id><pub-id pub-id-type="pmid">26559571</pub-id></element-citation></ref><ref id="bib155"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Signorelli</surname><given-names>J</given-names></name><name><surname>Shah Gandhi</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Cobimetinib: A novel MEK inhibitor for metastatic melanoma</article-title><source>The Annals of Pharmacotherapy</source><volume>51</volume><fpage>146</fpage><lpage>153</lpage><pub-id pub-id-type="doi">10.1177/1060028016672037</pub-id></element-citation></ref><ref id="bib156"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spit</surname><given-names>M</given-names></name><name><surname>Fenderico</surname><given-names>N</given-names></name><name><surname>Jordens</surname><given-names>I</given-names></name><name><surname>Radaszkiewicz</surname><given-names>T</given-names></name><name><surname>Lindeboom</surname><given-names>RG</given-names></name><name><surname>Bugter</surname><given-names>JM</given-names></name><name><surname>Cristobal</surname><given-names>A</given-names></name><name><surname>Ootes</surname><given-names>L</given-names></name><name><surname>van Osch</surname><given-names>M</given-names></name><name><surname>Janssen</surname><given-names>E</given-names></name><name><surname>Boonekamp</surname><given-names>KE</given-names></name><name><surname>Hanakova</surname><given-names>K</given-names></name><name><surname>Potesil</surname><given-names>D</given-names></name><name><surname>Zdrahal</surname><given-names>Z</given-names></name><name><surname>Boj</surname><given-names>SF</given-names></name><name><surname>Medema</surname><given-names>JP</given-names></name><name><surname>Bryja</surname><given-names>V</given-names></name><name><surname>Koo</surname><given-names>B-K</given-names></name><name><surname>Vermeulen</surname><given-names>M</given-names></name><name><surname>Maurice</surname><given-names>MM</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>RNF43 truncations trap CK1 to drive niche-independent self-renewal in cancer</article-title><source>The EMBO Journal</source><volume>39</volume><elocation-id>e103932</elocation-id><pub-id pub-id-type="doi">10.15252/embj.2019103932</pub-id><pub-id pub-id-type="pmid">32965059</pub-id></element-citation></ref><ref id="bib157"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Štětková</surname><given-names>M</given-names></name><name><surname>Growková</surname><given-names>K</given-names></name><name><surname>Fojtík</surname><given-names>P</given-names></name><name><surname>Valčíková</surname><given-names>B</given-names></name><name><surname>Palušová</surname><given-names>V</given-names></name><name><surname>Verlande</surname><given-names>A</given-names></name><name><surname>Jorda</surname><given-names>R</given-names></name><name><surname>Kryštof</surname><given-names>V</given-names></name><name><surname>Hejret</surname><given-names>V</given-names></name><name><surname>Alexiou</surname><given-names>P</given-names></name><name><surname>Rotrekl</surname><given-names>V</given-names></name><name><surname>Uldrijan</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Cdk9 activity is critical for maintaining mdm4 overexpression in tumor cells</article-title><source>Cell Death &amp; Disease</source><volume>11</volume><elocation-id>754</elocation-id><pub-id pub-id-type="doi">10.1038/s41419-020-02971-3</pub-id><pub-id pub-id-type="pmid">32934219</pub-id></element-citation></ref><ref id="bib158"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Su</surname><given-names>Y</given-names></name><name><surname>Wei</surname><given-names>W</given-names></name><name><surname>Robert</surname><given-names>L</given-names></name><name><surname>Xue</surname><given-names>M</given-names></name><name><surname>Tsoi</surname><given-names>J</given-names></name><name><surname>Garcia-Diaz</surname><given-names>A</given-names></name><name><surname>Homet Moreno</surname><given-names>B</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Ng</surname><given-names>RH</given-names></name><name><surname>Lee</surname><given-names>JW</given-names></name><name><surname>Koya</surname><given-names>RC</given-names></name><name><surname>Comin-Anduix</surname><given-names>B</given-names></name><name><surname>Graeber</surname><given-names>TG</given-names></name><name><surname>Ribas</surname><given-names>A</given-names></name><name><surname>Heath</surname><given-names>JR</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Single-cell analysis resolves the cell state transition and signaling dynamics associated with melanoma drug-induced resistance</article-title><source>PNAS</source><volume>114</volume><fpage>13679</fpage><lpage>13684</lpage><pub-id pub-id-type="doi">10.1073/pnas.1712064115</pub-id><pub-id pub-id-type="pmid">29229836</pub-id></element-citation></ref><ref id="bib159"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Su</surname><given-names>Y</given-names></name><name><surname>Ko</surname><given-names>ME</given-names></name><name><surname>Cheng</surname><given-names>H</given-names></name><name><surname>Zhu</surname><given-names>R</given-names></name><name><surname>Xue</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Lee</surname><given-names>JW</given-names></name><name><surname>Frankiw</surname><given-names>L</given-names></name><name><surname>Xu</surname><given-names>A</given-names></name><name><surname>Wong</surname><given-names>S</given-names></name><name><surname>Robert</surname><given-names>L</given-names></name><name><surname>Takata</surname><given-names>K</given-names></name><name><surname>Yuan</surname><given-names>D</given-names></name><name><surname>Lu</surname><given-names>Y</given-names></name><name><surname>Huang</surname><given-names>S</given-names></name><name><surname>Ribas</surname><given-names>A</given-names></name><name><surname>Levine</surname><given-names>R</given-names></name><name><surname>Nolan</surname><given-names>GP</given-names></name><name><surname>Wei</surname><given-names>W</given-names></name><name><surname>Plevritis</surname><given-names>SK</given-names></name><name><surname>Li</surname><given-names>G</given-names></name><name><surname>Baltimore</surname><given-names>D</given-names></name><name><surname>Heath</surname><given-names>JR</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Multi-omic single-cell snapshots reveal multiple independent trajectories to drug tolerance in a melanoma cell line</article-title><source>Nature Communications</source><volume>11</volume><elocation-id>2345</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-020-15956-9</pub-id><pub-id pub-id-type="pmid">32393797</pub-id></element-citation></ref><ref id="bib160"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szenker-Ravi</surname><given-names>E</given-names></name><name><surname>Altunoglu</surname><given-names>U</given-names></name><name><surname>Leushacke</surname><given-names>M</given-names></name><name><surname>Bosso-Lefèvre</surname><given-names>C</given-names></name><name><surname>Khatoo</surname><given-names>M</given-names></name><name><surname>Thi Tran</surname><given-names>H</given-names></name><name><surname>Naert</surname><given-names>T</given-names></name><name><surname>Noelanders</surname><given-names>R</given-names></name><name><surname>Hajamohideen</surname><given-names>A</given-names></name><name><surname>Beneteau</surname><given-names>C</given-names></name><name><surname>de Sousa</surname><given-names>SB</given-names></name><name><surname>Karaman</surname><given-names>B</given-names></name><name><surname>Latypova</surname><given-names>X</given-names></name><name><surname>Başaran</surname><given-names>S</given-names></name><name><surname>Yücel</surname><given-names>EB</given-names></name><name><surname>Tan</surname><given-names>TT</given-names></name><name><surname>Vlaminck</surname><given-names>L</given-names></name><name><surname>Nayak</surname><given-names>SS</given-names></name><name><surname>Shukla</surname><given-names>A</given-names></name><name><surname>Girisha</surname><given-names>KM</given-names></name><name><surname>Le Caignec</surname><given-names>C</given-names></name><name><surname>Soshnikova</surname><given-names>N</given-names></name><name><surname>Uyguner</surname><given-names>ZO</given-names></name><name><surname>Vleminckx</surname><given-names>K</given-names></name><name><surname>Barker</surname><given-names>N</given-names></name><name><surname>Kayserili</surname><given-names>H</given-names></name><name><surname>Reversade</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Rspo2 inhibition of RNF43 and znrf3 governs limb development independently of lgr4/5/6</article-title><source>Nature</source><volume>557</volume><fpage>564</fpage><lpage>569</lpage><pub-id pub-id-type="doi">10.1038/s41586-018-0118-y</pub-id><pub-id pub-id-type="pmid">29769720</pub-id></element-citation></ref><ref id="bib161"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takahashi</surname><given-names>N</given-names></name><name><surname>Yamaguchi</surname><given-names>K</given-names></name><name><surname>Ikenoue</surname><given-names>T</given-names></name><name><surname>Fujii</surname><given-names>T</given-names></name><name><surname>Furukawa</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Identification of two wnt-responsive elements in the intron of RING finger protein 43 (rnf43) gene</article-title><source>PLOS ONE</source><volume>9</volume><elocation-id>e86582</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0086582</pub-id><pub-id pub-id-type="pmid">24466159</pub-id></element-citation></ref><ref id="bib162"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Talantov</surname><given-names>D</given-names></name><name><surname>Mazumder</surname><given-names>A</given-names></name><name><surname>Yu</surname><given-names>JX</given-names></name><name><surname>Briggs</surname><given-names>T</given-names></name><name><surname>Jiang</surname><given-names>Y</given-names></name><name><surname>Backus</surname><given-names>J</given-names></name><name><surname>Atkins</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Novel genes associated with malignant melanoma but not benign melanocytic lesions</article-title><source>Clinical Cancer Research</source><volume>11</volume><fpage>7234</fpage><lpage>7242</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-05-0683</pub-id><pub-id pub-id-type="pmid">16243793</pub-id></element-citation></ref><ref id="bib163"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Talebi</surname><given-names>A</given-names></name><name><surname>Dehairs</surname><given-names>J</given-names></name><name><surname>Rambow</surname><given-names>F</given-names></name><name><surname>Rogiers</surname><given-names>A</given-names></name><name><surname>Nittner</surname><given-names>D</given-names></name><name><surname>Derua</surname><given-names>R</given-names></name><name><surname>Vanderhoydonc</surname><given-names>F</given-names></name><name><surname>Duarte</surname><given-names>JAG</given-names></name><name><surname>Bosisio</surname><given-names>F</given-names></name><name><surname>Van den Eynde</surname><given-names>K</given-names></name><name><surname>Nys</surname><given-names>K</given-names></name><name><surname>Pérez</surname><given-names>MV</given-names></name><name><surname>Agostinis</surname><given-names>P</given-names></name><name><surname>Waelkens</surname><given-names>E</given-names></name><name><surname>Van den Oord</surname><given-names>J</given-names></name><name><surname>Fendt</surname><given-names>S-M</given-names></name><name><surname>Marine</surname><given-names>J-C</given-names></name><name><surname>Swinnen</surname><given-names>JV</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Sustained srebp-1-dependent lipogenesis as a key mediator of resistance to braf-targeted therapy</article-title><source>Nature Communications</source><volume>9</volume><elocation-id>2500</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-018-04664-0</pub-id><pub-id pub-id-type="pmid">29950559</pub-id></element-citation></ref><ref id="bib164"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tauriello</surname><given-names>DVF</given-names></name><name><surname>Haegebarth</surname><given-names>A</given-names></name><name><surname>Kuper</surname><given-names>I</given-names></name><name><surname>Edelmann</surname><given-names>MJ</given-names></name><name><surname>Henraat</surname><given-names>M</given-names></name><name><surname>Canninga-van Dijk</surname><given-names>MR</given-names></name><name><surname>Kessler</surname><given-names>BM</given-names></name><name><surname>Clevers</surname><given-names>H</given-names></name><name><surname>Maurice</surname><given-names>MM</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Loss of the Tumor Suppressor CYLD Enhances Wnt/β-Catenin Signaling through K63-Linked Ubiquitination of Dvl</article-title><source>Molecular Cell</source><volume>37</volume><fpage>607</fpage><lpage>619</lpage><pub-id pub-id-type="doi">10.1016/J.MOLCEL.2010.01.035</pub-id><pub-id pub-id-type="pmid">20227366</pub-id></element-citation></ref><ref id="bib165"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tebar</surname><given-names>F</given-names></name><name><surname>Bohlander</surname><given-names>SK</given-names></name><name><surname>Sorkin</surname><given-names>A</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Clathrin assembly lymphoid myeloid leukemia (CALM) protein: Localization in endocytic-coated pits, interactions with clathrin, and the impact of overexpression on clathrin-mediated traffic</article-title><source>Molecular Biology of the Cell</source><volume>10</volume><fpage>2687</fpage><lpage>2702</lpage><pub-id pub-id-type="doi">10.1091/mbc.10.8.2687</pub-id><pub-id pub-id-type="pmid">10436022</pub-id></element-citation></ref><ref id="bib166"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tirosh</surname><given-names>I</given-names></name><name><surname>Izar</surname><given-names>B</given-names></name><name><surname>Prakadan</surname><given-names>SM</given-names></name><name><surname>Wadsworth</surname><given-names>MH</given-names></name><name><surname>Treacy</surname><given-names>D</given-names></name><name><surname>Trombetta</surname><given-names>JJ</given-names></name><name><surname>Rotem</surname><given-names>A</given-names></name><name><surname>Rodman</surname><given-names>C</given-names></name><name><surname>Lian</surname><given-names>C</given-names></name><name><surname>Murphy</surname><given-names>G</given-names></name><name><surname>Fallahi-Sichani</surname><given-names>M</given-names></name><name><surname>Dutton-Regester</surname><given-names>K</given-names></name><name><surname>Lin</surname><given-names>JR</given-names></name><name><surname>Cohen</surname><given-names>O</given-names></name><name><surname>Shah</surname><given-names>P</given-names></name><name><surname>Lu</surname><given-names>D</given-names></name><name><surname>Genshaft</surname><given-names>AS</given-names></name><name><surname>Hughes</surname><given-names>TK</given-names></name><name><surname>Ziegler</surname><given-names>CGK</given-names></name><name><surname>Kazer</surname><given-names>SW</given-names></name><name><surname>Gaillard</surname><given-names>A</given-names></name><name><surname>Kolb</surname><given-names>KE</given-names></name><name><surname>Villani</surname><given-names>AC</given-names></name><name><surname>Johannessen</surname><given-names>CM</given-names></name><name><surname>Andreev</surname><given-names>AY</given-names></name><name><surname>Van Allen</surname><given-names>EM</given-names></name><name><surname>Bertagnolli</surname><given-names>M</given-names></name><name><surname>Sorger</surname><given-names>PK</given-names></name><name><surname>Sullivan</surname><given-names>RJ</given-names></name><name><surname>Flaherty</surname><given-names>KT</given-names></name><name><surname>Frederick</surname><given-names>DT</given-names></name><name><surname>Jane-Valbuena</surname><given-names>J</given-names></name><name><surname>Yoon</surname><given-names>CH</given-names></name><name><surname>Rozenblatt-Rosen</surname><given-names>O</given-names></name><name><surname>Shalek</surname><given-names>AK</given-names></name><name><surname>Regev</surname><given-names>A</given-names></name><name><surname>Garraway</surname><given-names>LA</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq</article-title><source>Science</source><volume>352</volume><fpage>189</fpage><lpage>196</lpage><pub-id pub-id-type="doi">10.1126/science.aad0501</pub-id><pub-id pub-id-type="pmid">27124452</pub-id></element-citation></ref><ref id="bib167"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tiwary</surname><given-names>S</given-names></name><name><surname>Xu</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>FRIZZLED7 Is Required for Tumor Initiation and Metastatic Growth of Melanoma Cells</article-title><source>PLOS ONE</source><volume>11</volume><elocation-id>e0147638</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0147638</pub-id><pub-id pub-id-type="pmid">26808375</pub-id></element-citation></ref><ref id="bib168"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tower-Gilchrist</surname><given-names>C</given-names></name><name><surname>Zlatic</surname><given-names>SA</given-names></name><name><surname>Yu</surname><given-names>D</given-names></name><name><surname>Chang</surname><given-names>Q</given-names></name><name><surname>Wu</surname><given-names>H</given-names></name><name><surname>Lin</surname><given-names>X</given-names></name><name><surname>Faundez</surname><given-names>V</given-names></name><name><surname>Chen</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Adaptor protein-3 complex is required for vangl2 trafficking and planar cell polarity of the inner ear</article-title><source>Molecular Biology of the Cell</source><volume>30</volume><fpage>2422</fpage><lpage>2434</lpage><pub-id pub-id-type="doi">10.1091/mbc.E16-08-0592</pub-id><pub-id pub-id-type="pmid">31268833</pub-id></element-citation></ref><ref id="bib169"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsukiyama</surname><given-names>T</given-names></name><name><surname>Fukui</surname><given-names>A</given-names></name><name><surname>Terai</surname><given-names>S</given-names></name><name><surname>Fujioka</surname><given-names>Y</given-names></name><name><surname>Shinada</surname><given-names>K</given-names></name><name><surname>Takahashi</surname><given-names>H</given-names></name><name><surname>Yamaguchi</surname><given-names>TP</given-names></name><name><surname>Ohba</surname><given-names>Y</given-names></name><name><surname>Hatakeyama</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Molecular role of RNF43 in canonical and noncanonical wnt signaling</article-title><source>Molecular and Cellular Biology</source><volume>35</volume><fpage>2007</fpage><lpage>2023</lpage><pub-id pub-id-type="doi">10.1128/MCB.00159-15</pub-id><pub-id pub-id-type="pmid">25825523</pub-id></element-citation></ref><ref id="bib170"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsukiyama</surname><given-names>T</given-names></name><name><surname>Zou</surname><given-names>J</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Ogamino</surname><given-names>S</given-names></name><name><surname>Shino</surname><given-names>Y</given-names></name><name><surname>Masuda</surname><given-names>T</given-names></name><name><surname>Merenda</surname><given-names>A</given-names></name><name><surname>Matsumoto</surname><given-names>M</given-names></name><name><surname>Fujioka</surname><given-names>Y</given-names></name><name><surname>Hirose</surname><given-names>T</given-names></name><name><surname>Terai</surname><given-names>S</given-names></name><name><surname>Takahashi</surname><given-names>H</given-names></name><name><surname>Ishitani</surname><given-names>T</given-names></name><name><surname>Nakayama</surname><given-names>KI</given-names></name><name><surname>Ohba</surname><given-names>Y</given-names></name><name><surname>Koo</surname><given-names>BK</given-names></name><name><surname>Hatakeyama</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>A phospho-switch controls rnf43-mediated degradation of WNT receptors to suppress tumorigenesis</article-title><source>Nature Communications</source><volume>11</volume><elocation-id>4586</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-020-18257-3</pub-id><pub-id pub-id-type="pmid">32934222</pub-id></element-citation></ref><ref id="bib171"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uka</surname><given-names>R</given-names></name><name><surname>Britschgi</surname><given-names>C</given-names></name><name><surname>Krättli</surname><given-names>A</given-names></name><name><surname>Matter</surname><given-names>C</given-names></name><name><surname>Mihic</surname><given-names>D</given-names></name><name><surname>Okoniewski</surname><given-names>MJ</given-names></name><name><surname>Gualandi</surname><given-names>M</given-names></name><name><surname>Stupp</surname><given-names>R</given-names></name><name><surname>Cinelli</surname><given-names>P</given-names></name><name><surname>Dummer</surname><given-names>R</given-names></name><name><surname>Levesque</surname><given-names>MP</given-names></name><name><surname>Shakhova</surname><given-names>O</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Temporal activation of wnt/β-catenin signaling is sufficient to inhibit sox10 expression and block melanoma growth</article-title><source>Oncogene</source><volume>39</volume><fpage>4132</fpage><lpage>4154</lpage><pub-id pub-id-type="doi">10.1038/s41388-020-1267-7</pub-id><pub-id pub-id-type="pmid">32238882</pub-id></element-citation></ref><ref id="bib172"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ullrich</surname><given-names>O</given-names></name><name><surname>Reinsch</surname><given-names>S</given-names></name><name><surname>Urbé</surname><given-names>S</given-names></name><name><surname>Zerial</surname><given-names>M</given-names></name><name><surname>Parton</surname><given-names>RG</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>RAB11 regulates recycling through the pericentriolar recycling endosome</article-title><source>The Journal of Cell Biology</source><volume>135</volume><fpage>913</fpage><lpage>924</lpage><pub-id pub-id-type="doi">10.1083/jcb.135.4.913</pub-id><pub-id pub-id-type="pmid">8922376</pub-id></element-citation></ref><ref id="bib173"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Engelenburg</surname><given-names>SB</given-names></name><name><surname>Palmer</surname><given-names>AE</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Imaging type-iii secretion reveals dynamics and spatial segregation of salmonella effectors</article-title><source>Nature Methods</source><volume>7</volume><fpage>325</fpage><lpage>330</lpage><pub-id pub-id-type="doi">10.1038/nmeth.1437</pub-id><pub-id pub-id-type="pmid">20228815</pub-id></element-citation></ref><ref id="bib174"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Kappel</surname><given-names>EC</given-names></name><name><surname>Maurice</surname><given-names>MM</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Molecular regulation and pharmacological targeting of the β-catenin destruction complex</article-title><source>British Journal of Pharmacology</source><volume>174</volume><fpage>4575</fpage><lpage>4588</lpage><pub-id pub-id-type="doi">10.1111/bph.13922</pub-id><pub-id pub-id-type="pmid">28634996</pub-id></element-citation></ref><ref id="bib175"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>VanderVorst</surname><given-names>K</given-names></name><name><surname>Dreyer</surname><given-names>CA</given-names></name><name><surname>Konopelski</surname><given-names>SE</given-names></name><name><surname>Lee</surname><given-names>H</given-names></name><name><surname>Ho</surname><given-names>HYH</given-names></name><name><surname>Carraway</surname><given-names>KL</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Wnt/pcp signaling contribution to carcinoma collective cell migration and metastasis</article-title><source>Cancer Research</source><volume>79</volume><fpage>1719</fpage><lpage>1729</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-18-2757</pub-id><pub-id pub-id-type="pmid">30952630</pub-id></element-citation></ref><ref id="bib176"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wan</surname><given-names>PTC</given-names></name><name><surname>Garnett</surname><given-names>MJ</given-names></name><name><surname>Roe</surname><given-names>SM</given-names></name><name><surname>Lee</surname><given-names>S</given-names></name><name><surname>Niculescu-Duvaz</surname><given-names>D</given-names></name><name><surname>Good</surname><given-names>VM</given-names></name><name><surname>Jones</surname><given-names>CM</given-names></name><name><surname>Marshall</surname><given-names>CJ</given-names></name><name><surname>Springer</surname><given-names>CJ</given-names></name><name><surname>Barford</surname><given-names>D</given-names></name><name><surname>Marais</surname><given-names>R</given-names></name><collab>Cancer Genome Project</collab></person-group><year iso-8601-date="2004">2004</year><article-title>Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF</article-title><source>Cell</source><volume>116</volume><fpage>855</fpage><lpage>867</lpage><pub-id pub-id-type="doi">10.1016/S0092-8674(04)00215-6</pub-id><pub-id pub-id-type="pmid">15035987</pub-id></element-citation></ref><ref id="bib177"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>VE</given-names></name><name><surname>Xue</surname><given-names>JY</given-names></name><name><surname>Frederick</surname><given-names>DT</given-names></name><name><surname>Cao</surname><given-names>Y</given-names></name><name><surname>Lin</surname><given-names>E</given-names></name><name><surname>Wilson</surname><given-names>C</given-names></name><name><surname>Urisman</surname><given-names>A</given-names></name><name><surname>Carbone</surname><given-names>DP</given-names></name><name><surname>Flaherty</surname><given-names>KT</given-names></name><name><surname>Bernards</surname><given-names>R</given-names></name><name><surname>Lito</surname><given-names>P</given-names></name><name><surname>Settleman</surname><given-names>J</given-names></name><name><surname>McCormick</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Adaptive resistance to dual BRAF/MEK inhibition in braf-driven tumors through autocrine FGFR pathway activation</article-title><source>Clinical Cancer Research</source><volume>25</volume><fpage>7202</fpage><lpage>7217</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-18-2779</pub-id><pub-id pub-id-type="pmid">31515463</pub-id></element-citation></ref><ref id="bib178"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Webster</surname><given-names>MR</given-names></name><name><surname>Weeraratna</surname><given-names>AT</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>A wnt-er migration: The confusing role of β-catenin in melanoma metastasis</article-title><source>Science Signaling</source><volume>6</volume><elocation-id>pe11</elocation-id><pub-id pub-id-type="doi">10.1126/scisignal.2004114</pub-id><pub-id pub-id-type="pmid">23532332</pub-id></element-citation></ref><ref id="bib179"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Webster</surname><given-names>MR</given-names></name><name><surname>Xu</surname><given-names>M</given-names></name><name><surname>Kinzler</surname><given-names>KA</given-names></name><name><surname>Kaur</surname><given-names>A</given-names></name><name><surname>Appleton</surname><given-names>J</given-names></name><name><surname>O’Connell</surname><given-names>MP</given-names></name><name><surname>Marchbank</surname><given-names>K</given-names></name><name><surname>Valiga</surname><given-names>A</given-names></name><name><surname>Dang</surname><given-names>VM</given-names></name><name><surname>Perego</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>G</given-names></name><name><surname>Slipicevic</surname><given-names>A</given-names></name><name><surname>Keeney</surname><given-names>F</given-names></name><name><surname>Lehrmann</surname><given-names>E</given-names></name><name><surname>Becker</surname><given-names>KG</given-names></name><name><surname>Kossenkov</surname><given-names>AV</given-names></name><name><surname>Frederick</surname><given-names>DT</given-names></name><name><surname>Flaherty</surname><given-names>KT</given-names></name><name><surname>Xu</surname><given-names>X</given-names></name><name><surname>Herlyn</surname><given-names>M</given-names></name><name><surname>Murphy</surname><given-names>ME</given-names></name><name><surname>Weeraratna</surname><given-names>AT</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>WNT5A promotes an adaptive, senescent-like stress response, while continuing to drive invasion in melanoma cells</article-title><source>Pigment Cell &amp; Melanoma Research</source><volume>28</volume><fpage>184</fpage><lpage>195</lpage><pub-id pub-id-type="doi">10.1111/pcmr.12330</pub-id><pub-id pub-id-type="pmid">25407936</pub-id></element-citation></ref><ref id="bib180"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weeber</surname><given-names>F</given-names></name><name><surname>Becher</surname><given-names>A</given-names></name><name><surname>Seibold</surname><given-names>T</given-names></name><name><surname>Seufferlein</surname><given-names>T</given-names></name><name><surname>Eiseler</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Concerted regulation of actin polymerization during constitutive secretion by cortactin and pkd2</article-title><source>Journal of Cell Science</source><volume>132</volume><elocation-id>jcs232355</elocation-id><pub-id pub-id-type="doi">10.1242/jcs.232355</pub-id><pub-id pub-id-type="pmid">31727638</pub-id></element-citation></ref><ref id="bib181"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weeraratna</surname><given-names>AT</given-names></name><name><surname>Jiang</surname><given-names>Y</given-names></name><name><surname>Hostetter</surname><given-names>G</given-names></name><name><surname>Rosenblatt</surname><given-names>K</given-names></name><name><surname>Duray</surname><given-names>P</given-names></name><name><surname>Bittner</surname><given-names>M</given-names></name><name><surname>Trent</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>WNT5A signaling directly affects cell motility and invasion of metastatic melanoma</article-title><source>Cancer Cell</source><volume>1</volume><fpage>279</fpage><lpage>288</lpage><pub-id pub-id-type="doi">10.1016/S1535-6108(02)00045-4</pub-id><pub-id pub-id-type="pmid">12086864</pub-id></element-citation></ref><ref id="bib182"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wiese</surname><given-names>KE</given-names></name><name><surname>Nusse</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Wnt signalling: Conquering complexity</article-title><source>Development</source><volume>145</volume><elocation-id>dev165902</elocation-id><pub-id pub-id-type="doi">10.1242/dev.165902</pub-id><pub-id pub-id-type="pmid">29945986</pub-id></element-citation></ref><ref id="bib183"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Witte</surname><given-names>F</given-names></name><name><surname>Bernatik</surname><given-names>O</given-names></name><name><surname>Kirchner</surname><given-names>K</given-names></name><name><surname>Masek</surname><given-names>J</given-names></name><name><surname>Mahl</surname><given-names>A</given-names></name><name><surname>Krejci</surname><given-names>P</given-names></name><name><surname>Mundlos</surname><given-names>S</given-names></name><name><surname>Schambony</surname><given-names>A</given-names></name><name><surname>Bryja</surname><given-names>V</given-names></name><name><surname>Stricker</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Negative regulation of Wnt signaling mediated by CK1-phosphorylated Dishevelled via Ror2</article-title><source>FASEB Journal</source><volume>24</volume><fpage>2417</fpage><lpage>2426</lpage><pub-id pub-id-type="doi">10.1096/fj.09-150615</pub-id><pub-id pub-id-type="pmid">20215527</pub-id></element-citation></ref><ref id="bib184"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>Y</given-names></name><name><surname>Zamponi</surname><given-names>R</given-names></name><name><surname>Charlat</surname><given-names>O</given-names></name><name><surname>Ramones</surname><given-names>M</given-names></name><name><surname>Swalley</surname><given-names>S</given-names></name><name><surname>Jiang</surname><given-names>X</given-names></name><name><surname>Rivera</surname><given-names>D</given-names></name><name><surname>Tschantz</surname><given-names>W</given-names></name><name><surname>Lu</surname><given-names>B</given-names></name><name><surname>Quinn</surname><given-names>L</given-names></name><name><surname>Dimitri</surname><given-names>C</given-names></name><name><surname>Parker</surname><given-names>J</given-names></name><name><surname>Jeffery</surname><given-names>D</given-names></name><name><surname>Wilcox</surname><given-names>SK</given-names></name><name><surname>Watrobka</surname><given-names>M</given-names></name><name><surname>LeMotte</surname><given-names>P</given-names></name><name><surname>Granda</surname><given-names>B</given-names></name><name><surname>Porter</surname><given-names>JA</given-names></name><name><surname>Myer</surname><given-names>VE</given-names></name><name><surname>Loew</surname><given-names>A</given-names></name><name><surname>Cong</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Interaction with both ZNRF3 and LGR4 is required for the signalling activity of r-spondin</article-title><source>EMBO Reports</source><volume>14</volume><fpage>1120</fpage><lpage>1126</lpage><pub-id pub-id-type="doi">10.1038/embor.2013.167</pub-id><pub-id pub-id-type="pmid">24165923</pub-id></element-citation></ref><ref id="bib185"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>L</given-names></name><name><surname>Shen</surname><given-names>SS</given-names></name><name><surname>Hoshida</surname><given-names>Y</given-names></name><name><surname>Subramanian</surname><given-names>A</given-names></name><name><surname>Ross</surname><given-names>K</given-names></name><name><surname>Brunet</surname><given-names>JP</given-names></name><name><surname>Wagner</surname><given-names>SN</given-names></name><name><surname>Ramaswamy</surname><given-names>S</given-names></name><name><surname>Mesirov</surname><given-names>JP</given-names></name><name><surname>Hynes</surname><given-names>RO</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Gene expression changes in an animal melanoma model correlate with aggressiveness of human melanoma metastases</article-title><source>Molecular Cancer Research</source><volume>6</volume><fpage>760</fpage><lpage>769</lpage><pub-id pub-id-type="doi">10.1158/1541-7786.MCR-07-0344</pub-id><pub-id pub-id-type="pmid">18505921</pub-id></element-citation></ref><ref id="bib186"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>HHN</given-names></name><name><surname>Lai</surname><given-names>JCW</given-names></name><name><surname>Ho</surname><given-names>SL</given-names></name><name><surname>Leung</surname><given-names>WK</given-names></name><name><surname>Law</surname><given-names>WL</given-names></name><name><surname>Lee</surname><given-names>JFY</given-names></name><name><surname>Chan</surname><given-names>AKW</given-names></name><name><surname>Tsui</surname><given-names>WY</given-names></name><name><surname>Chan</surname><given-names>ASY</given-names></name><name><surname>Lee</surname><given-names>BCH</given-names></name><name><surname>Yue</surname><given-names>SSK</given-names></name><name><surname>Man</surname><given-names>AHY</given-names></name><name><surname>Clevers</surname><given-names>H</given-names></name><name><surname>Yuen</surname><given-names>ST</given-names></name><name><surname>Leung</surname><given-names>SY</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>RNF43 germline and somatic mutation in serrated neoplasia pathway and its association with BRAF mutation</article-title><source>Gut</source><volume>66</volume><fpage>1645</fpage><lpage>1656</lpage><pub-id pub-id-type="doi">10.1136/gutjnl-2016-311849</pub-id><pub-id pub-id-type="pmid">27329244</pub-id></element-citation></ref><ref id="bib187"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>W</given-names></name><name><surname>Garrett</surname><given-names>L</given-names></name><name><surname>Feng</surname><given-names>D</given-names></name><name><surname>Elliott</surname><given-names>G</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>N</given-names></name><name><surname>Wong</surname><given-names>YM</given-names></name><name><surname>Choi</surname><given-names>NT</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Gao</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Wnt-induced vangl2 phosphorylation is dose-dependently required for planar cell polarity in mammalian development</article-title><source>Cell Research</source><volume>27</volume><fpage>1466</fpage><lpage>1484</lpage><pub-id pub-id-type="doi">10.1038/cr.2017.127</pub-id><pub-id pub-id-type="pmid">29056748</pub-id></element-citation></ref><ref id="bib188"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zebisch</surname><given-names>M</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Krastev</surname><given-names>C</given-names></name><name><surname>MacDonald</surname><given-names>BT</given-names></name><name><surname>Chen</surname><given-names>M</given-names></name><name><surname>Gilbert</surname><given-names>RJC</given-names></name><name><surname>He</surname><given-names>X</given-names></name><name><surname>Jones</surname><given-names>EY</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Structural and molecular basis of ZNRF3/RNF43 transmembrane ubiquitin ligase inhibition by the WNT agonist R-spondin</article-title><source>Nature Communications</source><volume>4</volume><elocation-id>2787</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms3787</pub-id><pub-id pub-id-type="pmid">24225776</pub-id></element-citation></ref><ref id="bib189"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zebisch</surname><given-names>M</given-names></name><name><surname>Jones</surname><given-names>EY</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>ZNRF3/RNF43--A direct linkage of extracellular recognition and E3 ligase activity to modulate cell surface signalling</article-title><source>Progress in Biophysics and Molecular Biology</source><volume>118</volume><fpage>112</fpage><lpage>118</lpage><pub-id pub-id-type="doi">10.1016/J.PBIOMOLBIO.2015.04.006</pub-id><pub-id pub-id-type="pmid">25937466</pub-id></element-citation></ref></ref-list><app-group><app id="appendix-1"><title>Appendix 1</title><table-wrap id="keyresource" position="anchor"><label>Appendix 1—key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Reagent type (species) or resource</th><th align="left" valign="bottom">Designation</th><th align="left" valign="bottom">Source or reference</th><th align="left" valign="bottom">Identifiers</th><th align="left" valign="bottom">Additional information</th></tr></thead><tbody><tr><td align="left" valign="bottom">Strain, strain background (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom">NOD-Rag1<sup>null</sup> IL2rg<sup>null</sup></td><td align="left" valign="bottom">Jackson Laboratory</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:BCBC_1261">BCBC_1261</ext-link></td><td align="left" valign="bottom">9-week-old males</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">T-REx 293</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">R71007; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:CVCL_D585">CVCL_D585</ext-link></td><td align="left" valign="bottom">For TetON system using pcDNA4-TO backbone</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">T-REx 293 RNF43 TetON</td><td align="left" valign="bottom">This publication</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Cells inducibly overexpressing RNF43</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">T-REx 293 RNF43 Mut1 TetON</td><td align="left" valign="bottom">This publication</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Cells inducibly overexpressing inactive RNF43</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">T-REx 293 RNF43/ZNRF3 dKO</td><td align="left" valign="bottom">This publication</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Cells lacking RNF43/ZNRF3; CRISPR/Cas9</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">T-REx 293 RNF43/ZNRF3 dKO RNF43 TetON</td><td align="left" valign="bottom">This publication</td><td align="left" valign="bottom"/><td align="left" valign="bottom">RNF43/ZNRF3 dKO inducibly overexpressing RNF43</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">T-REx 293 DVL1/2/3 tKO</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib128">Paclíková et al., 2017</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom">Cells lacking all DVL isoforms; CRISPR/Cas9</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">T-REx 293 WNT5A/B KO</td><td align="left" valign="bottom">This publication</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Cells lacking WNT5A/B isoforms; CRISPR/Cas9</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">T-REx 293 ROR1 KO</td><td align="left" valign="bottom">This publication</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Cells lacking ROR1; CRISPR/Cas9</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">A375 (amelanotic malignant melanoma)</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib92">Kucerova et al., 2014</xref></td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:CVCL_0132">CVCL_0132</ext-link></td><td align="left" valign="bottom">BRAF V600E; GFP constitutive expression</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">A375 RNF43/ZNRF3 dKO</td><td align="left" valign="bottom">This publication</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Cells lacking RNF43/ZNRF3; CRISPR/Cas9</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">A375+ RNF43</td><td align="left" valign="bottom">This publication</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Stable overexpression of RNF43</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">A375 RNF43 TetON</td><td align="left" valign="bottom">This publication</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Cells inducibly overexpressing RNF43</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">A375 TetON ctrl</td><td align="left" valign="bottom">This publication</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Control cells for A375 RNF43 TetON</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">A375 IV (amelanotic malignant melanoma)</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib92">Kucerova et al., 2014</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom">BRAF V600E; GFP constitutive expression</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">A375 IV RNF43/ZNRF3 dKO</td><td align="left" valign="bottom">This publication</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Cells lacking RNF43/ZNRF3; CRISPR/Cas9</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">A375 IV + RNF43</td><td align="left" valign="bottom">This publication</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Stable overexpression of RNF43</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">A2058 (metastatic melanoma)</td><td align="left" valign="bottom">ECACC</td><td align="left" valign="bottom">91100402; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:CVCL_1059">CVCL_1059</ext-link></td><td align="left" valign="bottom">BRAF V600E</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">A2058 RNF43 TetON</td><td align="left" valign="bottom">This publication</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Cells inducibly overexpressing RNF43</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">MelJuso</td><td align="left" valign="bottom">Laboratory of Stjepan Uldrijan</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:CVCL_1403">CVCL_1403</ext-link></td><td align="left" valign="bottom">NRAS<sup><italic>Q61L/WT</italic></sup> HRAS<sup><italic>G13D/G13D</italic></sup></td></tr><tr><td align="left" valign="bottom">Cell line (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">MelJuso RNF43 TetON</td><td align="left" valign="bottom">This publication</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Cells inducibly overexpressing RNF43</td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">Recombinant human R-Sponidin-1</td><td align="left" valign="bottom">PeproTech</td><td align="char" char="hyphen" valign="bottom">120-38</td><td align="left" valign="bottom">Final concentration 50 ng/ml</td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">Recombinant human WNT3A</td><td align="left" valign="bottom">R&amp;D Systems</td><td align="char" char="hyphen" valign="bottom">5036-WN</td><td align="left" valign="bottom">Range 40–80 ng/ml</td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">Recombinant human WNT5A</td><td align="left" valign="bottom">R&amp;D Systems</td><td align="char" char="hyphen" valign="bottom">645-WN</td><td align="left" valign="bottom">Range 40–80 ng/ml</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">LGK-974, Porcupine inhibitor</td><td align="left" valign="bottom">PeproTech</td><td align="char" char="." valign="bottom">1241454</td><td align="left" valign="bottom">1 μM</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">C-59, Porcupine inhibitor</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">ab142216</td><td align="left" valign="bottom">0.5 μM</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Dansylcadaverine, inhibitor of clathrin-dependent endocytosis</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">D4008</td><td align="left" valign="bottom">50 µM</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Chloroquine, inhibitor of lysosomal hydrolases</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">C662</td><td align="left" valign="bottom">10 μM</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">MG-132, proteasome inhibitor</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">C2211</td><td align="left" valign="bottom">10 μM</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Vemurafenib BRAF V600E inhibitor</td><td align="left" valign="bottom">MedChem Express</td><td align="left" valign="bottom">HY-12057</td><td align="left" valign="bottom">Up to 5 μM</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Cobimetinib, Mek1 inhibitor</td><td align="left" valign="bottom">MedChem Express</td><td align="left" valign="bottom">HY-13064</td><td align="left" valign="bottom">Up to 0.5 μM</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">β-actin (rabbit monoclonal)</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">CS-4970; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2223172">AB_2223172</ext-link></td><td align="left" valign="bottom">WB (1:3000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">DVL-2 (rabbit polyclonal)</td><td align="left" valign="bottom">Cell Signaling Technology<break/><xref ref-type="bibr" rid="bib110">Mentink et al., 2018</xref><break/></td><td align="left" valign="bottom">CS-3216; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2093338">AB_2093338</ext-link></td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">DVL-3 (rabbit polyclonal)</td><td align="left" valign="bottom">Cell Signaling Technology<break/><xref ref-type="bibr" rid="bib110">Mentink et al., 2018</xref><break/></td><td align="left" valign="bottom">CS-3218; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_10694060">AB_10694060</ext-link></td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">DVL-3 (rabbit monoclonal)</td><td align="left" valign="bottom">Santa Cruz Biotechnology<break/> <xref ref-type="bibr" rid="bib77">Kaiser et al., 2019</xref><break/></td><td align="left" valign="bottom">SC-8027; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_627434">AB_627434</ext-link></td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) (rabbit polyclonal)</td><td align="left" valign="bottom">Cell Signaling Technology<break/> <xref ref-type="bibr" rid="bib135">Radaszkiewicz et al., 2020</xref></td><td align="left" valign="bottom">CS-9101; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_331646">AB_331646</ext-link></td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Total MAPK (Erk1/2) (rabbit monoclonal)</td><td align="left" valign="bottom">Cell Signaling Technology<break/> <xref ref-type="bibr" rid="bib136">Radaszkiewicz and Bryja, 2020</xref></td><td align="left" valign="bottom">CS-4695; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_390779">AB_390779</ext-link></td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">ROR1 (rabbit polyclonal)</td><td align="left" valign="bottom">Kind gift from <xref ref-type="bibr" rid="bib63">Ho et al., 2012</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom">WB (1:3000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">ROR2 (mouse monoclonal)</td><td align="left" valign="bottom">Santa Cruz Biotechnology<break/><xref ref-type="bibr" rid="bib123">Ozeki et al., 2016</xref></td><td align="left" valign="bottom">sc-374174; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_10989358">AB_10989358</ext-link></td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">WNT5A (rat monoclonal)</td><td align="left" valign="bottom">R&amp;D Systems<break/> <xref ref-type="bibr" rid="bib77">Kaiser et al., 2019</xref></td><td align="left" valign="bottom">MAB645; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_10571221">AB_10571221</ext-link></td><td align="left" valign="bottom">WB (1:500)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">WNT11 (rabbit polyclonal)</td><td align="left" valign="bottom">LifeSpan BioSciences<break/> <xref ref-type="bibr" rid="bib90">Kotrbová et al., 2020</xref></td><td align="left" valign="bottom">LS-C185754</td><td align="left" valign="bottom">WB (1:500)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">VANGL2 2 G4 (rat monoclonal)</td><td align="left" valign="bottom">Merck<break/> <xref ref-type="bibr" rid="bib110">Mentink et al., 2018</xref><break/></td><td align="left" valign="bottom">MABN750; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2721170">AB_2721170</ext-link></td><td align="left" valign="bottom">WB (1:500)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">MITF (rabbit monoclonal)</td><td align="left" valign="bottom">Cell Signaling Technology<break/> <xref ref-type="bibr" rid="bib95">Lavelle et al., 2020</xref><break/></td><td align="left" valign="bottom">CS-12590; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2616024">AB_2616024</ext-link></td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">HA-11 (mouse monoclonal)</td><td align="left" valign="bottom">Covance<break/> <xref ref-type="bibr" rid="bib128">Paclíková et al., 2017</xref></td><td align="left" valign="bottom">MMS-101R; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_291262">AB_291262</ext-link></td><td align="left" valign="bottom">WB (1:2000); IF (1:500); IP (1 µg)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">HA (rabbit polyclonal)</td><td align="left" valign="bottom">Abcam<break/> <xref ref-type="bibr" rid="bib128">Paclíková et al., 2017</xref></td><td align="left" valign="bottom">ab9110; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_307019">AB_307019</ext-link></td><td align="left" valign="bottom">WB (1:2000); IF (1:500); IP (1 µg); FC (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">c-Myc (9E10) (mouse monoclonal)</td><td align="left" valign="bottom">Santa Cruz Biotechnology<break/> <xref ref-type="bibr" rid="bib55">Hanáková et al., 2019</xref></td><td align="left" valign="bottom">sc-40; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2857941">AB_2857941</ext-link></td><td align="left" valign="bottom">WB (1:500); IF (1:250); IP (1 µg)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">GFP 3 H9 (rat monoclonal)</td><td align="left" valign="bottom">Chromotek<break/> <xref ref-type="bibr" rid="bib59">Harnoš et al., 2019</xref></td><td align="char" char="." valign="bottom">3 H9</td><td align="left" valign="bottom">WB (1:2000); IP (1 µg)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">GFP (rabbit polyclonal)</td><td align="left" valign="bottom">Fitzgerald<break/> <xref ref-type="bibr" rid="bib55">Hanáková et al., 2019</xref></td><td align="left" valign="bottom">20R-GR-011; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_1286217">AB_1286217</ext-link></td><td align="left" valign="bottom">WB (1:2000); IP (1 µg)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">FLAG M2 (mouse monoclonal)</td><td align="left" valign="bottom">Sigma-Aldrich<break/> <xref ref-type="bibr" rid="bib128">Paclíková et al., 2017</xref></td><td align="left" valign="bottom">F3165; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_259529">AB_259529</ext-link></td><td align="left" valign="bottom">WB (1:2000), IF (1:500)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">FLAG (rabbit polyclonal)</td><td align="left" valign="bottom">Sigma<break/> <xref ref-type="bibr" rid="bib128">Paclíková et al., 2017</xref></td><td align="left" valign="bottom">F7425; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_439687">AB_439687</ext-link></td><td align="left" valign="bottom">WB (1:2000); IF (1:500)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">V5 (mouse monoclonal)</td><td align="left" valign="bottom">Thermo Fisher Scientific<break/><xref ref-type="bibr" rid="bib77">Kaiser et al., 2019</xref></td><td align="left" valign="bottom">R96025; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_159313">AB_159313</ext-link></td><td align="left" valign="bottom">WB (1:1000), IF (1:1000); IP (1 µg)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Cortactin (mouse monoclonal)</td><td align="left" valign="bottom">Santa Cruz Biotechnology<break/><xref ref-type="bibr" rid="bib180">Weeber et al., 2019</xref></td><td align="left" valign="bottom">sc-55579; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_831187">AB_831187</ext-link></td><td align="left" valign="bottom">IF (1:250)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Golgin-97 (mouse monoclonal)</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">A-21270; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_221447">AB_221447</ext-link></td><td align="left" valign="bottom">IF (1:500)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">a-mouse IgG HRP (goat polyclonal)</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">A4416; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_258167">AB_258167</ext-link></td><td align="left" valign="bottom">WB (1:4000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">a-rabbit IgG HRP (goat polyclonal)</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">A0545; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_257896">AB_257896</ext-link></td><td align="left" valign="bottom">WB (1:4000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">a-rat IgG HRP (goat polyclonal)</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">A9037; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_258429">AB_258429</ext-link></td><td align="left" valign="bottom">WB (1:4000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Streptavidin-HRP conjugate</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">ab7403</td><td align="left" valign="bottom">WB (1:4000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Ror1-APC (mouse monoclonal)</td><td align="left" valign="bottom">Miltenyi Biotec<break/> <xref ref-type="bibr" rid="bib89">Kotašková et al., 2016</xref></td><td align="char" char="hyphen" valign="bottom">30-119-860</td><td align="left" valign="bottom">FC (1:25)</td></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="bottom">a-mouse Alexa Fluor 488 (goat polyclonal) and 568 (donkey polyclonal)</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="top">A-11001 (RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2534069">AB_2534069</ext-link>) and A10037 (RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2534013">AB_2534013</ext-link>)</td><td align="left" valign="top">IF (1:600)</td></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="bottom">a-rabbit Alexa Fluor 488 (donkey polyclonal) and 568 (goat polyclonal)</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="top">A21206 (RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2535792">AB_2535792</ext-link>) and A11011 (RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_143157">AB_143157</ext-link>)</td><td align="left" valign="top">IF (1:600)</td></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="bottom">Streptavidin, Alexa Fluor 488 conjugate</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="top">S-32354</td><td align="left" valign="top">IF (1:600)</td></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="bottom">Phalloidine Alexa Fluor 594</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="top">A12381</td><td align="left" valign="top">IF (1:600)</td></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="bottom">Phalloidine 4 Alexa Fluor 488</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="top">A12379</td><td align="left" valign="top">IF (1:600)</td></tr><tr><td align="left" valign="top">Recombinant DNA reagent</td><td align="left" valign="top">pcDNA4-TO-RNF43-2xHA-2xFLAG</td><td align="left" valign="bottom">Kindly gifted by Bon-Kyoung Koo (<xref ref-type="bibr" rid="bib88">Koo et al., 2012</xref>)</td><td align="left" valign="bottom"/><td align="left" valign="top">Inducible expression of RNF43; backbone for cloning</td></tr><tr><td align="left" valign="top">Recombinant DNA reagent</td><td align="left" valign="bottom">pcDNA4-TO-RNF43Mut1-2xHA-2xFLAG</td><td align="left" valign="bottom">Kindly gifted by Bon-Kyoung Koo (<xref ref-type="bibr" rid="bib88">Koo et al., 2012</xref>)</td><td align="left" valign="top"/><td align="left" valign="top">Inducible expression of inactive RNF43-HA-FLAG</td></tr><tr><td align="left" valign="top">Recombinant DNA reagent</td><td align="left" valign="bottom">pcDNA4-TO-RNF43-BirA*-HA</td><td align="left" valign="bottom">This publication</td><td align="left" valign="top"/><td align="left" valign="top">Inducible expression of RNF43 with BirA* and HA tags</td></tr><tr><td align="left" valign="top">Recombinant DNA reagent</td><td align="left" valign="bottom">pcDNA3-RNF43-HA</td><td align="left" valign="bottom">This publication</td><td align="left" valign="top"/><td align="left" valign="top">Expression of RNF43-HA</td></tr><tr><td align="left" valign="top">Recombinant DNA reagent</td><td align="left" valign="bottom">pCW57-RNF43</td><td align="left" valign="bottom">This publication</td><td align="left" valign="top"/><td align="left" valign="top">Lentiviral plasmid allowing inducible expression of HA/FLAG tagged RNF43</td></tr><tr><td align="left" valign="top">Recombinant DNA reagent</td><td align="left" valign="bottom">myc-Vangl1, GFP-Vangl2, GFP-Vangl2ΔN, GFP-Vangl2ΔC, GFP-Vangl2ΔNΔC</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib17">Belotti et al., 2012</xref></td><td align="left" valign="top"/><td align="left" valign="top">Expression of VANGL1 and VANGL2 and their variants</td></tr><tr><td align="left" valign="top">Recombinant DNA reagent</td><td align="left" valign="bottom">pLAMP1-mCherry</td><td align="left" valign="bottom">Addgene #45147 <break/><xref ref-type="bibr" rid="bib173">Van Engelenburg and Palmer, 2010</xref></td><td align="left" valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:Addgene_45147">Addgene_45147</ext-link></td><td align="left" valign="top">Expression of lysosomes marker</td></tr><tr><td align="left" valign="top">Recombinant DNA reagent</td><td align="left" valign="bottom">pEGFP-C1-Rab5a</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib28">Chen et al., 2009</xref></td><td align="left" valign="top"/><td align="left" valign="top">Expression of early endosomes marker</td></tr><tr><td align="left" valign="top">Recombinant DNA reagent</td><td align="left" valign="bottom">GFP-rab11 WT</td><td align="left" valign="bottom">Addgene #12674<break/> <xref ref-type="bibr" rid="bib30">Choudhury et al., 2002</xref></td><td align="left" valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:Addgene_12674">Addgene_12674</ext-link></td><td align="left" valign="top">Expression of recycling endosomes marker</td></tr><tr><td align="left" valign="top">Recombinant DNA reagent</td><td align="left" valign="bottom">His-ubiquitin</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib164">Tauriello et al., 2010</xref></td><td align="left" valign="top"/><td align="left" valign="top">Tagged ubiquitin for His-Ub pulldown assay</td></tr><tr><td align="left" valign="top">Recombinant DNA reagent</td><td align="left" valign="bottom">pcDNA3-Flag-mDvl1</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib164">Tauriello et al., 2010</xref></td><td align="left" valign="top"/><td align="left" valign="top">Expression of Dvl1 with Flag tag</td></tr><tr><td align="left" valign="top">Recombinant DNA reagent</td><td align="left" valign="bottom">pCMV5-3xFlag Dvl2</td><td align="left" valign="bottom">Addgene #24802<break/> <xref ref-type="bibr" rid="bib117">Narimatsu et al., 2009</xref></td><td align="left" valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:Addgene_24802">Addgene_24802</ext-link></td><td align="left" valign="top">Expression of DVL2 with Flag tag</td></tr><tr><td align="left" valign="top">Recombinant DNA reagent</td><td align="left" valign="bottom">pCDNA3.1-Flag-hDvl3</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib6">Angers et al., 2006</xref></td><td align="left" valign="top"/><td align="left" valign="top">Expression of DVL3 with Flag tag</td></tr><tr><td align="left" valign="top">Recombinant DNA reagent</td><td align="left" valign="bottom">pcDNA3.1-hROR1-V5-His</td><td align="left" valign="bottom">gifted by Kateřina Tmějová</td><td align="left" valign="top"/><td align="left" valign="top">Expression of ROR1 with V5 tag</td></tr><tr><td align="left" valign="top">Recombinant DNA reagent</td><td align="left" valign="bottom">pcDNA3-Ror2-Flag; pcDNA3-Ror2-dCRD-FLAG</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib147">Sammar et al., 2004</xref></td><td align="left" valign="top"/><td align="left" valign="top">Expression of ROR2 with FLAG tag and its mutant lacking CRD domain</td></tr><tr><td align="left" valign="top">Recombinant DNA reagent</td><td align="left" valign="bottom">pRRL2_ROR1ΔCYTO and pRRL2_ROR1ΔTail</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib50">Gentile et al., 2011</xref></td><td align="left" valign="top"/><td align="left" valign="top">Expression of ROR1 and its truncated versions</td></tr><tr><td align="left" valign="top">Recombinant DNA reagent</td><td align="left" valign="bottom">hCas9</td><td align="left" valign="bottom">Addgene #41815 <break/><xref ref-type="bibr" rid="bib105">Mali et al., 2013</xref></td><td align="left" valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:Addgene_41815">Addgene_41815</ext-link></td><td align="left" valign="top">Humanized Cas9</td></tr><tr><td align="left" valign="top">Recombinant DNA reagent</td><td align="left" valign="bottom">gRNA_GFP-T1</td><td align="left" valign="bottom">Addgene #41819 <break/><xref ref-type="bibr" rid="bib105">Mali et al., 2013</xref></td><td align="left" valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:Addgene_41819">Addgene_41819</ext-link></td><td align="left" valign="top">gRNA expression plasmid</td></tr><tr><td align="left" valign="top">Recombinant DNA reagent</td><td align="left" valign="bottom">PiggyBack-Hygro; Transposase</td><td align="left" valign="bottom">Gifted by Bon-Kyoung Koo</td><td align="left" valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:Addgene_64324">Addgene_64324</ext-link></td><td align="left" valign="top">PiggyBack transposase system for stable cell lines generation</td></tr><tr><td align="left" valign="top">Recombinant DNA reagent</td><td align="left" valign="bottom">pU6-(BbsI)CBh-Cas9-T2A-mCherry</td><td align="left" valign="bottom">Addgene #64324 <break/><xref ref-type="bibr" rid="bib31">Chu et al., 2015</xref></td><td align="left" valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:Addgene_64324">Addgene_64324</ext-link></td><td align="left" valign="top">All-in-1 Cas9 plasmid</td></tr><tr><td align="left" valign="top">Recombinant DNA reagent</td><td align="left" valign="bottom">pSpCas9(BB)-2A-GFP (PX458)</td><td align="left" valign="bottom">Addgene #48138 <break/><xref ref-type="bibr" rid="bib139">Ran et al., 2013</xref></td><td align="left" valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:Addgene_48138">Addgene_48138</ext-link></td><td align="left" valign="top">All-in-1 Cas9 plasmid</td></tr><tr><td align="left" valign="top">Sequence-based reagent</td><td align="left" valign="bottom"><italic>RNF43</italic> gRNA</td><td align="left" valign="bottom">This publication</td><td align="left" valign="top">gRNA</td><td align="left" valign="top"><named-content content-type="sequence">TGAGTTCCATCGTAACTGTGTGG</named-content></td></tr><tr><td align="left" valign="top">Sequence-based reagent</td><td align="left" valign="bottom"><italic>ZNRF3</italic> gRNA</td><td align="left" valign="bottom">This publication</td><td align="left" valign="top">gRNA</td><td align="left" valign="top"><named-content content-type="sequence">AGACCCGCTCAAGAGGCCGGTGG</named-content></td></tr><tr><td align="left" valign="top">Sequence-based reagent</td><td align="left" valign="bottom"><italic>WNT5A</italic> gRNA</td><td align="left" valign="bottom">This publication</td><td align="left" valign="top">gRNA</td><td align="left" valign="top"><named-content content-type="sequence">AGTATCAATTCCGACATCGAAGG</named-content></td></tr><tr><td align="left" valign="top">Sequence-based reagent</td><td align="left" valign="bottom"><italic>ROR1</italic> gRNA</td><td align="left" valign="bottom">This publication</td><td align="left" valign="top">gRNA</td><td align="left" valign="top"><named-content content-type="sequence">CCATCTATGGCTCTCGGCTGCGG</named-content></td></tr><tr><td align="left" valign="top">Sequence-based reagent</td><td align="left" valign="bottom"><italic>RNF43</italic> gRNA</td><td align="left" valign="bottom">This publication</td><td align="left" valign="top">gRNA</td><td align="left" valign="top"><named-content content-type="sequence">AGTTACGATGGAACTCATGG</named-content></td></tr><tr><td align="left" valign="top">Sequence-based reagent</td><td align="left" valign="bottom"><italic>ZNRF3</italic> gRNA</td><td align="left" valign="bottom">This publication</td><td align="left" valign="top">gRNA</td><td align="left" valign="top"><named-content content-type="sequence">CTCCAGACAGATGGCACAGTCGG</named-content></td></tr><tr><td align="left" valign="top">Sequence-based reagent</td><td align="left" valign="bottom"><italic>B2M</italic>_F</td><td align="left" valign="bottom">This publication</td><td align="left" valign="top">qPCR primer</td><td align="left" valign="top"><named-content content-type="sequence">CACCCCCACTGAAAAAGATG</named-content></td></tr><tr><td align="left" valign="top">Sequence-based reagent</td><td align="left" valign="bottom"><italic>B2M</italic>_R</td><td align="left" valign="bottom">This publication</td><td align="left" valign="top">qPCR primer</td><td align="left" valign="top"><named-content content-type="sequence">ATATTAAAAAGCAAGCAAGCAGAA</named-content></td></tr><tr><td align="left" valign="top">Sequence-based reagent</td><td align="left" valign="bottom"><italic>GAPDH</italic>_F</td><td align="left" valign="bottom">This publication</td><td align="left" valign="top">qPCR primer</td><td align="left" valign="top"><named-content content-type="sequence">GACAGTCAGCCGCATCTTCT</named-content></td></tr><tr><td align="left" valign="top">Sequence-based reagent</td><td align="left" valign="bottom"><italic>GAPDH</italic>_R</td><td align="left" valign="bottom">This publication</td><td align="left" valign="top">qPCR primer</td><td align="left" valign="top"><named-content content-type="sequence">TTAAAAGCAGCCCTGGTGAC</named-content></td></tr><tr><td align="left" valign="top">Sequence-based reagent</td><td align="left" valign="bottom"><italic>HSPCB</italic>_F</td><td align="left" valign="bottom">This publication</td><td align="left" valign="top">qPCR primer</td><td align="left" valign="top"><named-content content-type="sequence">TCTGGGTATCGGAAAGCAAGCC</named-content></td></tr><tr><td align="left" valign="top">Sequence-based reagent</td><td align="left" valign="bottom"><italic>HSPCB</italic>_R</td><td align="left" valign="bottom">This publication</td><td align="left" valign="top">qPCR primer</td><td align="left" valign="top"><named-content content-type="sequence">GTGCACTTCCTCAGGCATCTTG</named-content></td></tr><tr><td align="left" valign="top">Sequence-based reagent</td><td align="left" valign="bottom"><italic>RPS13</italic>_F</td><td align="left" valign="bottom">This publication</td><td align="left" valign="top">qPCR primer</td><td align="left" valign="top"><named-content content-type="sequence">CGAAAGCATCTTGAGAGGAACA</named-content></td></tr><tr><td align="left" valign="top">Sequence-based reagent</td><td align="left" valign="bottom"><italic>RPS13</italic>_R</td><td align="left" valign="bottom">This publication</td><td align="left" valign="top">qPCR primer</td><td align="left" valign="top"><named-content content-type="sequence">TCGAGCCAAACGGTGAATC</named-content></td></tr><tr><td align="left" valign="top">Sequence-based reagent</td><td align="left" valign="bottom"><italic>RNF43</italic>_F</td><td align="left" valign="bottom">This publication</td><td align="left" valign="top">qPCR primer</td><td align="left" valign="top"><named-content content-type="sequence">TTTCCTGCCTCCATGAGTTC</named-content></td></tr><tr><td align="left" valign="top">Sequence-based reagent</td><td align="left" valign="bottom"><italic>RNF43</italic>_R</td><td align="left" valign="bottom">This publication</td><td align="left" valign="top">qPCR primer</td><td align="left" valign="top"><named-content content-type="sequence">CAGGGACTGGGAAAATGAATC</named-content></td></tr><tr><td align="left" valign="top">Sequence-based reagent</td><td align="left" valign="bottom"><italic>ZNRF3</italic>_F</td><td align="left" valign="bottom">This publication</td><td align="left" valign="top">qPCR primer</td><td align="left" valign="top"><named-content content-type="sequence">GCTTTCTTCGTCGTGGTCTC</named-content></td></tr><tr><td align="left" valign="top">Sequence-based reagent</td><td align="left" valign="bottom"><italic>ZNRF3</italic>_R</td><td align="left" valign="bottom">This publication</td><td align="left" valign="top">qPCR primer</td><td align="left" valign="top"><named-content content-type="sequence">GCCTGTTCATGGAATTCTGAC</named-content></td></tr><tr><td align="left" valign="top">Sequence-based reagent</td><td align="left" valign="bottom"><italic>DVL2</italic>_F</td><td align="left" valign="bottom">This publication</td><td align="left" valign="top">qPCR primer</td><td align="left" valign="bottom"><named-content content-type="sequence">TCCTTCCACCCTAATGTGTCCA</named-content></td></tr><tr><td align="left" valign="top">Sequence-based reagent</td><td align="left" valign="bottom"><italic>DVL2</italic>_R</td><td align="left" valign="bottom">This publication</td><td align="left" valign="top">qPCR primer</td><td align="left" valign="top"><named-content content-type="sequence">CATGCTCACTGCTGTCTCTCCT</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>DVL3</italic>_F</td><td align="left" valign="bottom">This publication</td><td align="left" valign="bottom">qPCR primer</td><td align="left" valign="bottom"><named-content content-type="sequence">ACCTTGGCGGACTTTAAGGG</named-content></td></tr><tr><td align="left" valign="top">Sequence-based reagent</td><td align="left" valign="bottom"><italic>DVL3</italic>_R</td><td align="left" valign="bottom">This publication</td><td align="left" valign="top">qPCR primer</td><td align="left" valign="top"><named-content content-type="sequence">TCACCACTCCGAAATCGTCG</named-content></td></tr><tr><td align="left" valign="top">Sequence-based reagent</td><td align="left" valign="bottom"><italic>WNT5A</italic>_F</td><td align="left" valign="bottom">This publication</td><td align="left" valign="top">qPCR primer</td><td align="left" valign="top"><named-content content-type="sequence">GCAGCACTGTGGATAACACCTCTG</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>WNT5A</italic>_R</td><td align="left" valign="bottom">This publication</td><td align="left" valign="bottom">qPCR primer</td><td align="left" valign="bottom"><named-content content-type="sequence">AACTCCTTGGCAAAGCGGTAGCC</named-content></td></tr><tr><td align="left" valign="top">Sequence-based reagent</td><td align="left" valign="bottom"><italic>ROR1</italic>_F</td><td align="left" valign="bottom">This publication</td><td align="left" valign="top">qPCR primer</td><td align="left" valign="top"><named-content content-type="sequence">TCTCGGCTGCGGATTAGAAAC</named-content></td></tr><tr><td align="left" valign="top">Sequence-based reagent</td><td align="left" valign="bottom"><italic>ROR1</italic>_R</td><td align="left" valign="bottom">This publication</td><td align="left" valign="top">qPCR primer</td><td align="left" valign="top"><named-content content-type="sequence">TCCAGTGGAAGAAACCACCTC</named-content></td></tr><tr><td align="left" valign="top">Sequence-based reagent</td><td align="left" valign="bottom"><italic>ROR2</italic>_F</td><td align="left" valign="bottom">This publication</td><td align="left" valign="top">qPCR primer</td><td align="left" valign="top"><named-content content-type="sequence">GTGCGGTGGCTAAAGAATGAT</named-content></td></tr><tr><td align="left" valign="top">Sequence-based reagent</td><td align="left" valign="bottom"><italic>ROR2</italic>_F</td><td align="left" valign="bottom">This publication</td><td align="left" valign="top">qPCR primer</td><td align="left" valign="top"><named-content content-type="sequence">ATTCGCAGTCGTGAACCATATT</named-content></td></tr><tr><td align="left" valign="top">Sequence-based reagent</td><td align="left" valign="bottom"><italic>MITF</italic>_F</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib159">Su et al., 2020</xref></td><td align="left" valign="top">qPCR primer</td><td align="left" valign="top"><named-content content-type="sequence">TGCCCAGGCATGAACACAC</named-content></td></tr><tr><td align="left" valign="top">Sequence-based reagent</td><td align="left" valign="bottom"><italic>MITF</italic>_R</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib159">Su et al., 2020</xref></td><td align="left" valign="top">qPCR primer</td><td align="left" valign="top"><named-content content-type="sequence">GGGAAAAATACACGCTGTGAG</named-content></td></tr></tbody></table><table-wrap-foot><fn><p>WB: western blot; IF:immunofluorescence; IP: immunoprecipitation.</p></fn></table-wrap-foot></table-wrap></app></app-group></back><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.65759.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Robles-Espinoza</surname><given-names>C Daniela</given-names></name><role>Reviewing Editor</role><aff><institution>International Laboratory for Human Genome Research</institution><country>Mexico</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="box1"><p>Our editorial process produces two outputs: (i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/10.1101/2021.02.08.430210">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/10.1101/2021.02.08.430210v1">the preprint</ext-link> for the benefit of readers; (ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Acceptance summary:</bold></p><p>This study will be of interest to scientists studying pathways involved in cancer metastasis, as it reveals a novel regulatory mechanism involved in cancer cell invasion. Here, the authors have shown that RNF43, a ubiquitin ligase, can regulate non-canonical Wnt signaling through influencing turnover of ROR1 and ROR2, co-receptors found on the surface of cells involved in Wnt signaling. Expression of RNF43 in melanoma cell lines blocks their invasive properties, prevents resistance to BRAF and MEK inhibitors, and improves response to targeted therapies in vivo. Therefore, RNF43 is a newly discovered negative regulator of WNT5A-mediated biological responses.</p><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;RNF43 inhibits WNT5A driven signaling and suppresses melanoma invasion&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 3 peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Erica Golemis as the Senior Editor. The reviewers have opted to remain anonymous.</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>The reviewers have discussed with each other and have agreed that some major issues that would need to be addressed before publication in <italic>eLife</italic>.</p><p>Major Points:</p><p>1. in vivo experiments would be needed to show the effect of RNF43 in the context of resistance to vemurafenib. If these cannot be performed, amend the title of the paper to better reflect the experiments performed, as at the moment it refers to melanoma invasion.</p><p>2. The number of cell lines used is not sufficient. All reviewers noted that, in order to rule out cell-line specific effects, the effects of RNF43 on the WNT5A pathway and their functional relevance should be tested in at least one additional melanoma cell line. One reviewer noted that &quot;The findings in melanoma are weakened by the fact that only 1 pair of isogenic cell lines is used. An additional distinct cell line would greatly strengthen the paper findings and impact.&quot; It is essential to perform these experiments in additional melanoma cell models.</p><p>3. Mechanistic function of RNF43. Please provide data to clarify the following points:</p><p>– The authors mention that RNF43 ubiquitination of VANGL2 leads to downregulation of ROR1. Does it also lead to a downregulation of ROR2, in melanoma cells?</p><p>– What happens to WNT5A expression in the RNF43-KO cell lines (A375 WT and A375 WT VR)?</p><p>– What causes a loss of expression of RNF43 during melanoma progression?</p><p>4. Figure 5A. How do the authors address the lack of effect, on migration, in A375 IV overexpressing RNF43? Also, what statistical test was used to compare the graphs? There is one line comparing 48 h in A375 WT +/- RNF43 showing a difference, but it is difficult to tell if there is a difference between A375 IV without and with overexpression of RNF43.</p><p>– Figure 5B and 5C. What is the explanation for the lack of effect of RNF43 KO?</p><p>– Figure 6F. How do the authors explain the increase in sensitivity to vemurafenib following RNF43 KO?</p><p>5. Due to the clinical relevance of combined treatment, it would be more appropriate to test the effects of RNF43 in the context of BRAF and MEK inhibition, rather than BRAF inhibition alone. Please add these experiments.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.65759.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>The reviewers have discussed with each other and have agreed that some major issues that would need to be addressed before publication in eLife.</p></disp-quote><p>We would like to thank all reviewers for their valuable comments and useful suggestions, which helped us to improve our manuscript. We have expanded our work in all directions suggested by the editor. Namely, (i) we have introduced new cell lines and also new and more robust invasion/chemotaxis assays, (ii) the work on targeted therapies has been improved by introduction of MEK inhibitors and their combination with BRAF V600E inhibition, and finally, (iii) we have repeated the key findings (the effect on Vemurafenib resistance) in the in vivo xenograft experiment. We also decided to modify the title of our study to reflect better the actual content of our publication:</p><p>“RNF43 inhibits WNT5A driven signaling, suppresses melanoma invasion and resistance to the targeted therapy”.</p><disp-quote content-type="editor-comment"><p>Major Points:</p><p>1. In vivo experiments would be needed to show the effect of RNF43 in the context of resistance to vemurafenib. If these cannot be performed, amend the title of the paper to better reflect the experiments performed, as at the moment it refers to melanoma invasion.</p></disp-quote><p>To address this issue, we have set up an in vivo assay where A375 were administered intradermally into immunodeficient NOD-Rag1<sup>null</sup> IL2rg<sup>null</sup> mice. We have used a panel of A375 derivatives representing <italic>RNF43</italic>-low, <italic>RNF43</italic>-medium and <italic>RNF43</italic>-high conditions and questioned if <italic>RNF43</italic> expression level affects tumor formation and response to Vemurafenib. The sets of in vivo experiments are presented as the novel Figure 7 and associated supplementary figure. Importantly, mouse xenograft data confirm our concept defined in the in vitro conditions and strengthen our study as such.</p><disp-quote content-type="editor-comment"><p>2. The number of cell lines used is not sufficient. All reviewers noted that, in order to rule out cell-line specific effects, the effects of RNF43 on the WNT5A pathway and their functional relevance should be tested in at least one additional melanoma cell line. One reviewer noted that &quot;The findings in melanoma are weakened by the fact that only 1 pair of isogenic cell lines is used. An additional distinct cell line would greatly strengthen the paper findings and impact.&quot; It is essential to perform these experiments in additional melanoma cell models.</p></disp-quote><p>Thank you for this suggestion. As part of work on the revision we have expanded our panel of cell lines and included two additional melanoma cell lines: A2058 (BRAF V600E) and MelJuso (NRAS<sup>Q61L/WT</sup> HRAS<sup>G13D/G13D</sup>). These cell lines were genetically modified to inducibly express RNF43. Both lines were analyzed for their ability to respond to WNT5A (Figure 4J and Figure 4 figure supplement 3A). A2058 were also tested in the functional assays – wound healing (Figure 5E), collagen I hydrogel invasion assay (Figure 5H) and acquisition of resistance to Vemurafenib, Cobimetinib and combined therapy (Figure 6H-I and Figure 6 figure supplement 1C-F). We could confirm our earlier T-REx 293 and A375-based observations that RNF43 inhibits WNT5A signaling, melanoma invasion and acquired resistance.</p><disp-quote content-type="editor-comment"><p>3. Mechanistic function of RNF43. Please provide data to clarify the following points:</p><p>– The authors mention that RNF43 ubiquitination of VANGL2 leads to downregulation of ROR1. Does it also lead to a downregulation of ROR2, in melanoma cells?</p></disp-quote><p>We understand that by “downregulation of ROR1” reviewer meant “downregulation of ROR1 cell surface level” and “downregulation of ROR1 phosphorylation” that we show in the manuscript. Based on known similarities between ROR1 and ROR2 we expected that ROR2 will behave similarly as ROR1 and updated Figure 4 in this respect. Indeed, electrophoretic mobility shift of ROR2 is blocked in A2058 RNF43 TetON (Figure 4J) and A375 RNF43 TetON (Figure 4 figure supplement 3B) cells. Thus, we concluded that RNF43 decreases phosphorylation of ROR1 as well as ROR2.</p><disp-quote content-type="editor-comment"><p>– What happens to WNT5A expression in the RNF43-KO cell lines (A375 WT and A375 WT VR)?</p></disp-quote><p>To answer this issue, we showed in the Figure 6 data analyzing <italic>WNT5A</italic> expression. We can conclude that during the process for resistance acquisition <italic>WNT5A</italic> expression is increased. It is true in Vemurafenib resistant A375 cells (Figure 6E) as well as A2058 cells resistant to Vemurafenib, Cobimetinib and their FDA-approved combination (Figure 6K). The process is accompanied by decreased <italic>RNF43</italic> (Figure 6J) and <italic>ZNRF3</italic> (Figure 6 supplement 1D) expression compared to the parental cells. We also noticed possible changes in the melanoma phenotypes descried by <italic>WNT5A</italic>/<italic>MITF</italic>, which is now part of the <italic>Discussion</italic> part.</p><disp-quote content-type="editor-comment"><p>– What causes a loss of expression of RNF43 during melanoma progression?</p></disp-quote><p>We were unable to answer this question experimentally. However, in the revised version of the manuscript, we have updated <italic>Discussion</italic> to speculate on this issue. Specifically, we propose that the loss of RNF43 is a marker of phenotypic changes associated with <italic>MITF</italic>-low/<italic>WNT5A</italic>-high phenotype (Figure 6I and 6K). <italic>RNF43</italic>, similarly to <italic>MITF</italic>, is a target gene of the canonical Wnt pathway main component – β-catenin (Takahashi et al., 2014). High expression of <italic>WNT5A</italic> and low transcriptional activity of β-catenin are factors describing invasive and therapy resistant cells, as discussed previously (Ahn et al., 2017; Arozarena and Wellbrock, 2019; Eichhoff et al., 2011; Kaur et al., 2016; Prasad et al., 2015).</p><disp-quote content-type="editor-comment"><p>4. Figure 5A. How do the authors address the lack of effect, on migration, in A375 IV overexpressing RNF43? Also, what statistical test was used to compare the graphs? There is one line comparing 48 h in A375 WT +/- RNF43 showing a difference, but it is difficult to tell if there is a difference between A375 IV without and with overexpression of RNF43.</p></disp-quote><p>In the revised manuscript we present all 2D migration (wound healing assay) data in the same format; statistically compared after 48 h of migration (Figure 5A-E) for all four experimental models – A375 and A375 IV stable cell lines, and A375 and A2058 RNF43 TetON cell lines. Data presented in this format clearly show the effects of increased RNF43 on wound healing in all cases. In addition, we present novel data analyzing directional 3D invasion with very clear effects of RNF43 overexpression both in A375 and A2058 cells. Unpaired two-tailed t-test has been used to demonstrate the significance of the RNF43 effect.</p><disp-quote content-type="editor-comment"><p>– Figure 5B and 5C. What is the explanation for the lack of effect of RNF43 KO?</p></disp-quote><p>Lack of <italic>RNF43</italic>/<italic>ZNRF3</italic> dKO effect in Matrigel invasion, invadopodia formation and gelatin degradation in both A375 and A375 IV lines suggests that already wild type cells have negligible activity of RNF43. Indeed, <italic>RNF43</italic> expression in these lines is very low (see Figure 4 figure supplement 2B). As such the deletion of <italic>RNF43</italic>/<italic>ZNRF3</italic> does not further improve their Wnt-driven capacity for migration and invasion that is already very high.</p><disp-quote content-type="editor-comment"><p>– Figure 6F. How do the authors explain the increase in sensitivity to vemurafenib following RNF43 KO?</p></disp-quote><p>Both A375 and IV <italic>RNF43</italic>/<italic>ZNRF3</italic> dKO survived Vermurafenib selection, although <italic>RNF43</italic>/<italic>ZNRF3</italic> dKO cells seem to be in lower numbers (new Figure 6G). We do not know what mechanism is behind this phenotype, but we think that it can be a consequence of decreased proliferation rate of <italic>RNF43</italic>/<italic>ZNRF3</italic> dKO cells. <italic>RNF43</italic>/<italic>ZNRF3</italic> dKO cells have elevated WNT5A pathway activity (i.e. Figure 3B and Figure 4H, I) and increased <italic>WNT5A</italic> expression accompanies the acquisition of resistance to melanoma targeted therapies (Figure 6E and K). It was shown before that high <italic>WNT5A</italic> expression causes a senescence-like phenotype of melanoma after Vemurafenib (Webster et al., 2015). This explanation has been added to the main manuscript text.</p><disp-quote content-type="editor-comment"><p>5. Due to the clinical relevance of combined treatment, it would be more appropriate to test the effects of RNF43 in the context of BRAF and MEK inhibition, rather than BRAF inhibition alone. Please add these experiments.</p></disp-quote><p>In response to the reviewer´s comment we have added this experiment to our study. We tested the cellular responses to the short term and chronic exposure to MEK inhibitor Cobimetinib and its FDA-approved combination with Vemurafenib using A2058 cells (Figure 6H – L and Figure 6 supplement 1C-F). As expected, RNF43 overexpressing cells did not survive selection (Figure 6L). Interestingly, cells resistant to MEK inhibition alone and to combo BRAF V600Ei+MEKi have decreased <italic>RNF43</italic> and <italic>ZNRF3</italic> expression and increased <italic>WNT5A</italic>. The new data and their discussion are now present in Figure 6 and accompanying text.</p><p>References</p><p>Ahn A, Chatterjee A, Eccles MR. 2017. The slow cycling phenotype: A growing problem for treatment resistance in melanoma. Mol Cancer Ther. doi:10.1158/1535-7163.MCT-16-0535</p><p>Arozarena I, Wellbrock C. 2019. Phenotype plasticity as enabler of melanoma progression and therapy resistance. Nat Rev Cancer. doi:10.1038/s41568-019-0154-4</p><p>Eichhoff OM, Weeraratna A, Zipser MC, Denat L, Widmer DS, Xu M, Kriegl L, Kirchner T, Larue L, Dummer R, Hoek KS. 2011. Differential LEF1 and TCF4 expression is involved in melanoma cell phenotype switching 24:631–642. doi:10.1111/j.1755-148X.2011.00871.x</p><p>Feng D, Wang J, Yang W, Li J, Lin X, Zha F, Wang X, Ma L, Choi NT, Mii Y, Takada S, Huen MSY, Guo Y, Zhang L, Gao B. 2021. Regulation of Wnt/PCP signaling through p97/VCP-KBTBD7–mediated Vangl ubiquitination and endoplasmic reticulum–associated degradation. Sci Adv 7:eabg2099. doi:10.1126/sciadv.abg2099</p><p>Guo Y, Zanetti G, Schekman R. 2013. A novel GTP-binding protein-adaptor protein complex responsible for export of Vangl2 from the trans Golgi network. eLife 2013:160. doi:10.7554/eLife.00160</p><p>Kaur A, Webster MR, Weeraratna AT. 2016. In the Wnt-er of life: Wnt signalling in melanoma and ageing. Br J Cancer 115:1273–1279. doi:10.1038/bjc.2016.332</p><p>Prasad C, Mohapatra P, Andersson T. 2015. Therapy for BRAFi-Resistant Melanomas: Is WNT5A the Answer? Cancers (Basel) 7:1900–1924. doi:10.3390/cancers7030868</p><p>Takahashi N, Yamaguchi K, Ikenoue T, Fujii T, Furukawa Y. 2014. Identification of two wnt-responsive elements in the intron of RING finger protein 43 (RNF43) gene. PLoS One. doi:10.1371/journal.pone.0086582</p><p>Tower-Gilchrist C, Zlatic SA, Yu D, Chang Q, Wu H, Lin X, Faundez V, Chen P. 2019. Adaptor protein-3 complex is required for Vangl2 trafficking and planar cell polarity of the inner ear. Mol Biol Cell 30:2422–2434. doi:10.1091/mbc.E16-08-0592</p><p>Webster MR, Xu M, Kinzler KA, Kaur A, Appleton J, O’Connell MP, Marchbank K, Valiga A, Dang VM, Perego M, Zhang G, Slipicevic A, Keeney F, Lehrmann E, Wood W, Becker KG, Kossenkov A V., Frederick DT, Flaherty KT, Xu X, Herlyn M, Murphy ME, Weeraratna AT. 2015. Wnt5A promotes an adaptive, senescent-like stress response, while continuing to drive invasion in melanoma cells 28:184–195. doi:10.1111/pcmr.12330</p><p>Yang W, Garrett L, Feng D, Elliott G, Liu X, Wang N, Wong YM, Choi NT, Yang Y, Gao B. 2017. Wnt-induced Vangl2 phosphorylation is dose-dependently required for planar cell polarity in mammalian development. Cell Res 27:1466–1484. doi:10.1038/cr.2017.127</p></body></sub-article></article>